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We developed a data-mining method, Model-Based Multifactor Dimensionality Reduction 
(MB-MDR) to detect epistatic interactions for different types of traits. MB-MDR enables the 
fast identification of gene-gene interactions among 1000nds of SNPs, without the need to 
make restrictive assumptions about the genetic modes of inheritance. This thesis primarily 
focused on applying Model-Based Multifactor Dimensionality Reduction for quantitative 
traits, its performance and application to a variety of data problems. We carried out several 
simulation studies to evaluate quantitative MB-MDR in terms of power and type I error, 
when data are noisy, non-normal or skewed and when important main effects are present. 
Firstly, we assessed the performance of MB-MDR in the presence of noisy data. The error 
sources considered were missing genotypes, genotyping error, phenotypic mixtures and 
genetic heterogeneity. Results from this study showed that MB-MDR is least affected by 
presence of small percentages of missing data and genotyping errors but much affected in the 
presence of phenotypic mixtures and genetic heterogeneity.  This is in line with a similar 
study performed for binary traits. Although both Multifactor Dimensionality Reduction 
(MDR) and MB-MDR are data reduction techniques with a common basis, their ways of 
deriving significant interactions are substantially different. Nevertheless, effects on power of 
introducing error sources were quite similar.  Irrespective of the trait under consideration, 
epistasis screening methodologies such as MB-MDR and MDR mainly suffer from the 
presence of phenotypic mixtures and genetic heterogeneity.  
Secondly, we extensively addressed the issue of adjusting for lower-order genetic effects 
during epistasis screening, using different adjustment strategies for SNPs in the functional 
SNP-SNP interaction pair, and/or for additional important SNPs. Since, in this thesis, we 
restrict attention to 2-locus interactions only, adjustment for lower-order effects always (and 
only) implies adjustment for main genetic effects. Unfortunately most data dimensionality 
reduction techniques based on MDR do not explicitly require that lower-order effects are 
included in the ‗model‘ when investigating higher-order effects (a prerequisite for most 
traditional, especially regression-based, methods). However, epistasis results may be 
hampered by the presence of significant lower-order effects. Results from this study showed 
hugely increased type I errors when main effects were not taken into account or were not 
properly accounted for. We observed that additive coding (the most commonly used coding 
in practice) in main effects adjustment does not remove all of the potential main effects that 




MB-MDR (via a regression framework), whatever coding is adopted, does not control type I 
error in all scenarios. From this study, we concluded that correction for lower-order effects 
should preferentially be done via codominant coding, to reduce the chance of false positive 
epistasis findings. The recommended way of performing an MB-MDR epistasis screening is 
to always adjust the analysis for lower-order effects of the SNPs under investigation, ―on-the-
fly‖. This correction avoids overcorrection for other SNPs, which are not part of the 
interacting SNP pair under study.  
Thirdly, we assessed the cumulative effect of trait deviations from normality and 
homoscedasticity on the overall performance of quantitative MB-MDR to detect 2-locus 
epistasis signals in the absence of main effects. Although MB-MDR itself is a non-parametric 
method, in the sense that no assumptions are made regarding genetic modes of inheritance, 
the data reduction part in MB-MDR relies on association tests. In particular, for quantitative 
traits, the default MB-MDR way is to use the Student‘s t-test (steps 1 and 2 of MB-MDR). 
Also when correcting for lower-order effects during quantitative MB-MDR analysis, we 
intrinsically maneuver within a regression framework. Since the Student‘s t-statistic is the 
square root of the ANOVA F-statistic. Hence, along these lines, for MB-MDR to give valid 
results, ANOVA assumptions have to be met. Therefore, we simulated data from normal and 
non-normal distributions, with constant and non-constant variances, and performed 
association tests via the student‘s t-test as well as the unequal variance t-test, commonly 
known as the Welch‘s t-test. At first somewhat surprising, the results of this study showed 
that MB-MDR maintains adequate type I errors, irrespective of data distribution or 
association test used.  On the other hand, MB-MDR give rise to lower power results for non-
normal data compared to normal data. With respect to the association tests used within MB-
MDR, in most cases, Welch‘s t-test led to lower power compared to student‘s t-test.  To 
maintain the balance between power and type I error, we concluded that when performing 
MB-MDR analysis with quantitative traits, one ideally first rank-transforms traits to 
normality and then applies MB-MDR modeling with Student‘s t-test as choice of association 
test.  Clearly, before embarking on using a method in practice, there is a need to extensively 
check the applicability of the method to the data at hand. This is a common practice in 
biostatistics, but often a forgotten standard operating procedure in genetic epidemiology, in 
particular in GWAI studies. 
In addition to the presentation of extensive simulation studies, we also presented some MB-




quantitative as well as binary complex disease traits, primarily in the context of 
asthma/allergy and Crohn‘s disease. In two of the presented analyses, MB-MDR confirmed 
logistic regression and transmission disequilibrium test (TDT) results. Part of the 
aforementioned methodological developments was initiated on the basis of observations of 
MB-MDR behavior on real-life data.  
Both the practical and theoretical components of this thesis confirm our belief in the potential 
of MB-MDR as a promising and versatile tool for the identification of epistatic effects, 
irrespective of the design (family-based or unrelated individuals) and irrespective of the 
targeted disease trait (binary, continuous, censored, categorical, multivariate).  A thorough 


















Nous avons développé une méthode d‘exploration de données, à savoir la Réduction de 
dimensionnalité multifactorielle basée sur un modèle Model-Based Multifactor 
Dimensionality Reduction (MB-MDR) afin d‘identifier des interactions épistatiques pour 
différents types de caractères. La méthode MB-MDR permet une identification rapide des 
interactions entre gènes parmi 1000 marqueurs ou SNP, sans devoir faire des hypothèses 
restrictives concernant les modes de transmission génétique. Cette thèse porte principalement 
sur l‘application de la réduction de dimensionnalité multifactorielle basée sur un modèle MB-
MDR aux caractères quantitatifs, leur performance et leur application à une série de 
problèmes relatifs aux données. Nous avons mené une série d‘études de simulation en vue 
d‘évaluer la MB-MDR quantitative en termes de performance et d‘erreur de type I, dans le 
cas où les données sont bruyantes, anormales ou faussées et en présence d‘effets importants 
principaux. 
Premièrement, nous avons évalué la performance de la MB-MDR en présence de données 
bruyantes. Les sources d‘erreur considérées étaient les génotypes manquants, les erreurs de 
génotype, les mélanges phénotypiques et l‘hétérogénéité génétique. Les résultats de cette 
étude ont démontré que la MB-MDR est influencée dans une moindre mesure en présence 
d‘un faible pourcentage de données manquantes et d‘erreurs de génotype. Elle est toutefois 
fortement influencée en présence de mélanges phénotypiques et d‘une hétérogénéité 
génétique. Ces résultats sont conformes à une étude similaire menée dans le cadre des 
caractères binaires. Même si la Réduction de dimensionnalité multifactorielle (MDR) et la 
MB-MDR sont des techniques de réduction de données sur base commune, leur mode de 
dérivation d‘interactions significatives est substantiellement différent. Toutefois, les 
conséquences constatées sur la capacité d‘introduction d‘erreurs sources sont assez similaires. 
Indépendamment du caractère en question, les méthodes de détection de l‘épistasie comme la 
MB-MDR et MDR sont principalement gênées par la présence de mélanges phénotypiques et 
de l‘hétérogénéité génétique.   
Deuxièmement, nous avons largement traité du problème que constitue l‘adaptation des effets 
génétiques d‘ordre inférieur pendant la détection de l‘épistasie, moyennant l‘utilisation de 
différentes stratégies d‘adaptation pour les marqueurs dans la paire interactive SNP-SNP 
fonctionnelle et/ou les principaux marqueurs supplémentaires. Comme nous nous sommes 
limités dans cette thèse aux interactions à 2 loci, l‘adaptation des effets d‘ordre inférieur 




Malheureusement, la plupart des techniques de réduction de dimensionnalité basées sur la 
MDR ne nécessitent pas explicitement la présence d‘effets d‘ordre inférieur dans le 
‗modèle‘   lors de l‘étude des effets d‘ordre supérieur (une condition indispensable pour la 
plupart des méthodes traditionnelle à base de régression). Cependant, les résultats 
épistasiques peuvent être entravés par la présence d‘effets significatifs d‘ordre inférieur. Les 
résultats de cette étude ont montré une importante hausse des erreurs de type I lorsque les 
principaux effets ne sont pas pris en compte ou correctement comptabilisés. Nous avons 
également constaté que le codage additif (le code le plus utilisé en pratique) dans l‘adaptation 
des effets principaux n‘annule pas tous les effets principaux potentiels découlant de la 
variance génétique additive. Par ailleurs, l‘adaptation des principaux effets précédant la MB-
MDR (sur la base d‘un modèle à régression), peu importe le codage utilisé, ne contrôle pas 
l‘erreur de type I dans tous les cas. Dans le cadre de cette étude, nous avons conclu que la 
correction des effets d‘ordre inférieur devrait se faire de préférence moyennant le codage 
codominant, afin de réduire le risque de résultats épistasiques faussement positifs. Il est 
conseillé de réaliser une détection épistasique MB-MDR en adaptant toujours l‘analyse en 
fonction des effets d‘ordre inférieur des marqueurs étudiés, ―on-the-fly‖. Cette correction 
évite la surcorrection des autres marqueurs, qui ne font pas partie de la paire SNP interactive 
étudiée.  
Troisièmement, nous avons étudié l‘effet cumulé des déviations de caractère par rapport à la 
normalité et à l'homoscédasticité sur l‘ensemble des performances de la MB-MDR afin 
d‘identifier l‘épistasie entre 2 loci en l‘absence des principaux effets. Même si la méthode 
MB-MDR est une technique non paramétrique, autrement dit aucune hypothèse n‘est faite 
concernant les modes de transmission génétique, la réduction des données dans la MB-MDR 
dépend de tests d‘association. Plus particulièrement en ce qui concerne les caractères 
quantitatifs, la méthode MB-MDR standard à utiliser est le test t de Student (étapes 1 et 2 de 
la MB-MDR). Lorsque nous adaptons les effets d‘ordre inférieur pendant l‘analyse MB-MDR 
quantitative, nous agissons de manière intrinsèque dans un cadre de régression. Le test t de 
Student étant la racine carrée du test f ANOVA, les hypothèses ANOVA doivent dès lors être 
rencontrées pour que la MB-MDR donne des résultats valides. C‘est pourquoi, nous avons 
simulé des données de distributions normales et anormales, avec des variances constantes et 
non constantes et avons réalisé des tests d‘association via le test t et la variance inégale du 
test t, mieux connu sous le nom de test de Welch. Il est étonnant de voir à première vue, que 




appropriées, indépendamment de la distribution des données ou du test d‘association utilisé. 
D‘un autre côté, la méthode MB-MDR donne lieu à des résultats moins performants pour les 
données anormales en comparaison avec les données normales. Conformément aux tests 
d‘association utilisés dans le cadre de la méthode MB-MDR, le test de Welch est le plus 
souvent, moins performant que le test t. Afin de garder l‘équilibre entre les performances et 
l‘erreur de type I, nous avons conclu que lorsque nous réalisons une analyse MB-MDR avec 
des caractères quantitatifs, il convient idéalement de ramener les caractères à la normalité 
avant d‘appliquer une MB-MDR avec comme test d‘association, le test t de Student. Il est 
évident qu‘il convient de vérifier de manière approfondie, avant d‘utiliser concrètement une 
méthode, son applicabilité aux données en question. Il s‘agit là d‘une pratique commune des 
biostatistiques et d‘une procédure d‘exploitation standard souvent oubliée dans 
l‘épidémiologie génétique, en particulier dans les études GWAI.  
En outre de la présentation des vastes études de simulation, nous avons également appliqué la 
méthode MB-MDR à certains problèmes de données réels. Ces analyses comprennent des 
analyses MB-MDR faites sur des traits de maladie complexe quantitative et binaire, 
premièrement dans le cas de l‘asthme/allergie et ensuite dans le cas de la maladie de Crohn. 
Dans deux des analyses présentées, la méthode MB-MDR a confirmé les résultats du test de 
régression logistique et du TDT. Le chapitre sur les développements méthodologiques 
susmentionnés a été initié sur la base d‘observations de la méthode MB-MDR sur des 
données réelles.  
Les composantes pratiques et théoriques de cette thèse confirment notre foi dans le potentiel 
du MB-MDR comme un moyen prometteur et polyvalent dans le cadre de l‘identification des 
effets épistatiques, indépendamment du concept (familial ou anonyme) et des traits de la 
maladie étudiée (binaires, continus, censurés, catégoriques, multi-varié). Cette polyvalence 
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Chapter 1: Introduction 
1.1 Complex Diseases 
Healthy functioning of the immune system is of paramount importance to everyone since it 
controls the ability to fend off illness and disease. What really causes disease and why it is 
that some people develop cancers while others develop heart attacks or why some people 
rather develop debilitating disorders such as arthritic conditions, Crohn‘s disease, Alzheimer 
disease, asthma, diabetes, multiple sclerosis, Parkinson disease, osteoporosis, glaucoma, 
depression, during their life-time, are easily formulated questions, yet with non-trivial 
answers. In contrast to diseases that are driven by a single gene (i.e., monogenic disease), the 
aforementioned diseases have a multifactoral genetic underpinning (i.e., polygenic). By 
definition, the etiology of complex diseases usually involves a combination of genetic, 
environmental, and lifestyle factors, most of which have not yet been identified [1]. This 
combination of different gene varieties, possibly having a modifying effect on each other (as 
the result of gene-gene interactions) or the potential modifying effect of the surrounding 
environment (as the result of gene-environment interactions) may lead to the development or 
progression of disease in some individuals but not in others. Complex diseases are indeed 
―complex‖ and it leaves no doubt that finding the causal mechanisms of a complex disease 
will be a challenge in genetic epidemiology for several years to come [2]. In an attempt to 
characterize genetic contributors to (complex) diseases, there exist several tools to collect 
genetic data, analyze or process in order to derive useful information from them.  
This chapter presents a brief overview of important developments in genetic association 
studies that are relevant for the sequel of this thesis. We start by outlying how genetic 
information can be captured and summarize commonly used criteria to check data quality. In 
Section 1.8, we motivate studying gene-gene interactions and describe the foundations on 
which this work is built.  
1.2 Human Genetic Information 
Individual genomes stored in the sequence of deoxyribonucleic acid (DNA) can differ 
greatly, from single-letter changes to complex structural differences over chunks of up to a 




nucleotide bases: adenine (A), guanine (G), cytosine (C), and thymine (T). Several sources of 
genomic variation in humans exist causing uniqueness from one individual to the other. 
1.2.1 Single Nucleotide Polymorphisms  
Single nucleotide polymorphism (SNP) refers to a single base pair change that is variable 
across the general population at a frequency of at least 1%.  Each SNP represents a difference 
in a single DNA building block. There are two types of nucleotide base substitutions resulting 
in SNPs: 1) a transition substitution which occurs between purines (A, G) or between 
pyrimidines (C, T) and 2) a transversion substitution which occurs between a purine and a 
pyrimidine. The former constitutes two thirds of all SNPs [5]. A SNP in a coding region may 
be referred to as synonymous if the substitution causes no amino acid change to the protein it 
produces or as non-synonymous if the substitution results in an alteration of the encoded 
amino acid. The different bases, either A, T, C or G, present at a SNP location are known as 
alleles. In humans, most SNPs are bi-allelic, indicating there are two possible bases at the 
corresponding site within a gene (e.g. A and a).   From these SNP bases, three allele 
combinations known as genotypes in a population can be observed: the homozygous 
wildtype, AA, heterogeneous, Aa and homozygous rare, aa. In this thesis, we will use SNPs 
as genetic markers. 
1.2.2 Copy Number Variations  
While most initial studies of genetic variation concentrated on individual nucleotide 
sequences (SNPs), investigators have also found that large-scale changes involving loss or 
gain of the DNA sequence occur in many locations throughout the genome. Structural 
variations such as insertions, deletions, inversions, duplications, translocations and copy 
number variations (CNVs) result in changes in the physical arrangement of genes on 
chromosomes. Redon et al. [6] defined a CNV as a DNA segment of one kilobase or larger 
that is present at a variable copy number in comparison with a reference genome.  During the 
past several years, hundreds of new variations in repetitive regions of DNA have been 
identified, leading researchers to believe that CNVs are also an important component of 







Epigenetics is another type of genetic variation used to describe
 
heritable features that control 
the functioning of genes within an individual cell but do not constitute a physical change in 
the corresponding DNA sequency [9]. This type of variation arises from chemical tags that 
attach to DNA and affect how it gets read. At some alleles, the epigenetic state of the DNA 
and associated phenotype can be inherited transgenerationally [10, 11]. 
1.3 Quality Control 
It is important that prior to any statistical analysis, a quality control step is carried out. This 
step is needed to carefully consider and account for potential marker errors that could lead to 
false significant association [12]. Essential criteria used for genomic data quality control 
involve Hardy-Weinberg equilibrium handling, minor allele frequency checks and genotype 
call rate control. For more details about the standard quality control filters for genome-wide 
association studies, we refer to the Travemunde Criteria [13, 14]. Our lab is currently 
developing a minimal protocol for genome-wide association interaction screening. 
1.3.1 Hardy-Weinberg Equilibrium  
Hardy-Weinberg equilibrium (HWE) refers to the independence of alleles at a single site 
between two homologous chromosomes. Unless specific disturbing influences (e.g. non-
random mating, random genetic drift) are introduced the allele and genotype frequencies 
remain constant from generation to generation [15]. HWE is recommended to be checked 
only in founders or in controls due to the fact that departures from HWE may arise in 
diseased individuals if a genuine association exists between the SNP and the disease [16-20]. 
SNPs that are out of HWE (after multiple correction) are excluded from further analysis. For 
a bi-allelic locus, the de Finetti diagram is extensively used to graphically represent 
relationships between genotype frequencies [19, 21]. No consensus exists on the appropriate 
threshold for HWE p-values [22]. 
1.3.2 Minor Allele Frequency  
The minor allele frequency (MAF) refers to the frequency of the least common allele at a 
variable site. Most genetic association studies are based on the common disease-common 




variant (CDRV) hypothesis is gradually taking place [23]. In the context of former CDCV 
hypothesis, rare SNPs with MAFs less than 5% are often excluded from analysis.   
1.3.3 Genotype Call Rate  
The (per SNP) genotype call rate refers to proportion of genotypes per marker with non-
missing data (i.e. the proportion of observed genotype counts). It is common practice to 
remove markers with a call rate less than 95% [12, 24-26].  
1.4 The Principles of Genetic Association 
A genetic association refers to statistical relationships in a population between an individual's 
genetic information and a phenotype. The genetic association can be either direct or indirect, 
depending on whether the allele under investigation directly influences the phenotype or 
whether the allele is in linkage disequilibrium (LD) with the disease-predisposing mutation 
[27]. LD refers to the non-random association between two alleles at two loci on a 
chromosome in a natural breeding population [28]. An important advance towards enabling 
efficient genetic association studies was the determination of LD patterns on a genome-wide 
scale through the HapMap project [29].  
According to Foulkes [9], genetic association studies can be roughly divided into four 
categories: candidate polymorphism, candidate gene, fine mapping and whole genome-wide 
scans. Two fundamentally different designs are used in genetic association studies: family-
based designs and population designs that use unrelated individuals (see Table 2 of [30] for a 
comprehensive list of commonly used designs). 
1.4.1 Candidate Polymorphism Studies 
Candidate polymorphism studies involve investigations of associations between a marker and 
a trait for which there is an a priori hypothesis about functioning.  These studies rely on prior 
scientific evidence suggesting that the set of SNPs under investigation is relevant to the 
disease trait.  The goal of these studies is to determine whether a given SNP or a set of SNPs 
is functional and has a direct influence on the trait.   
1.4.2 Candidate Gene Studies 
Unlike candidate polymorphism studies which look at SNPs irrespective of common location 




choice of SNPs depends on predefined linkage disequilibrium blocks. The SNPs being 
studied in these studies are not necessarily functional. Recall that the underlying criterion 
linked to LD is that the SNPs under investigation capture information about the genetic 
variability of the gene under consideration, though the SNPs may not serve as the true 
disease-causing variants. Currently, candidate gene studies are mainly used to validate 
findings from genome-wide association studies as well as further exploring of additional 
associations based on clinical variables (see Section 1.4.4).   
1.4.3 Fine Mapping Studies 
Fine-mapping involves the identification of markers that are very tightly linked to a targeted 
gene. These studies aim to determine precisely where on the genome the mutation that causes 
the disease is positioned. Within the context of mapping studies, the term quantitative trait 
loci (QTL) is used to refer to stretches of DNA containing or linked to the genes that underlie 
a quantitative trait.  
1.4.4 Genome-wide Association Studies 
Like candidate gene approaches, genome-wide association (GWA) studies aim at identifying 
associations between genetic markers and a trait. However, GWA studies tend to be less 
hypothesis driven and involve characterization of a much larger number of SNPs [9]. The 
shift from candidate gene to GWA studies  has been made possible through the completion of 
the Human Genome Project in 2003 [31]  and the International HapMap Project in 2005 [32]. 
GWA studies have been successful in identifying genetic associations with more than 1600 
published GWA studies on SNPs at a genome-wide significance level 8105 p  for more 
than 280 traits [33, 34]. 
1.5 Sequencing 
Recent advances in sequencing technology has enabled the identification of rare variants 
(MAF<5%) [35]. Apart from SNPs, rare variants have been reported to contribute to the 
genetic variation of complex diseases as well [36].  Sequencing is the process of reading the 
nucleotide bases in a DNA molecule hereby looking at all portions of the genome, not just 
those that include instructions for making proteins [37]. Sequencing a person‘s entire genetic 
code is known as whole-genome sequencing.  Exome sequencing refers to the processing of 




genome [38]. Although exome sequencing has recently been shown to expedite disease gene 
discovery, it misses non-coding variation and some structural variations [39-44]. As the cost 
difference between exome and whole-genome sequencing shrinks, additional methods are 
needed to analyze the wealth of information whole-genome sequencing provides [45, 46].  
1.6 Genetic Models in GWA Studies 
In order to determine the appropriate test for association, a genetic model must first be 
specified [47]. One of the important components of a genetic model involves the inheritance 
pattern, the transmission of material from parent to offspring. When the transmission 
involves genetic material, the inheritance is termed genetic inheritance. There are several 
modes of inheritance (genetic and non-genetic) and these can be categorized into three 
groups: single gene or Mendelian (genetic conditions caused by a mutation in a single gene 
follow predictable patterns of inheritance within families), Multifactorial (inheritance pattern 
resulting from an interplay between genetic factors and environmental factors as in complex 
diseases) and Mitochondrial (inheritance from the mother's egg) [48]. Mendelian inheritance 
can be further categorized into autosomal dominant, autosomal recessive, X-linked dominant, 
X-linked recessive. Dominant conditions are expressed in individuals who have just one copy 
of the mutant allele whereas recessive conditions are clinically manifest only when an 
individual has two copies of the mutant allele. For X-linked inheritance, the gene causing the 
trait or the disorder is located on the X chromosome [49]. 
However, due to the absence of sufficient biological understanding of genetically complex 
diseases, the true underlying mode of inheritance is rarely known [50, 51]. Researchers 
customarily test several genetic models and choose the most parsimonious model to explain 
the data at hand [52, 53]. In other words, the choice is often driven by convention or 
convenience.  Most used genetic models include, but are not limited to additive, recessive, 
dominant, codominant, multiplicative [54]. These models are defined based on another 
component of genetic models called the penetrance parameter of the trait allele. Penetrance 
parameters specify the relationship between genotype and trait [55]. For a dichotomous trait, 
a penetrance parameter is defined for each genotype as the P(trait|genotype). For a 
quantitative trait, Y, the penetrance function describes the distribution of the trait conditional 
on an individual's genotype, f(Y|genotype).   
In population association studies (e.g. case-control studies), the risk of disease is interpreted 




disease when having two copies of affected allele is arbitrarily different from having a single 
copy. Under the dominant model, a single affected allele increases disease risk whereas under 
the recessive model, two copies of the affected allele are required for increased risk. Under 
the additive model, having two affected alleles have twice increased risk as compared to 
having a single affected allele.  Under the multiplicative model, the increased risk of having 
two affected alleles is a square of having a single affected allele [56, 57].  The analysis for the 
multiplicative model is performed by allele not genotype and requires both case and control 
genotypes to be in be in Hardy–Weinberg Equilibrium [58]. 
In the context of quantitative traits, phenotype variability can be attributed to genetic 
variation and environmental variation. The proportion of phenotypic variance that is 
attributable to genotypic variance is known as heritability [59]. In quantitative GWA studies, 
genetic variance is often further divided into additive and dominance variance.  Variance in 
phenotype can also result from epistatic effects and hence the variance decomposition can be 
extended to multiple loci. For instance, for a two-locus interaction, the epistatic variance 
decomposition can be attributed to additive-additive (interactive effect of two alleles, one 
from each locus), additive-dominance (interaction effects of three alleles, one from one locus 
and two from the other) and dominance-dominance (interactive combinations of four alleles, 
two from each locus) [60].  
1.7 From GWA Studies to Genome-wide Association Interaction Studies 
Hundreds of millions of dollars have been spent on GWA studies and more than 400 
susceptibility regions identified but still most of the genetic variance in risk or quantitative 
trait for most common diseases remains undiscovered. Genome-wide association studies have 
led to the identification of >1 600 loci harboring genetic variants associated with >280 
common human diseases and traits [34].  
Although great progress in genome-wide association studies has been made, the significant 
SNP associations identified by GWA studies account for only a few percent of the genetic 
variance, leading many to question where and how we can find the missing heritability. The 
proportion of heritability apparently explained by GWA studies has grown (to 20–30% in 
some well-studied cases and >50% in a few), but, for most traits, the majority of the 
heritability remains unexplained [61]. This has led the field of genetics to be faced with a 
dilemma now known as the missing heritability problem [62]. Several possible explanations 




with small effects (small effects virtually eliminates any detectable signal and requires 
unfeasibly large sample sizes to allow detection), rare variants (when GWA studies began, 
the field was dominated by the simple common disease–common variant hypothesis), 
population differences (most genetic variations are associated with the geographical and 
historical populations in which the mutations first arose), disease heterogeneity (some 
diseases are actually simply collections of symptoms, which may stem from multiple, distinct 
genetic causes), copy number variation (see Section 1.2.2), epigenetic inheritance (see 
Section 1.2.3), and lastly the focus of this thesis, epistatic interactions (genes associated with 
the same disease, compared to genes associated with different diseases, more often tend to 
share a protein-protein interaction and a gene ontology biological process). 
1.8 Genome-wide Association Interaction (GWAI) Studies   
The complexity of genetics of human complex diseases can be largely attributed to epistatic 
or gene-gene interactions [66]. The presence of gene-gene interactions is of particular 
concern in complex disease genetics because if the effect of one locus is altered or masked by 
effects at another locus, power to detect the first locus is likely to be reduced and elucidation 
of the combination of independent effects at the two loci will be hindered by their interaction. 
If more than two loci are involved, the situation is likely to be further complicated by the 
possibility of complex multi-way interactions among some or all of the contributing loci. 
The term ‗epistasis‘ was initially used by Bateson [67] to refer to a masking effect whereby a 
variant or allele at one locus prevents the variant at another locus from manifesting its effect. 
In other words, it refers to a distortion of Mendelian segregation ratios due to one gene 
making the effect of another. Few years later, Fisher [68] defined epistasis in a statistical way 
in terms of deviations from a model of multiple additive effects  with respect to a quantitative 
phenotype. 
Note that, depending on the scale used to assess these deviations, different definitions for 
epistasis are implied. Moreover, the same terminology has been used in different areas with a 
totally different meaning. What is meant by epistasis may vary depending on whether 
biologists, epidemiologists, statisticians, or human and quantitative geneticists are involved 
[69]. This has led in the past to a lot of confusion and uncertainty about how to best approach 





1.8.1 Biological Epistasis and Statistical Epistasis  
Epistasis can be viewed from two major perspectives, biological and statistical, each derived 
from and leading to different assumptions and research strategies. The two perspectives have 
been reviewed in detail by Moore and Williams [70]. We use this article as an anchor article 
for this and the next section to illustrate biological and statistical epistasis.  
It should be noted that biological epistasis results from physical interactions among 
biomolecules (e.g. DNA, RNA, proteins, enzymes, etc.) within gene regulatory networks and 
biochemical pathways and occurs at the cellular level in an individual. On the other hand, 
statistical epistasis (in the Fisher sense, extended to non-qualitative traits) occurs at the 
population level and is realized when there is inter-individual variation in DNA sequences 
(vertical bars, Figure 1.1). Here it is assumed that the relationship between multi-locus 
genotypes and phenotypic variation in a population is not predictable based solely on the 
actions of the genes considered singly. The existence of biological epistasis may go 
undetected at a population level, due to a variety of reasons, including power of the statistical 
analysis approach. Hence, under ―optimal‖ conditions, biological variation may be viewed as 
sufficient for the statistical detection of epistasis. Biological epistasis can nevertheless occur 
in the absence of statistical epistasis when every individual sampled from a population is the 
same with respect to their DNA sequence variations and biomolecules (circle, square and 
triangle, Figure 1.1). Vice versa, evidence for statistical epistasis may not always be easily 
translated into biological epistasis. The key challenge is to develop methodologies that can 







Figure 1. 1 The conceptual relationship between biological and statistical epistasis. Source: 
Moore and Williams [70].  
1.8.2 Importance of Epistasis 
The limitations of data collection when considering humans (ideally several 1000nds of 
homogeneous samples are obtained to unravel disease-related gene-gene interactions [71-
73]), as well as the inability to perform rigorous genetic experiments on human subjects, 
hampers the quest for knowledge about genetic mechanisms operating on human complex 
disease traits.  The progress in understanding human disease genes owes much to research in 
experimental organisms [74-76]. Animal models have greatly improved our understanding of 
the cause and progression of human genetic diseases and have proven to be a useful tool for 
discovering targets for therapeutic drugs [77].   
An important lesson learnt from model organisms is that orthologous genes are ubiquitously 
present in living organisms (i.e. there are certain genes that all living organisms from a 
common ancestor have because they perform very basic life functions). This knowledge has 
been extremely important in human genetics. The function of many identified human disease 
genes has been inferred from functional information about its ortholog in model organisms 
[78, 79]. Of human genes, 50% are orthologous with yeast. In addition, the near-complete 
sequence of the mouse genome reveals that 99% of mouse genes turn out to have analogues 
in humans and that most mouse and human ortholog pairs have a high degree of protein 




clearly share some similar biochemical processes, evidence in one organism may give 
important clues about functioning and existing processes in another.  
Just as model organisms have been instrumental in defining the roles of genes and the 
structure of genetic pathways that are important for human disease in GWA studies, they are 
equally useful in defining the principles of epistasis or to detect gene-gene interactions. 
Moreover, experimental organisms may be even more useful in the context of gene-gene 
interactions than for the characterization of the functions of individual genes, because – to 
date - the power resulting from genetic tractability (i.e. one can take genes out of an organism 
or put genes into it very easily) is often compounded in studies of gene interaction [76]. Mice 
is the most genetically tractable of mammalian species [81]. 
Studies in model organisms have shown that epistatic interactions may occur frequently and 
can even involve more than two loci [82, 83]. For instance, novel loci that act through 
epistatic pathways have been identified through multidimensional scans of complex traits in 
mice [84, 85], Drosophila [86], chicken [83, 87], plants [88, 89] and rats [90, 91]. These 
studies suggest that multiple interacting genes can influence complex phenotypes often in the 
absence of significant single-locus effects [92]. However, other similar studies have reported 
only low levels of epistasis or no epistasis at all, despite being thorough and involving large 
sample sizes [91, 93, 94]. This clearly indicates the complexity with which multifactorial 
traits are regulated; no single mode of inheritance can be expected to be the rule in all 
populations and traits. 
A handful of evidences exist for humans. Some of the  existing ones have been cited in 
Phillips [95]. Examples include diabetes [96], coronary artery disease [97], bipolar effective 
disorder [98], and autism [99]. To date, only for some of the reported findings additional 
support could be provided by functional analysis, as was the case for multiple sclerosis. Here, 
Gregersen et al. [100] found evidence that natural selection might be maintaining linkage 
disequilibrium between several different histocompatibility loci (DR2a and DR2b) known to 
be associated with multiple sclerosis. A more recent example involves Alzheimer‘s disease 
(AD). Combarros et al. [101] replicated an interaction between IL-6 and IL-10 on AD  that 
was found in their preliminary study in the Rotterdam dataset and had been reported earlier 
by Infante et al. [102]. 
Finally, looking into epistatic interactions might lead to the uncovering of cryptic genetic 




way to a better understanding of the mechanism of disease-causing genetic variants and of the 
role epistasis may play in explaining human variation and human health. In this thesis, we 
make the assumption that epistasis is a natural thing to occur but we remark that there are 
also complicating factors that make its detection difficult (discussed in the next section).   
1.8.3 Statistical methods to detect epistasis 
The number of identified epistatic effects in humans (not necessarily replicated!), showing 
susceptibility to common complex human diseases, follows a steady growth curve [106, 107], 
due to the growing number of toolbox methods and approaches.  
Most of the developed methods to detect epistasis have not yet been successfully applied in 
the context of genome-wide real-life data (success here defined as biologically or clinically 
relevant), mainly due to two issues; 1) GWAI methods are computationally intensive and 2) a 
large number of samples are needed to be translated into sufficient power to detect epistatic 
effects from 100 thousands of SNPs, which are usually not available. In the absence of 
efficient computational algorithms or a powerful IT environment, GWAI studies may become 
practically infeasible, since the number of possible SNP-SNP interactions grows 
exponentially with the number of involved SNPS. One way to deal with the exponential 
increase is to pre-select ―interesting‖ regions of the genome, hereby reducing the 
computational burden. Typical for large-scale epistasis studies, such as GWAI studies, is that 
one has to deal with a ‗small n big p‘ problem, where the number of samples (n) is much 
smaller than the number of variables (p) [20, 108], potentially giving rise to curse of 
dimensionality problems. The expression curse of dimensionality is due to Bellman [109] and 
in statistics it relates to the fact that the convergence of any estimator to the true value of a 
smooth function defined on a space of high dimension is very slow. This curse is particularly 
a problem when solving the epistasis detection problem within a parametric paradigm, such 
as when adopting a regression framework.  
Standard (automatic) stepwise procedures that are popular in regression-based model-
building may also miss interactions that occur in the absence of detectable main effects [110].  
In addition, regression-based approaches may not be optimal in identifying interactions when 
they are applied to rare variants because of the rare variants‘ low frequencies and weak 
signals [42, 111]. Hence, more advanced and efficient methods are needed to identify gene–




To date, several methods (beyond simple regression approaches) in epistasis screening 
methodology have been released [20], and several criteria have been used in an attempt to 
make a classification of the available approaches. Some of these criteria are:  the strategy is 
exploratory in nature or not, modeling is the main aim or testing is, the epistatic effect is 
tested indirectly or directly, the approach is parametric or non-parametric, the strategy uses 
exhaustive search algorithms or takes a reduced set of input-data, that may be derived from 
prior expert knowledge or some filtering approaches. Shang et al. [112] based on Kilpatrick 
[113] identified thirty-six methods and classified them into three categories according to their 
search strategies. The classifications used as presented in Figure 1.2 are exhaustive search, 
stochastic search, and heuristic search.  
Despite the fact that Shang et al. [112] classified several methods into a category based on a 
general search strategy, issues still remain on how to compare performances of these 
methods. Comparing epistatic methods (mainly done via simulation-based power studies) 
seems to be comparing ―apples and oranges‖ because the comparison is not a direct 
comparison of key characteristics of the methods themselves but of a ―total approach‖.  For 
instance,  BOOST of Wan et al. [114] and AntEpiSeeker  of Wang et al. [115] both involve 
two-stages testing in order to determine whether the interactive effect of a SNP pair is 
significant. BOOST uses a likelihood ratio test in the first stage and a chi-squared test in the 
second stage. On the other hand, AntEpiSeeker, a two-stage ant colony optimization 
algorithm uses a chi-squared test in the first stage and in the second stage it conducts an 
exhaustive search of interactions within the highly suspected SNP sets, and within the 
reduced set of SNPs with top ranking trait levels. When data consist of binary observations, 
the score statistic is the same as the chi-squared statistic in the Pearson's chi-squared test. 
Only when the sample size becomes large, the statistical power of the score test will be 
similar to that of the likelihood ratio test. Hence, the question of interest is to know how 
methods would compare when making them as alike as possible, in the sense of replacing test 
statistics by their (statistically) most optimal counterparts and using the same multiple testing 
correction strategy (when the nature of the method allows doing so). This requires adapting 







Figure 1. 2 Classification of the methods that detect epistasis. 
Legend All methods can be classified into three categories according to their search 
strategies, i.e., exhaustive search, stochastic search, and heuristic search. Methods with bold 





Among the methods presented in Figure 1.2 is the Multifactor Dimensionality Reduction 
(MDR), a non-parametric method of Ritchie et al. [116]. MDR offers an alternative to 
traditional statistical methods such as logistic regression. The method is model-free and non-
parametric in the sense that it does not assume any particular genetic model and that it does 
not estimate any parameters, respectively. MDR nicely tackles the dimensionality problem 
involved in interaction detection for binary traits by pooling multi-locus genotypes into two 
groups of risk based on some threshold value. Those cells with a case/control ratio equal to or 
above the threshold are labeled as High-risk and the remaining cells as Low-risk. The main 
steps of MDR are presented in Figure 1.3.   
However, the first versions of the MDR method had some ‗major‘ drawbacks including that 
some important interactions could be missed due to pooling too many cells together. For 
instance, in the case where there are cases but no controls, the cell is labeled High risk and 
when there are controls but no cases, the cell is labeled Low risk. It is only restricted to binary 
traits (case-control studies and discordant sib-pairs) with balanced designs (i.e., it strictly 
required each individual in the dataset to have observed data for each variable otherwise the 
program would crash). The method could not adjust for lower-order effects and confounding 
factors. In addition, an MDR analysis could only reveal at most one significant epistasis 
model with the selection based on computationally demanding cross-validation and 
permutation strategies. For each number of factors under consideration, the best model 
selected by MDR is the one with the lowest prediction error and maximum cross-validation 
consistency. The 10-fold cross-validation procedure may be repeated a number of times to 
reduce the possibility of poor estimates of the prediction error that are due to chance divisions 
of the data. In this case, selection criteria are averaged over runs.  
The easy-to-use and well-documented MDR software supporting the MDR method and its 
initial successes in practice (e.g. [117-120] ), stimulated researchers to look more closely into 
dimensionality reduction methodologies as a way to make progress in GWAI studies. The 
MDR community was born. MDR open source version is freely available via 
www.epistasis.org and http://ritchielab.psu.edu. 
Since its conception, about 400 methodological and applied papers have emerged that build 
on or use multifactor dimensionality reduction principles. Table 1.1 shows a list of MDR-
related (methodological) papers that were published since the first publication of MDR in 
2001, till the time this thesis was submitted. In particular, Table 1.1 provides information 




individuals), the outcome type that the method was applied to, the ability to deal with 
population stratification, the ability to handle missingness or requires complete cases 
(requiring a priori imputation impute) and whether the method allows for covariates or 
confounders adjustment. The last column of Table 1.1 summarizes/discusses the key features 
of the variation to the initial MDR method. We remark that although some of the methods 
can be extended beyond what has currently been described for the study design, we limited 
our categorization to those situations explicitly discussed in the referenced research papers. 
While it ‗might not be exhaustive‘, we tried our best to collect all available papers; the 
collection was obtained through PubMed searches (www.ncbi.nlm.nih.gov/pubmed: with 
―multifactor dimensionality reduction‖ in the abstract or main body of the manuscript) and 
the ―epistasis blog‖ (www.epistasis.org). We also appended our own work (published or 
submitted papers, papers under construction and presented abstracts).   
 
Figure 1. 3 Summary of steps involved in implementation of the MDR method. 
Legend A set of n genetic and/or discrete environmental factors is selected; the n factors and 
their possible multifactor classes or cells are represented in n-dimensional space; each 
multifactor cell in n-dimensional space is labeled as either ―High-risk‖ or ―Low-risk‖; and the 
prediction error of each model is estimated. For each multifactor combination, hypothetical 
distributions of cases (left bars in boxes) and of controls (right bars in boxes) are shown.  




















Extensions to the original method 
MDR 1 1 2 4 3 Ritchie et al. 2001 [116] 
 
MDR 1 1 2 3 3 Hahn et al. 2003 [121] 
handles missing data by defining a new fourth  level to be used when missing data is encountered, overcoming 
the need to only use complete data for analysis 
EMDR 3 1 2 3 3 Mei et al. 2005 [122] 
provides model selection without cross validation, and use a chi-square statistic as an alternative to prediction 
error. 
MDR-PDT 3,4 1 2 3 3 Martin et al. 2006 [123] 
handles families of diverse structure, overcoming the restriction of MDR  to family data of  discordant-sib-pairs  
or trios  
MDR 1 1 2 3 3 Motsinger et al. 2006 [124] reduces  the number of MDR Cross validation intervals  from ten to five hence  reduced computation time 
OR MDR 1 1 2 3 1 Chung et al. 2007 [125] 
uses the odds ratio as a quantitative measure of disease risk, allowing one to quantify the  measure of disease risk 
for each combination of genotypes. In addition it reduces false positives and negative errors when the ratio of 
cases to controls in a cell is equal to the preset threshold  
MDR 1 1 2 3 3 Velez et al. 2007 [126] 
accommodates imbalanced designs and utilizes balanced accuracy instead of accuracy, overcoming restriction to 
only balanced designs 
GMDR 1,2 1,2 2 3 2 Lou et al. 2007 [127] 
applicable to both dichotomous and continuous outcomes in population studies and permits adjustment for all 
forms of confounding factors, overcoming restriction to only binary traits with no adjustment of confounders 
LM MDR 1 1 2 3 3 Lee et al. 2007 [128] 
estimates frequencies for empty cells from a parsimonious log-linear model,  improving  the MDR in classifying 
sparse or empty cells 
MDR-Phenomics 3 1 2 3 1 Mei et al. 2007 [129] 
identifies genetic effects within triad families by integration of phenotypic variables into MDR, hereby  
controlling for genetic heterogeneity 
MDR 1 1 2 3 3 Bush et al. 2008 [130] 
replaces classification error with different contingency measures to score model quality in order to improve the 
ability of MDR to detect gene-gene interactions 
PGMDR 3,4 1,2 2 3 2 Lou et al. 2008 [131] 
accommodates family-based designs of diverse structure  instead of only sib-pairs and trios, also accommodating 
continuous traits  
MB-MDR 1 1 2 1 2 Calle et al. 2008a,2008b [132, 133] 
R-based method that introduces 3 risk group categories to avoid over pooling of individuals to 2 groups, outputs 
more than 1 model, adjusts for confounding factors and uses simulation-based null distribution to test for 
multiple testing, performs multiple testing separately for the high-and low-risk groups and averages the 
respective corrected p-values to obtain an overall significance, uses logistf to address the issue of parameter 
separation  
FAM-MDR 4,5 2 2 1 2 Cattaert et al. 2008a, 2010 [134, 135] 
extends the MB-MDR to family data with the familial structure is removed  via a polygenic model using the 
GenABLE package and residuals are used as the new traits, adjusts for covariates on polygenic residuals  in a 
regression step and uses the new residuals at the new traits for FAM-MDR modeling, adopts a permutation 




MDR 1 1 2 3 3 Motsinger 2008 [136] 
uses n-locus permutation test, a separate null distribution is created for each n-level of interaction rather than an 
omnibus permutation test where a single null distribution is generated from the best model of each of at least 
1000 randomized datasets. The comparison analysis confirmed the need to stick to the omnibus permutation test 
since it controls false positives without limiting power. 
MDR 1 1 2 3 3 Pattin et al. 2009 [137] 
tests hypothesis  using an extreme value distribution instead of permutation test , overcoming the computational 
burden while maintaining power 
MB-MDR 1 1 2 1 2 Van Steen et al. 2010a, 2011 [138, 139] 
C++ based MB-MDR that adopts step-down maxT procedure to adjust for multiple testing  instead of a simple 
permutation strategy, applied to noisy data on binary outcomes  
MB-MDR 2 2 2 1 2 
Mahachie John et al. 2010aa, 2011 [140, 
141] 
extends C++ MB-MDR to noisy data on continuous outcomes with and without adjusting for functional SNPs. 
Adjustment of the functional SNPs is performed in a regression based model and the residuals are considered as 
new traits for MB-MDR  
MB-MDR 2 2 2 1 2 
Mahachie John et al. 2010ba, 2012 [142, 
143] 
extends adjustment of SNPs to non-functional SNPs as well. Different strategies are used to adjust prior to C++ 
MB-MDR as well as "on the fly adjustment", where the main effects of the interaction pair under investigation 
are adjusted for while running MB-MDR 
MB-MDR 2 4,5 2 1 3 Savenije et al. 2010a [144] 
extends C++ MB-MDR to multiple continuous traits using the Hotelling's T2 test to allocate risk groups. When 
the original outcome is discrete, multinomial logistic regression if first applied and residuals are used as new 
traits in MB-MDR 
MB-MDR 1 1 2 1 2 Cattert et al. 2010a [145] 
multi-locus genotype cells in C++ MB-MDR are allocated based on ranking procedures (e.g. ranked according to 
their case to control ratios and apply the Wilcoxon rank-sum test of association between disease status and  these 
ratios) hereby improving allocation of cells  to High- and Low-risk groups and performance of MB-MDR 
MB-MDR 1,2 1,2 2 1 2 Urrea et al. 2010 [146] 
R package for R-based MB-MDR. The package now incorporates continuous outcomes in addition to only binary 
as at conception  
PWMDR 1 1 2 3 3 He et al. 2010 [147] 
addresses the issue of sparse and empty cells in higher dimensional contingency table by scoring each pair-wise 
interaction of the genetic factors involved and combine the scores of all such pair wise interactions 
MDR 1 1 2 3 1 Gui et al. 2010 [148] extends MDR to adjustment of  only discrete covariates, allows MDR to at least incorporate some confounders 
SDR 1 3 2 3 3 Beretta et al. 2010 [149] 
extends MDR to survival outcomes while estimating individual multi-locus cells survival functions in a non-
parametric way via the Kaplan-Meier method hereby able to handle censored data too. 
RMDR 1 1 2 3 3 Gui et al. 2011a [150] 
extends MDR to 3 categories (High-, Low- and unknown risk- groups) while using the Fisher‘s Exact Test for 
determining whether specific genotype combinations should be included in the overall MDR.  The ―unknown risk 
group‖ is excluded when calculating the balanced accuracy of the MDR model.  
Surv-MDR 1 3 2 3 2 Gui et al. 2011b [151] 
extends MDR to survival outcomes. Instead of comparing the case–control ratio of each multi-locus genotype to 
a fixed threshold T, here  log-rank test statistics are used to compare the survival distributions of each multi-locus 
genotype combination and its complement 
MDR 1 1 2 3 1 Winham et al. 2011 [152] Extends MDR to R software for R friendly users via  MDR package 
PedGMDR 4 1,2 2 3 2 Chen et al. [153] 
builts a minimal sufficient statistic approach  [154]  into the GMDR framework, informative nonfounder 
generates a pair of statistics for transmitted and pseudo nontransmitted individuals, infers the nontransmitted 




PedG-MDR II 4 1,2 2 3 2 Chen  et al. 2011 [155] 
calculates the statistics on the observed sample directly (undoubled), and evaluates their p values by constructing 
the empirical reference distributions on the basis of the sufficient statistic on a null distribution, hence  
theoretically halve the computing burden and memory requirement of PedGMDR 
MDR-SP 1 1 1 3 2 Niu et al. 2011 [156] 
extends MDR to structured populations, uses an association test that is robust to population stratification, instead 
of using the ratio of cases to controls by MDR, to divide the multi-marker genotypes into high- and low risk 
groups 
SVM-based PGMDR 3,4 1,2 2 3 2 Fang et al. 2012 [157] 
allows detection for  the main and interaction effects from multiple genotype combinations in family data while 
accounting for confounding factors 
MB-MDR GWAI  
Protocol 
1,2,3,4,5 1,2,3,4,5 2 1,2 2 Gusareva et al. 2011a [158] 
GWA epistasis screening to enhance MB-MDR analysis on large-scale data 
 
MB-MDR  2 2 1 1,2 2 Gusareva et al. 2012aa, 2012b [159, 160] 
extends the MB-MDR to population structure which  is removed  via a polygenic model using the GenABLE 
package and residuals are used as the new traits in MB-MDR 
MB-MDR  2 2 2 1,2 2 Van Lishout et al. 2012a [161]  
 MB-MDR software description  with details on An Efficient Algorithm to Perform Multiple Testing in Epistasis 
Screening 
MB-MDR 1 3 2 1,2 2 Van Lishout et al. 2012ba* [162] extends MB-MDR to survival outcomes while using log-rank test to allocate risk groups 
Filter-based MDR 1 1 2 3 3 Dai et al. 2012 [163] involves global testing of p-values in conjunction with filtration process performed via ReliefF algorithm  
  
Explanation coding: 
1Subject design: 1) case-control, 2) other-unrelateds, 3) trios, 4) nuclear families, 5) extended pedigrees 
2Outcome Type: 1) binary, 2) continuous, 3) survival, 4) multivariate, 5) discrete other than binary 
3Population Stratification: 1) yes, 2) no 
4Missing genotypes allowed: 1) available cases, 2) method procedure deletes missing genotypes and only uses complete cases, 3) other, 4) no 
5Covariates allowed: 1) only categorical, 2) all form of covariates including SNP lower order effects, 3) no 





1.8.3.1 Model-Based Multifactor Dimensionality Reduction 
Within the context of extending the MDR method of Ritchie et al. [116], Calle et al. [132] 
developed the Model-Based Multifactor dimensionality reduction (MB-MDR) method, 
initially also focusing on dichotomous traits, accommodating confounding factors. The 
principal difference between MDR and MB-MDR, applied to binary traits, is that MB-MDR 
merges multi-locus genotypes exhibiting some significant evidence of H(igh) or L(ow) risk, 
based on association testing, rather than on comparison with a threshold value. In addition, 
those multilocus genotypes that either show no evidence of association or have no sufficient 
sample size contribute to an additional MB-MDR category, that of ‗no evidence‘. The 
introduction of the third category avoids pooling too many multilocus genotype cells together 
or forcing either a high risk or low risk label on them. The MB-MDR method, which now 
incorporates continuous traits as well, was first made available via an R package mbmdr 
[146].  
It should be noted that the original MB-MDR method, although overcoming the MDR 
weaknesses mentioned in Section 1.8.3, has some major shortcomings. Firstly, it outputs p-
values corrected for multiple testing via a simulation-based null distribution based on minor 
allele frequencies (MAFs). This leads to different null distributions for interaction pairs with 
different MAF combinations. As a consequence, the multiple testing procedure remains a 
cumbersome component. Secondly, Wald test statistics are used to test for associations. The 
Wald test is an asymptotic test and it assumes infinite amount of data [164, 165]. This is not 
the case when one compares multilocus genotypes, small sample sizes tend to be involved. In 
practice, infinite amounts of recorded data are never available. Hence, the Wald test is 
unreliable to use with MB-MDR or dimensionality reduction methods in general since it tends 
to be biased when data are sparse [166].  Thirdly, two types of null-distribution adjusted p-
values are obtained, one p-value for the H-labeled multilocus genotypes (tested versus the L 
risk genotypes) and one p-value for the L-labeled multilocus genotypes (tested versus the H 
risk genotypes), say PH and PL respectively. In order to correct for multiple aggregation of 
cells, the overall adjusted p-value for the interaction pair under investigation is then computed 
as the minimum of PH and PL. To note, the ‗no evidence‘ for risk category is not used when 
computing the adjusted p-values which is a drawback since, for data that are already hard to 
acquire, not all samples were used in the process. Fourthly, MB-MDR uses R package logistf 
[167], Firth's bias reduced logistic regression approach with penalized profile likelihood based 




guard against near-to-complete data separation problems leading to parameter estimation 
difficulties. However, logistf only targets binary traits with link function logit. 
Accommodating other link functions in the binomial family requires the implementation of 
package brglm (bias reduction in generalized linear models) [169]. Supported link functions 
are logit, probit, cloglog and cauchit.  Although brglm is currently implemented only for the 
binomial family, the upcoming version is expected to work with all families supported by 
generalized linear models [170]. 
Based on the aforementioned issues related to the first implementation of MB-MDR [132], 
our  lab decided to shift gears. We kept the ―core features‖ of the method and then used these 
as foundations to develop different ―faces‖ of the MB-MDR methodology, hereby addressing 
possible complications that emerged from practical applications on the fly. The software 
supporting this new viewpoint is also called MB-MDR and was written in C++ [171]. 
Because of its importance, we summarize again the core features of MB-MDR: 1) 
dimensionality reduction via multilocus genotype cell-labeling, allowing for a variety of label 
choices, depending on the evidence to enhance or reduce disease risk/mean trait/survival 
outcome, 2) association testing-based model selection instead of cross-validation-based model 
selection, where association tests are also used to derive the cell labels, 3) flexible multiple 
testing correction based on what is known from the ―multiple testing community‖.  
In what follows, we explain the different steps involved in MB-MDR analyses in more detail. 
For a sufficiently frequent bi-allelic marker, there are 3 theoretically possible genotypes. 
Hence, 2 bi-allelic markers give rise to 9 multilocus cells. Each of the 9 multilocus genotype 
cells alternatively constitute group 1. The remaining 8 multilocus genotypes constitute group 
2. The key MB-MDR steps, translated to analyze quantitative traits, using the default options 
of the MB-MDR software, are summarized in Figure 1.4. In MB-MDR step 1, a Student t-test 
at significance level 0.1 is used to compare the mean trait values in the 2 aforementioned 
groups of multi-locus genotypes. In step 2, the cell-based results of step 1 are used to label 
significant cells as H(igh) or L(ow) and non significant ones as ‗no evidence‘, O. The sign of 
the Student's t-test statistic is used to distinguish between H and L: a positive (negative) sign 
refers to H (L). The result is a dimensionality reduction from a categorical multilocus genetic 
explanatory variable with 9 factor levels, to a new categorical explanatory variable with factor 
levels (labels) H, L and O. A new association test is subsequently performed to assess the 
relation between the newly created construct and the quantitative trait, Y, of interest. In 




{L,O}-cells and one comparing the L-cells versus {H,O}-cells. In step 3, the overall 
significance is assessed by adopting the permutation-based maxT correction of Westfall and 
Young [172] with 999 replicates. This criterion uses all observations for every interaction 
under investigation and is independent of the minor allele frequencies. Thus, instead of being 
model allele frequency specific as in the original MB-MDR, we make use of permutation data 
to generate a reference distribution while maintaining type I control. Part of the computational 
concerns related to the aforementioned permutation-based significance assessment of multiple 
epistasis hypothesis tests jointly, were elevated by an improved implementation of the 
algorithm [171].  
The first evaluation of our method was on simulated binary data with and without noise by 
Cattaert et al. [139]. It showed that MB-MDR has increased power over MDR to identify 
gene–gene interactions for most considered genetic models, even in the presence of error 
sources. From a clinical point of view, binary outcomes may be preferred as they facilitate 
setting diagnostic criteria for disease and offer a simpler interpretation of common effect 
measures from statistical models (such as odds ratios and relative risks). These advantages 
come with some information-loss. From a statistical point of view, this loss of information 
implies that more human samples may be required to attain prespecified power levels [173]. 
In addition, since many diseases are not uniquely defined by a binary trait (e.g., there exist 
several non-categorical asthma-related phenotypes such as log IgE and sensitization level), 
the need to develop a continuous face of MB-MDR emerged. This is the subject of this thesis.  
Some of the challenges include dealing with a more refined/detailed phenotype, with potential 
outliers and a wide variety of underlying distributions, as well as fully exploiting this potential 
wealth of information in the search for gene-gene interactions. We remark that other faces of 
MB-MDR exist, which address censored traits, and multivariate traits as well. Their 
implementation in the MB-MDR software and their validation is ongoing. Although Figure 
1.4 presents a scenario for 2-order interactions using bi-allelic genetic markers, the ―core 
features‖ of MB-MDR naturally accommodate higher-order interactions and multi-allelic 
markers as well.  
  





Figure 1. 4 Summary of the steps involved in MB-MDR analysis.  Source: Mahachie John et 





Chapter 2: Aims and Thesis Organization 
2.1 Aims 
The main aim of this thesis was to investigate the performance of the MB-MDR methodology 
adapted to quantitative traits, to identify the bottlenecks and to develop solutions accordingly. 
Validation of new developments was mainly done via simulated data on quantitative traits for 
unrelateds, using a variety of 2-locus epistasis models and scenarios‘. Programs to simulate 
the data needed for our studies were written in R [174] and can be obtained upon request. In 
the validation assessment, special attention was given to power performance and false positive 
control properties. In addition to using simulated data, the ability to detect epistasis on real-
life data (binary and quantitative traits) was investigated as well.  
All MB-MDR based analyses were carried out with the C++ based MB-MDR software as 
introduced in Van Lishout et al. [171] and freely downloadable as an executable file from 
http://www.statgen.ulg.ac.be. Throughout this thesis, we will use MB-MDR interchangeably 
to indicate the ―method‖ and the ―software‖. Note that both method and C++ based software 
differ substantially from the MB-MDR method as developed by Calle et al. [175] (to date, 
accommodating both binary and continuous traits) and the associated R package ―mbmdr‖ 
with its implementation, as outlined in the main introduction section of this thesis. 
2.2 Thesis Organization 
The work presented in this thesis can be divided into two components: a methodological 
development component and a practical application component. Having presented the general 
introduction in PART 1, we present the methodological aspects of the thesis in PART 2, 
consisting of 3 chapters. In chapter 1, we investigate the power of MB-MDR to detect gene–
gene interactions in the absence or presence of error sources or noise (including genotyping 
errors, missing genotypes, phenotypic mixtures and genetic heterogeneity). In Chapter 2, we 
assess the performance of different corrective measures for lower-order genetic effects in 
MB-MDR epistasis detection. In Chapter 3, we evaluate the cumulative effect of deviations 
from normality and homoscedasticity on the overall performance of MB-MDR giving leads 
on the importance of adhering to general assumptions related to the implemented tests for 
association. We present practical applications in PART 3. In PART 4, we give a general 
discussion and future perspectives. Lastly, PART 5 presents a short curriculum vitae and the 
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Chapter 1 
Model-Based Multifactor Dimensionality Reduction to Detect Epistasis 






Detecting gene-gene interactions or epistasis in studies of human complex diseases is a big 
challenge in the area of epidemiology. To address this problem, several methods have been 
developed. One of these methods, Model-Based Multifactor Dimensionality Reduction, has so 
far mainly been applied to case-control studies. In this chapter, we evaluate the power of 
Model-Based Multifactor Dimensionality Reduction for quantitative traits to detect gene-gene 
interactions (epistasis) in the presence of error-free and noisy data. Considered sources of 
error are genotyping errors, missing genotypes, phenotypic mixtures and genetic 
heterogeneity. Our simulation study encompasses a variety of settings with varying minor 
allele frequencies and genetic variance for different epistasis models.  On each simulated data, 
we have performed Model-Based Multifactor Dimensionality Reduction in two ways: with 
and without adjustment for main effects of (known) functional SNPs. In line with binary trait 
counterparts, our simulations show that the power is lowest in the presence of phenotypic 
mixture or genetic heterogeneity compared to scenarios with missing genotypes or genotyping 
errors. In addition, empirical power estimates reduce even further with main effects 
corrections, but at the same time, false positive percentages are reduced as well. In 
conclusion, phenotypic mixtures and genetic heterogeneity remain challenging for epistasis 
detection, and careful thought must be given to the way important lower-order effects are 





Understanding the effects of genes on the development of complex diseases and traits in 
humans is a major aim of genetic epidemiology. These kinds of diseases are controlled by 
complex molecular mechanisms characterized by the joint action of several genes which 
could have different effect sizes, from small to large. In this context, traditional methods 
within a regression paradigm involving single markers have limited use and more advanced 
and efficient methods are needed to identify gene-gene interactions and epistatic patterns of 
susceptibility. Over the past few years, data dimensionality reduction methods such as 
Multifactor Dimensionality Reduction (MDR) developed by Ritchie et al. [1] and introduced 
in PART 1 of this thesis, have gained popularity as epistasis screening tool and alternative to 
the more traditional methods.  
Despite the fact that Luo et al. [2] in part recognized the necessity to adjust for covariates and 
to extend MDR to quantitative traits, issues related to significance assessment remain, as 
explained in detail by Cattaert et al. [3]. In addition, as much as geneticists try to avoid errors 
in the field of genetics, in reality, due to one reason or the other, data can be found to be 
associated with different error sources [4].  Given that the ―core features‖ of the Model-Based 
Multifactor Dimensionality Reduction (MB-MDR) methodology, as explained in PART 1 
(Section 1.8.3.1), naturally extend to quantitative traits, we evaluate the power of quantitative 
MB-MDR [5]  to detect 2-locus gene-gene interactions with bi-allelic SNPs, for data affected 




1.2 Materials and Methods 
1.2.1 Introducing noise 
Apart from simulating error-free data, we also simulate different error-sources to investigate 
their impact on the performance of MB-MDR. These involve introducing 5 and 10% missing 
genotypes (MG5 and MG10), 5 and 10% genotyping error (GE5 and GE10), 25 and 50% 
phenotypic mixtures (PM25 and PM50) and 50% genetic heterogeneity (GH). It is important 
to realize that the foregoing derivations of variance decomposition relate to a population as 
whole. When generating sources of error, estimates of variability will no longer tend to the 
estimates at the population level. In other words, the actual genotypic variance will no longer 
equal the assumed genetic variance. Missing genotypes (MG5 and MG10) and genotyping 
errors (GE5 and GE10) are also introduced in the null data, leading to a total of 255 
simulation settings, so as to be able to assess the impact of these on MB-MDR‘s type I error 
control in the presence of noise. 
In particular, scenarios MG5 and MG10 are generated by selecting genotypes completely at 
random from the original data and by setting them to missing. This introduces different per-
individual and per-SNP percentages of missingness, reducing the effective sample size, yet 
maintaining the validity of the variance components estimates. 
As in Ritchie et al. [6] genotyping error is simulated using a directed-error model of Akey et 
al. [7]. This model postulates that there is a larger probability for the minor allele to be 
consistently mis-genotyped (over-represented). In this study, either 5% (GE5) or 10% (GE10) 
of the available genotypes in the original data set are sampled. From these, homozygous 
genotypes for the common allele become heterozygous and heterozygous genotypes for the 
rare allele become homozygous.  The effect of adding genotyping errors to the original data is 
that the actual genetic contribution 
2
gen   to the trait variance is reduced compared to the 
assumed genetic variance 
2
g , of the simulation setting
 
due to the additional variability 




Table 1.1 Proportion  
22
ggen   of the total genetic variance in error-free data that is due to 
genetics in the error-prone data, exhibiting either 5% (GE5) or 10% (GE10) genotyping 




5% 10% 25% 50% 
 0.1 0.673 0.494 0.563 0.250 
M27 0.25 0.857 0.742 0.563 0.250 
 0.5 0.926 0.858 0.563 0.250 
 0.1 0.667 0.489 0.563 0.250 
M170 0.25 0.701 0.507 0.563 0.250 
 0.5 0.740 0.546 0.563 0.250 
 
Genetic heterogeneity is simulated such that there are actually two different two-locus 
combinations increasing/decreasing the phenotypic mean. Half of the individuals have one 
pair of functional SNPs (SNP1 and SNP2), and the other half have the other pair of functional 
SNPs (SNP3 and SNP4). Introducing the notations GL (GH) as the multi-locus genotypes 






Minor allele frequencies of all 4 functional SNPs are taken to be equal, i.e., 
0.5} 0.25, {0.1,p . 
Phenotypic mixing in genetics may occur when a percentage of individuals with high 
phenotypic mean have genotype combinations that are consistent with low phenotypic mean.  
In particular, a mixing proportion of  1,0w  of phenotypic mixture, trait values are 
simulated according to  
 
 
with mixing proportion either 25% (PM25) or 50% (PM50), and π, the probability of a multi-
locus genotype giving rise to a high phenotypic mean µH. 
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1.2.2 Adjustment for main effects 
In epistasis screening, some interactions can be identified simply because of highly significant 
lower-order effects, and are therefore not genuine. That is why we also in this chapter 
consider MB-MDR adjusted analyses in the following way: with and without adjustment for 
main effects of functional SNPs. Main effects are adjusted for in MB-MDR by first regressing 
them out in a data preparation step and then considering the residuals from the regression 
model as new traits. Two extreme ways of correcting are considered: the additive model and 
the codominant model. When adjusting for main effects in the presence of genetic 
heterogeneity, we take into account that different functional pairs are relevant for 
heterogeneous sub-populations.  
1.2.3 Data Simulation 
Data are simulated with 500 replicates in each simulation setting. Each replicate consists of 
1500 unrelated individuals and 10 SNPs, 2 of which are functional. The minor allele 
frequencies of functional SNPs (SNP1, SNP2) are taken to be equal, and varying 
as 0.5} 0.25, {0.1,),(=) ( ppp,p,p 21 , whereas the minor allele frequencies of a non-
functional marker SNPj are fixed at ,10…3,=j0.05,3)-(j+0.1= jp . All SNPs are 
assumed to be in Hardy-Weinberg Equilibrium and in linkage equilibrium. 
Two epistasis models that incorporate varying degrees of epistasis are considered: Model 27 
and Model 170 of Evans et al. [8], hereafter referred to as M27 and M170 respectively. The 
models can be illustrated as follows: 































Each row indexes the genotype at the first locus and each column refers to the genotype at the 
second locus. The number in each cell is the phenotypic mean for that genotype. In order to 
increase the phenotypic mean, M27 requires an individual to have at least one copy of the 
increaser allele at both loci whereas M170 requires an individual to be heterozygous at one 
locus and homozygous at the other. As p increases, the contribution to the total genetic 
variance of epistasis variance relative to main effects variances increases for M170 (decreases 




take two values, µL (Low phenotypic mean) and µH (High phenotypic mean). The total 
phenotypic variance 2tot , i.e. the sum of genetic variance at both loci 
22
12 main   (the minor 
allele frequencies for the functional SNPs are taken to be the same), epistasis variance
2
epi , 




epi , has an interpretation of a broad heritability measure. Throughout this 
thesis, it will further be referred to as 
2
g , to clearly indicate that the interpretation as a 
heritability is due to the imposed normalization constraints. The parameter 
2
g  is varied as 
0.1} 0.05, 0.03, 0.02, {0.01,2 g . Explicit formulae for these variance components can be 
obtained from Evans et al. [8].  
In addition, 1000 null data sets are generated under the most general null hypothesis of no 
association between any of the 10 SNPs and the trait (i.e., 
2






1.3.1 The impact of not correcting for lower-order effects 
Table 1.2 gives an overview of MB-MDR empirical type I error rates in the presence and 
absence of noise (MG and GE). We observe that MB-MDR empirical type I error percentages 
are close to the nominal type I error percentage of 5%, when no correction for main effects is 
performed.  When we adjust for main effects, type I error percentages are further reduced and 
seem to drop below the theoretical value. Similar trends are observed when genotyping errors 
and missing genotypes are introduced in the data. 
Table 1. 2 Type I error percentages for data generated under the general null hypothesis of no 
genetic association in the absence and presence of noise. 




 No Correction 
Main  Effects Correction 
p Noisiness Additive Codominant 
0.1 
 
0.055 0.055 0.049 
0.25 None 0.051 0.038 0.036 
0.5 
 
0.054 0.039 0.030 
0.1 
 
0.046 0.039 0.038 
0.25 MG5 0.051 0.034 0.036 
0.5 
 
0.052 0.044 0.047 
0.1 
 
0.046 0.041 0.041 
0.25 MG10 0.054 0.043 0.043 
0.5 
 
0.048 0.045 0.038 
0.1 
 
0.051 0.037 0.037 
0.25 GE5 0.048 0.038 0.036 
0.5 
 
0.038 0.035 0.031 
0.1 
 
0.049 0.037 0.032 
0.25 GE10 0.049 0.033 0.031 
0.5 
 




Power estimates of MB-MDR to detect the correct interacting pair, SNP1 x SNP2 (in the 
absence of genetic heterogeneity) from error-free and noisy data are shown in Figure 1.1. The 
actual numerical results of the power profiles plotted in Figure 1.1 are presented in Appendix 
Table A1. This table also includes the corresponding empirical power estimates related to 
main effects adjusted analyses. 
In the absence of any adjustment for lower order genetic effects (i.e., main effects), we notice 
that power profiles largely follow the same trajectory, except in the presence of 50% 
phenotypic mixture (PM50). For all scenarios of p, power increases with increasing 
2
g (Figure 1.1 and Table A1).  Moreover, the power of MB-MDR (ranging from 54% to 
100%, p=0.1, 38% to 100%, p=0.25, 33% to 100%, p=0.5  under M170 and from 44% to 
100%, p=0.1, 43% to 100%, p=0.25,  39% to 100%, p=0.5 under M27 for error-free data; 
Table A1) is hardly affected by introducing small percentages of missing genotypes (MG5 in 
Figure 1.1), irrespective of the epistasis model under investigation. Power estimates for MG5 
range from 42% to 100%, p=0.1, 33% to 100%, p=0.25, 28% to 100%, p=0.5 and from 33% 
to 100%, p=0.1, 34% to 100%, p=0.25, 31% to 100%, p=0.5 under M170 and M27, 
respectively (Table A1). For MG10, power obviously reduces further, but not in a dramatic 
way compared to MG5: power estimates reduce to a minimum of 31%, p=0.1, 25%, p=0.25, 
25%, p=0.5 and to a minimum of 31%, p=0.1, 28%, p=0.25, 22%, p=0.5 for M170 and M27, 
respectively).  
When 5% genotyping errors are introduced in the population, systematically lower power 
curves are obtained than in the presence of randomly missing genotypes. However, high 
percentages of genotyping error (GE10) or high percentages of phenotypic mixture (PM50) 
generally lead to the lowest power performance of MB-MDR (Figure 1.1). For model M170 
power estimates in the presence of 10% genotyping errors are in the range of 12% to 100%, 
p=0.1, 8% to 100%, p=0.25, 12% to 100%, p=0.5 and in the range of 9% to 100%, p=0.1, 
20% to 100%, p=0.25, 26% to 100% , p=0.5 for model M27 (Table A1). High percentages of 
phenotypic mixture have a negative impact on MB-MDR power, which is also indicated by 
the minimally observed empirical power estimates for PM50. Power estimates for the latter 
are in the range of 3% to 98%, p=0.1, 3% to 97%, p=0.25, 2% to 95%, p=0.5 for M170 and in 








Figure 1. 1 Empirical power estimates of MB-MDR as the percentage of analyses where the 
correct interaction (SNP1 x SNP2) is significant at the 5% level, for error-free and noise-
induced simulation settings. 
Legend Results are shown for MB-MDR analysis without main effects adjustment and 





Not surprisingly, there is a higher chance of identifying epistasis models for analyses without 
main effects correction as compared to analyses that do account for lower-order effects. The 
latter epistasis models usually involve other SNPs pairing with one of the functional SNPs 
(results not shown) and should therefore be considered as false positives. Empirically 
estimated false positive percentages, for a variety of scenarios, excluding GH settings, are 
reported in Table A2 (―No Correction‖ versus ―Main Effects Correction‖ estimates). For 
error-free data, and no adjustments for main effects, the false positive percentage of MB-
MDR of identifying a significant epistasis model not involving the actual functional pair of 
SNPs ranges from 28% to 100%, p=0.1, 6% to 53%, p=0.25, 6% to 7%, p=0.5 for M170 and 
from 15% to 99%, p=0.1, 26% to 100%, p=0.25, 38% to 100%, p=0.5 for M27. When main 
effects are accounted for in error-free data, the false positive percentage ranges from 3% to 
39%, p=0.1, 3% to 12%, p=0.25, 3% to 6%, p=0.5 under M170 and from 3% to 7%, p=0.1, 
3% to 21%, p=0.25, 2% to 98%, p=0.5 under M27 (Table A2). In general, Table A2 shows 
that irrespective of how the main effects adjustment is performed (using an additive or 
codominant model) and irrespective of the type of noisiness introduced, false positive 
percentages are typically lower than their ‖uncorrected‖ counterparts. 
1.3.2 The impact of appropriately correcting an epistasis analysis for lower-order effects 
Profiles for the empirical power estimates of MB-MDR to detect the correct two functional 
loci from error-free data with (additive and codominant) main effects correction and without 
main effects adjustment are plotted in Figure 1.2. Here, we observe that the power to identify 
the correct causal pair is reduced when a main effects correction is performed, with the lowest 
power levels obtained for codominant correction. The discrepancy between additive and 
codominant main effects adjustment is particularly pronounced for M27 and p=0.5. For M170 
and p=0.5, the nature of the lower-order effects adjustment has virtually no influence on 
power. Power profiles for different sources of noise, according to main effects adjustment 
method, are given in Figure A1-i (missing genotypes), Figure A1-ii (genotyping errors) and 
Figure A1-iii (phenotypic mixture). The empirical power estimates used to generate Figures 
A1 are also presented in Table A1. Here, drawing conclusions is more subtle, although 
generally speaking, empirical power estimates are smaller with codominant correction as 





Figure 1. 2  Empirical power estimates of MB-MDR as the percentage of analyses where the 
correct interaction (SNP1 x SNP2) is significant at the 5% level, for error-free simulation 
settings. 
Legend No main effects adjustment (—), main effects adjustment via additive coding (…), 




Numerical values on the effect of using different main effects adjustments on the false 
positive percentage to identify incorrect two-locus models can be derived from Table A2. For 
error-free data, the false positive percentages after additive main effects correction range from 
5% to 39%, p=0.1, 5% to 12%, p=0.25, 3% to 6%, p=0.5 for M170 and from 4% to 7%, 
p=0.1, 4% to 21%, p=0.25, 9% to 98%, p=0.5 for M27. Using codominant coding to adjust for 
lower order effects, the false positive percentages range from 3% to 6%, p=0.1, 3% to 4%, 
p=0.25 or p=0.5 for M170 and from 3% to 6%, p=0.1, 3% to 3%, p=0.25 and from 2% to 4%, 
p=0.5 for M27. In fact, the practice of correcting an MB-MDR epistasis analysis using a 
codominant main effects model has the tendency to be over-conservative (Table A2).  
Genetic heterogeneity 
So far, we have not yet discussed the performance of MB-MDR for quantitative traits in the 
presence of genetic heterogeneity. Figure 1.3 shows empirical power curves to identify true 
genetic interactions in the presence of GH in a variety of simulation settings. Results are 
shown for MB-MDR analysis without main effects correction (Figure 1.3, row 1 for M170 
and row 3 for M27) and with main effects correction (additive coding) adjustment (Figure 1.3, 
row 2 for M170 and row 4 for M27).  As in non-GH settings, power estimates are larger when 
no correction for main effects is performed than when main effects are accounted for, with 
generally the most severe power loss observed for codominant main effects correction. 
However, when the contribution of main effects to the total genetic variance is ignored, false 
positive percentages rise as well, ranging from 7% to 100% for M27 and from 4% to 97% for 
M170. When we adjust for main effects (additive coding), power estimates to identify the first 
pair (SNP1 x SNP2) drop to less than 50% for both M27 and M170, with the exception of 
M170. For the latter, and a genetic variance of 0.1, MB-MDR power is estimated to be 95% 
and 92% for p=0.25 and 0.5, respectively. Under a codominant correction, power estimates 
drop to less than 7% for both models with the exception of p=0.25 or 0.5 and 
2
g = 0.05 or 
0.1. For the latter, power is estimated to be 15% and 26% for M170 and M27, respectively 
when p=0.1 and 
2
g =0.1. For M27, power=31%, p=0.25 and 
2
g =0.1. For M170, p=0.25 or 
0.5, power estimates are around 30% and 88% for 
2
g =0.05 and 0.1, respectively. Detailed 







Figure 1. 3 Empirical power estimates of MB-MDR as the percentage of analyses where the 
correct interactions (SNP1 x SNP2) and/or (SNP3 x SNP4) are significant at the 5% level, in 
the presence GH. 
Legend First 2 rows: MB-MDR without and with main effects correction for model M170 
respectively. Last 2 rows: MB-MDR without and with main effects correction for model M27 
respectively. Main effects are corrected for via additive coding. Different definitions for 
power are adopted: power to identify both interacting pairs SNP1 x SNP2 and SNP3 x SNP4 
(cyan); power to identify SNP1 x SNP2 (black); power to identify SNP3 x SNP4 (magenta), 






Understanding the effects of genes on the development of complex diseases is a major aim of 
genetic epidemiology. Several studies have indicated that MDR has good power to identify 
gene-gene interactions in both simulated and real-life data [6].  Although MB-MDR has 
profiled itself as a promising extension of MDR accommodating study designs that are more 
complex than unrelated case-control settings [3, 9-11], a thorough investigation of its full 
potential, under a variety of real-life distorting factors, such as missing genotypes, genotyping 
errors, phenotypic mixtures and last but not least genetic heterogeneity, has never been carried 
out in the context of quantitative traits.  
This study has evaluated the power of MB-MDR for quantitative traits and unrelated 
individuals, in identifying gene-gene interactions for two different epistasis models. Scenarios 
with and without noisy data, as well as epistasis screening with and without lower-order 
effects adjustments have been considered. Although our simulations only involved 10 SNPS, 
conclusions about observed patterns largely remain the same when increasing the number of 
genetic markers (e.g. empirical power results for non-GH settings without main effects 
adjustment, Figure A2). Note that, an increasing number of SNPs will lead to an increasing 
number of interacting pairs, resulting in an elevated multiple testing burden, and hence 
resulting in reduced power.  
A first important finding is that MB-MDR adequately deals with one of the most major 
concerns in genetic association analysis studies (especially those targeting higher-order gene-
gene interactions), namely avoiding that the overall type I rate is out of control (Table 1.2). 
The apparent slightly conservative results obtained when MB-MDR screening explicitly 
accounts for lower-order main effects, are not surprising. Indeed, under the general null 
hypothesis of no genetic association, adjusting for main effects involves over-fitting and 
hence unnecessary over-correction. However, all the empirical estimates of the MB-MDR 
type I error rate in Table 1.2 fall within the interval [0.025,0.075], satisfying  Bradley‘s [12] 
liberal criterion of robustness. This criterion requires that the type I error rates are controlled 
for any level α of significance, if the empirical type I error rate ˆ  is contained in the 
interval  5.1ˆ5.0  . Note that we remark that, since MB-MDR assesses global 
significance using resampling-based maxT adjusted p-values, the FWER will always be 
weakly controlled at 5%, provided the assumptions of the Westfall and Young approach [13] 




A second important finding is that MB-MDR‘s power performance under different scenarios 
can be largely explained by the quantification of the actual genetic variance 
2
gen  and by the 
decomposition of the total genetic variance into contributions of main effects and epistasis, 
and/or by the decomposition of main effects into additive and dominance variance. Empirical 
decompositions based on classical variance components analysis of Sham [14], are reported in 
Tables A3 for M170 and A4 for M27 in the absence of GH, and in Tables A5 in the presence 
of GH. Each of these estimates is based on simulation setting‘s sample size (750 000 
individuals).  These results support our theoretically derived variance components, which are 
summarized in Table A6. 
In particular, the observed lowest power performances of non-GH settings for GE10 and 
PM50 can be explained by the fact that over-representation of the minor allele as well as 
introducing phenotypic mixture result in a loss of actual genetic variance (Table 1.1) and 
therefore a loss of power. The theoretical results, indicating that a 50% reduction in total 
genetic variability is established when 50% phenotypic mixture is introduced in error-free 
data (Table 1.1) are supported by our empirical results (e.g., Tables A3 for M170 and A4 for 
M27, comparing 
2
gen  with 
2
g .  
When 50% genetic heterogeneity is present, theory supports our empirical results in that the 
total actual genetic variance due to the two causal pairs of markers is twice the total actual 
genetic variance due to a single pair (Tables A5). Moreover, since we have introduced two 
possible genetic routes for an individual to be genetically predisposed for the trait of interest 
under GH (route 1 via SNP1 x SNP2 or route 2 via SNP3 x SNP4), the actual genetic variance 
in the pooled data will be half the genetic variance in the error-free data (see also Tables A5-ii 
for M170 and A5-iv for M27). The total genetic variance due to a single causal pair 
approximates 4
2
g  (Table A5-i and A5-iii), which is due to the fact that the 2 pairs have the 
same minor allele frequencies. Therefore, the theoretical genetic variance is split between the 
two pairs and thereafter between the 2 SNPs. MB-MDR was shown to be rather robust in the 
presence of missing genotypes and genotyping error. Note that MB-MDR that MB-MDR 
handles missing genotypes by using all available cases for the SNP pair under investigation. 
Hence, no individuals with missing data are a priori removed from the analysis, except when 
functional SNPs that are adjusted for in regression models have (partially) missing 




A third finding is that accounting for important lower-order genetic effects in epistasis 
screening should be made standard. There is a debate about how to best model and test for 
both main effects and interactions or for interactions only when epistasis is present [15]. 
Although a fully non-parametric screening approach (e.g., such as MDR) is beautiful in that it 
does not require specifying particular genetic models, there is still a need to adjust for lower-
order genetic effects via a parametric paradigm when targeting significant gene-gene 
interaction models.  The Model-Based MDR (MB-MDR) offers a flexible framework to make 
these adjustments. For MDR-like applications other than MB-MDR this is far from obvious. 
For instance, MDR for binary traits, Ritchie et al. [6] does not accommodate taking corrective 
measures for lower order effects. Although significant main effects can be filtered out prior to 
an MDR screening, this happens at the cost of missing out on genuinely true interactions. 
Furthermore, examining the decomposition of the total genetic variance has shed more light 
on the scenarios in which an adjusted MB-MDR analysis is warranted. For instance, when the 
minor allele frequency of the causal loci is 0.5, model M170 is a pure epistatic model (Table 
A3: empirical estimates 
22
genepi   approximate 1). Hence in this scenario the effects of 
correcting for main effects are taken to the extreme. Clearly, any correction for lower-order 
effects would be an over-correction. On the other hand, since there is no true evidence for 
main effects in this model, any adjustment for main effects will only remove a small portion 
of the variability (Table A3: M170, p=0.5; empirical estimates of 
22
genmain   are close to 
zero), resulting in false positives for the corrective analysis that are similar to those for the un-
corrective analysis (Table S2: M170, p=0.5; empirical estimates close to 5% also when not 
adjusting for main effects). In effect, the contribution of main effects becomes increasingly 
important with increasing p for M27 (≈32%, p=0.1, ≈61%, p=0.25 and ≈85%, p=0.5) and the 
reverse holds for M170 (≈59%, p=0.1, ≈11%, p=0.25 and ≈0%, p=0.5) (Table A3, A4 and 
Table A6).  
For model M170 and GH scenarios involving p either 0.25 or 0.5 for the causal pairs, the 
epistatic variance explains a relatively large proportion of the total genetic variance in the data 
(
22
genepi  >87%; Table A5-ii), and correcting for main effects therefore has little effect on 
power. In contrast, for Model M170 and p=0.1 for the causal pairs, main effects do make an 
important contribution to the total genetic variance (
22
genmain  > 57%; Table A5-i and Table 




power is dramatically reduced when proper accountancy for lower order effects is being made 
(Figure 1.3).  
Summarizing, dealing with phenotypic mixtures and genetic heterogeneity will remain 
challenging for epistasis screening methods, for some time to come. Our empirical results 
suggest that more work is needed to better accommodate these particularities.  Benefits may 
be gained from identifying the trait-specific factors (genetic or non-genetic) that best 
characterize mixed phenotypic populations. For genetic heterogeneity, the genes in which the 
loci are present can be part of different etiological pathways leading to the same disease or be 
part of the same pathway. According to Heidema et al. [16], irrespective of the biological 
mechanism that gives rise to genetic heterogeneity, the association of the loci with the disease 
will be reduced if the total sample is used for measuring the association, as was done in this 
study. A method that is not robust in the presence of genetic heterogeneity will most likely 
suffer from a decrease in power to detect genetic effects. As our main effects corrective 
analyses have suggested, a way forward may be to use methods to identify the latent classes 
and to adapt the epistasis screening accordingly.  
Finally, any epistasis screening should properly account for lower-order effects in order to be 
able to claim that an identified interaction involves a significant epistatic contribution to the 
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Chapter 2 
Lower-order Effects Adjustment in Quantitative Traits Model-Based 






Identifying gene-gene interactions or gene-environment interactions in studies of human 
complex diseases remains a big challenge in genetic epidemiology. An additional challenge, 
often forgotten, is to account for important lower-order genetic effects during this process. 
These may hamper the identification of genuine epistasis. If lower-order genetic effects 
contribute to the genetic variance of a trait, identified statistical interactions may simply be 
due to a signal boost of these effects. Via simulations, we assess the performance of different 
corrective measures for lower-order genetic effects in Model-Based Multifactor 
Dimensionality Reduction epistasis detection, using additive and codominant coding schemes. 
Performance is evaluated in terms of power and family-wise error rate. Our simulations 
indicate that empirical power estimates are reduced with correction of lower-order effects, 
likewise family-wise error rates. Easy-to-use automatic SNP selection procedures, SNP 
selection based on ―top‖ findings, or SNP selection based on p-value criterion for interesting 
main effects result in reduced power but also almost zero false positive rates. Always 
accounting for main effects in the SNP-SNP pair under investigation during Model-Based 
Multifactor Dimensionality Reduction analysis adequately controls false positive epistasis 
findings. This is particularly true when adopting a codominant corrective coding scheme. In 
conclusion, automatic search procedures to identify lower-order effects to correct for during 
epistasis screening should be avoided. The same is true for procedures that adjust for lower-
order effects prior to Model-Based Multifactor Dimensionality Reduction and involve using 
residuals as the new trait. We advocate using ―on-the-fly‖ lower-order effects adjusting when 







Complex diseases commonly occur in a population and are a major source of discomfort, 
disability and death worldwide. They are believed to arise from multiple predisposing factors, 
both genetic and non-genetic, each factor potentially having a modifying effect on the other.  
Detecting gene-gene interactions or epistasis in studies of human complex diseases is a big 
challenge in genetic epidemiology. An additional challenge is to account for important lower-
order genetic effects in order to reduce false positive epistasis results.  
To date, several strategies are available, within the context of genetic association studies that 
specifically aim to identify and characterize gene-gene interactions.  Among these strategies is 
the Model-Based Multifactor Dimensionality Reduction (MB-MDR) which was first 
introduced by Calle et al. [1]. The strategy of MB-MDR to tackle the dimensionality problem 
in interaction detection involves reducing a potentially high dimensional problem to a one-
dimensional problem by pooling multi-locus genotypes into three groups based on association 
testing or modeling (PART 1, Figure 1.4). It has been suggested that Model-Based 
Multifactor Dimensionality Reduction is a useful method for identifying gene-gene 
interactions in case-control or family-based design for both dichotomous and quantitative 
traits [1-6]. Although  a  power study of MB-MDR detection with and without main effects 
adjustment has been performed before by Cattaert et al. [3] and Mahachie et al. [6], these 
studies only involved adjusting for the known functional SNPs contributing to an epistasis 
effect. The preliminary results these studies gave rise to, emphasized the importance of lower-
order effects adjustment when searching for gene-gene interactions and warranted a more 
detailed investigation, which is the topic of this chapter. 
In this study, we perform a thorough simulation-based investigation of the power of 
quantitative trait MB-MDR to identify gene-gene interactions, using different strategies to 
adjust for lower-order genetic effects that may or not be part of the (functional) SNP-SNP 
interaction under investigation. Performance criteria used are power and family-wise error 
rate. We perform MB-MDR epistasis analyses first without any adjustment for main effects 
and then with adjustments using several strategies. The proposed main effects corrections can 
be grouped into two categories: 1) main effects screening followed by MB-MDR applied to 
an adjusted trait and 2) main effect adjustment integrated in step 1 and step 2 of MB-MDR 











2.2 Materials and Methods 
2.2.1 Strategies to adjust for lower-order genetic effects 
Several methods exist to correct for lower-order effects in the context of quantitative MB-
MDR epistasis screening. An overview of the considered methods in this study is given in 
Figure 2.1.  A first strategy is to extensively look for potentially confounding main effects, to 
transform the original trait to an adjusted trait accordingly, and to submit this newly defined 
trait to MB-MDR for epistasis screening.  
When correcting for main effects, a note about how to best code lower-order effects is 
warranted.  In a GWA study, SNPs are often coded in an additive way [7]. This coding works 
well in practice, although power can be gained by acknowledging the true underlying genetic 
models [8]. For instance, if  the two  homozygote genotypes at a locus exhibit the same risk, 
different from the heterozygote risk (over-dominance), then the additive coding will have 
reduced power irrespective of the sample size [9]. Alternatively, several coding schemes may 
be investigated and a maximum statistic over screened main effects models may be selected 
[10]. The differing unknown operating modes of inheritance throughout the genome make it 
hard to flexibly and automatically acknowledge this complex inheritance spectrum. 
Therefore, the route chosen in this paper, now in an epistasis context is to correct for main 
effects by either assuming an additive or a codominant coding scheme, in scenarios that 
involve different contributions of additive and dominance variance to main effects variance. 
Although some of these scenarios may be better captured by non-additive and non-
codominant codings, the interest is in finding an all-purpose acceptable (in terms of power 
and type I error) way to remove the main effects signals influencing epistasis signals. 
Choosing between additive and codominant coding schemes implies choosing between the 
least and most severe such removal of effects. 
2.2.1.1 Main effects screening prior to MB-MDR 
This screening procedure involves first adjusting for a chosen subset of main effects via 
parametric (linear) regression models and then considering residuals from the fitted models as 
a new trait for MB-MDR. For the adjustment methods involving significance assessments, we 






Single (univariate) regression-based searches 
Important main effects can be identified via single-SNP regression models, as is done in a 
classical GWA setting. Hence, SNPs that meet a stringent criterion (such as governed by a 
Bonferroni criterion) will be labelled as ―important‖ and are therefore good candidates to 
correct for in an epistasis screening. In this study, we prefer to take a less conservative route, 
such as a selection based on step-down maxT adjusted p-values with 999 replicates (Figure 
2.1; SRperm). However, targeting effects standing out in a GWA main effects screening while 
maintaining overall type I error is quite different from targeting main effects to adjust for in 
an epistasis screening. Therefore, we also consider selecting  ―optimal‖ SNPs for main effects 
correction in the quantitative MB-MDR screening on the basis of their significance without 
correction for multiple testing (Figure 2.1; SR0.05) or on the basis of a ranking of the 
corresponding raw p-values (Figure 2.1; SRtop5, SRtop10, SRtop15).  
Multiple regression-based searches 
Due to a large number of SNPs that are involved in a main effects genome-wide analysis, 
multiple regression-based searches are often automated. One such automated approach uses 
stepwise selection based on AIC (stepAIC in R package MASS, R 2.10.0).  This procedure 
iteratively adds and/or drops variables to seek the lowest AIC score. The final model 
generates the list of main effects to correct for in the quantitative trait MB-MDR analysis 
(Figure 2.1; MRAIC).  
2.2.1.2 Main effects adjustment as an integral part of MB-MDR 
In this scenario, main effects are adjusted for ―on-the-fly‖, i.e.  SNPs are adjusted for during 
the first 2 MB-MDR epistasis screening steps. Three types of adjustment are considered. A 
first type is to always adjust for the SNPs in the pair under investigation (Figure 2.1; MB-
MDRadjust). Hence, the adjustment is done irrespective of whether a main effect is truly 
present. A second type is to only adjust for SNPs that are identified by MB-MDR1D as 
significant. Here, MB-MDR1D is run first and a list of genome-wide significant SNPs is 
identified (based on step-down maxT with 999 permutation replicates). MB-MDR epistasis 
screening is then performed while only adjusting for the identified SNPs for the pair under 
investigation (Figure 2.1; MB-MDR1D).  A third type is to only adjust for significant SNPs 




MDRlist). Thus, for MB-MDR1D and MB-MDRlist, any of the following 3 situations can arise: 
a) None of the 2 SNPs is significant and no correction is performed b) One of the 2 SNPs is 
significant and this is adjusted for c) Both SNPS are significant and both SNPs are adjusted 
for.   
In order to account for potentially important SNPs as an integral part of MB-MDR, we remark 
that the Student‘s t-test in MB-MDR steps 1-2 (PART 1, Figure 1.4) is replaced by the Wald 
test for the interaction effect in a regression framework. 
2.2.2 Data Simulation 
Simulated  data  as generated in Mahachie John et al. [6] are based on two epistasis models 
for SNP1 and SNP2 that incorporate varying degrees of epistasis: Model M27 and Model 
M170 of Evans et al. [11].  In order to increase the phenotypic mean, M27 requires an 
individual to have at least one copy of the minor allele at both loci whereas M170 requires an 
individual to be heterozygous at one locus and homozygous at the other. The phenotypic 
means for the aforementioned epistasis models only take two values, µL (Low phenotypic 
mean) and µH (High phenotypic mean).  The total phenotypic variance
2
tot , i.e. the sum of 
genetic variance at both loci 
22
12 main   (the minor allele frequencies for the functional 
SNPs are taken to be the same), epistasis variance
2
epi , and environmental variance
2
env , is 
fixed at 1. SNP1 and SNP2 have minor allele frequency equal to p, with p one 
of 0.5} 0.25, {0.1, . The minor allele frequencies of the other 98 markers are generated from a 
random uniform distribution, U(0.05,0.5). MB-MDR screening is performed on 100 SNPs in 
Hardy-Weinberg Equilibrium and linkage equilibrium. The total genetic variance 
2
g  is 
varied as 0.1} 0.05, 0.03, 0.02, {0.01,
2 g .  The main effects variance 
2
main   consists of 
additive variance 2add   and dominance variance 
2
dom .  As p increases, the contribution to the 
total genetic variance of epistasis variance relative to main effects variance increases for 
M170 and decreases for M27, and also the contributions of additive and dominance variance 




Table 2. 1 Theoretically derived proportions of the genetic variance due to main effects 
(additive and dominance) or epistasis. 
















 0.1 0.319 0.947 0.053 0.681 
M27 0.25 0.609 0.857 0.143 0.391 
 0.5 0.857 0.667 0.333 0.143 
 0.1 0.581 0.780 0.220 0.419 
M170 0.25 0.118 0.400 0.600 0.882 
 0.5 0.000 0.947 0.053 1.000 
 
For SNP3 and SNP4, main effects are imposed with associated variances 23  and 
2
4 , 
selected from a uniform distribution U(0, 0.06) such that the total main effects variance of the 
4 loci (SNP1, SNP2, SNP3, SNP4) is  2222 2 431main   . The respective modes of 
inheritance for SNP3 and SNP4 are additive and advantageous heterozygous. Note that SNP4 
will therefore contribute to both the additive and dominance components of the main effects 
variance. This scenario allows us to investigate the effect of global main effects correction 
approaches for functional SNPs that are not part of a two-locus interaction.  
In addition data are simulated under the null model for the functional pair (i.e. 02 g ) in two 
ways, giving rise to two null hypotheses H01 and H02.  H01: No genetic contribution apart from 
SNP3 and SNP4 as main effects and H02: any genetic contribution from any of the SNPs 
whatsoever.  
In summary, a total of 36 simulation settings are considered.  For each parameter setting, we 






2.3.1 Familywise error rates and false positive rates 
Table 2.2 shows results for settings simulated under the null hypotheses H01 and H02 of no 
genetic associations with the trait, yet in the presence or absence of additional main effects 
(SNP3 and SNP4). 
We observe that MB-MDR type I error percentages are close to the nominal type I error rate 
of 5%, when no correction for main effects is performed under settings where no additional 
main effects act on the quantitative trait. Type I error rates are also kept under control when 
correction for main effects is integrated in MB-MDR epistasis screening as well as prior to 
MB-MDR for permutation based regression-based approach (MB-MDRadjust, MD-MDR1D, 
MB-MDRlist and SRperm, respectively).  In particular, additive correction under H02 and 
codominant correction for both H01 and H02. When additional main effects are present in the 
data, adjusting for their effects using additive correction give rise to inflated type I error rates 
ranging from 55 to 74%.  In contrast, when adopting a codominant correction, type I error is 
under control for MRAIC, and single regression-based correction methods (except SRperm) 






Table 2. 2 Type I error percentages for data generated under the null hypothesis of no genetic 
association of the interacting pair. 
Without correction  and additional main effects 
P  present absent 
0.1  0.982 0.046 
0.25 No correction 0.984 0.050 
0.5  0.982 0.050 
  With Correction and additional main effects 
 
Way  of 
Correction Additive Codominant 
  present absent present absent 
0.1  0.676 0.048 0.040 0.052 
0.25 MB-MDRadjust 0.710 0.034 0.054 0.038 
0.5  0.740 0.044 0.036 0.050 
0.1  0.676 0.036 0.058 0.030 
0.25 MB-MDR1D 0.722 0.040 0.042 0.036 
0.5  0.746 0.040 0.038 0.030 
0.1  0.682 0.038 0.056 0.030 
0.25 MB-MDRlist 0.726 0.036 0.044 0.032 
0.5  0.748 0.046 0.040 0.032 
0.1  0.628 0.038 0.048 0.030 
0.25 SRperm 0.660 0.036 0.058 0.030 
0.5  0.678 0.046 0.044 0.032 
0.1  0.576 0.014 0.006 0.010 
0.25 SR0.05 0.604 0.006 0.012 0.000 
0.5  0.636 0.022 0.008 0.008 
0.1  0.552 0.008 0.000 0.002 
0.25 MRAIC 0.578 0.004 0.002 0.000 
0.5  0.616 0.012 0.000 0.006 
0.1  0.582 0.014 0.008 0.008 
0.25 SRtop5 0.616 0.002 0.020 0.000 
0.5  0.638 0.026 0.010 0.010 
0.1  0.560 0.012 0.000 0.008 
0.25 SRtop10 0.592 0.006 0.004 0.000 
0.5  0.626 0.022 0.006 0.006 
0.1  0.556 0.010 0.000 0.006 
0.25 SRtop15 0.588 0.006 0.002 0.000 
0.5  0.618 0.016 0.004 0.006 
Results are for scenarios: with and without additional main effects (SNP3 and SNP4) contributing to 





False positive rate estimates generated  by MB-MDR (i.e. referring to scenarios for which one 
or more significantly interacting pairs other than the causal SNP pair (SNP1, SNP2)) using no 
correction or an additive or codominant correction of main effects, are shown in Figure 2.2. 
When no correction is performed, false positive rate estimates are around 100% under both 
M170 and M27 genetic epistasis models. In general, for additive correction false positive rate 
estimates range from 53 to 100% whereas for codominant correction, false positive rate 
estimates are lower and range from 0 to 19%.  In particular, false positive rates for  MB-
MDRadjust (always adjusting for main effects SNPs)  in a codominant way range from 4 to 7%, 
rates that are within the interval (0.025, 0.075), satisfying  Bradley‘s [12] liberal criterion of 
robustness. This criterion requires that the type I error rates are controlled for any level α of 
significance, if the empirical type I error rate ˆ  is contained in the interval  5.1ˆ5.0  . 
For MB-MDR1D and MB-MDRlist, false positive rates are not kept under control. The actual 
numerical results of the false positive profiles plotted in Figure 2.2 are presented in the 





Figure 2. 2 False positive percentages of MB-MDR based on additive (A) and co-dominant (B) correction. 







The main reason why we observe higher false positive rates under additive correction is due 
to the fact that SNP4 contributes to both an additive and dominance component of the main 
effects variance. Hence, there is also a higher chance of identifying ‗significant‘ interactions 
for pairs involving SNP4. False positive rates are reduced when co-dominant correction is 
performed.  Table 2.3 shows observed false positive rates that involve pairing with SNP3 
and/or SNP4 under additive and co-dominant correction. Only MB-MDRadjust (―on-the-fly‖ 
adjustment) results are shown. From Table 2.3, 
2
g >0, we observe that under additive 
codings, false positive rates range from 51 to 61% for interactions between SNP3 and SNP4. 
However, for interactions with SNP3 (excluding SNP3, SNP4 interaction), false positive rates 
range from 0 to 6%, except for Model 27,  p=0.5 and 
2
g  
of 0.05 and 0.1 where false positive 
rates are 27 and 92%, respectively. As observed in Table 2.1, model M27, p=0.5 has the 
highest relative contribution of dominance variance, hence, additive correction does not fully 




Table 2. 3 False positive percentages of MB-MDRadjust involving SNP3 and/or SNP4. 
False positive percentages shown are for identifying interaction between SNP3 and SNP4 and or 
interactions between SNP3 or SNP4 and at least one other SNP for null data scenario under  H01 and 
for models M170 and M27. 
 

















0.002 0.520 0.660 0.000 0.000 0.000 




0.002 0.608 0.722 0.004 0.000 0.002 
  
0.01 0.002 0.584 0.704 0.004 0.000 0.000 
  
0.02 0.008 0.582 0.724 0.002 0.000 0.000 
 
0.1 0.03 0.000 0.572 0.690 0.000 0.000 0.000 
  
0.05 0.008 0.534 0.676 0.002 0.000 0.000 
  
0.1 0.072 0.540 0.752 0.000 0.000 0.000 
  
0.01 0.002 0.598 0.714 0.000 0.000 0.004 
  
0.02 0.000 0.558 0.712 0.002 0.000 0.002 
M170 0.25 0.03 0.000 0.544 0.686 0.000 0.000 0.000 
  
0.05 0.004 0.536 0.706 0.002 0.000 0.000 
  
0.1 0.032 0.566 0.738 0.000 0.000 0.000 
  
0.01 0.000 0.526 0.664 0.000 0.000 0.002 
  
0.02 0.000 0.588 0.708 0.000 0.000 0.002 
 
0.5 0.03 0.002 0.544 0.692 0.002 0.000 0.002 
  
0.05 0.002 0.550 0.666 0.000 0.000 0.000 
  
0.1 0.002 0.528 0.662 0.002 0.000 0.000 
  
0.01 0.002 0.532 0.662 0.000 0.000 0.000 
  
0.02 0.000 0.564 0.690 0.000 0.000 0.000 
 
0.1 0.03 0.000 0.554 0.680 0.002 0.000 0.000 
  
0.05 0.000 0.562 0.704 0.002 0.000 0.000 
  
0.1 0.000 0.518 0.638 0.000 0.000 0.000 
  
0.01 0.002 0.512 0.652 0.000 0.000 0.002 
  
0.02 0.004 0.520 0.682 0.004 0.000 0.000 
M27 0.25 0.03 0.000 0.562 0.700 0.002 0.000 0.000 
  
0.05 0.000 0.546 0.700 0.000 0.000 0.002 
  
0.1 0.042 0.564 0.734 0.002 0.000 0.000 
  
0.01 0.000 0.546 0.672 0.000 0.000 0.002 
  
0.02 0.020 0.508 0.684 0.000 0.000 0.000 
 
0.5 0.03 0.060 0.518 0.706 0.000 0.000 0.002 
  
0.05 0.272 0.536 0.806 0.000 0.000 0.000 
  




2.3.2 Empirical power estimates 
Power profiles of MB-MDR to detect the correct interacting pair (SNP1, SNP2) without and 
with different ways of adjustment of main effects are shown in Figure 2.3. Empirical power 
estimates are presented as Supplementary information (Table A8 for M170 and Table A9 for 
M27).  In this section, we focus on scenarios where there is some remarkable degree of main 
effects contributing to the genetic variance (M170: p=0.1, M27: p=0.25 and 0.5). For a 
detailed view on variance decomposition into main and epistatic effects, we refer to Sham 
[13]. Under the aforementioned scenarios, the profile for no correction always has the highest 
power.  
Under M170, the empirical power estimates for this profile range from 33 to 100% for p=0.1. 
Under M27, the power estimates range from 27 to 100% and from 15 to 100%, for p=0.25 and 
0.5 respectively. Irrespective of whether main effects are corrected for using additive or 
codominant coding, profiles for the considered multiple-regression, MRAIC and single 
regression-based methods that do not involve multiple testing (SR0.05, SRtop5, SRtop10 and 
SRtop15) tend to follow the same trajectory, giving rise to the lowest empirical power 
estimates. With additive adjustments, empirical power estimates for these corrective ways 
range from 0 to 100% for both models M27 and M170. With codominant adjustments, power 
estimates range from 0 to 94% , for M170, p=0.1,  from 0 to 100% and from 0 to 18%,  for 
model M27, p=0.25 and p=0.5 respectively. Estimates for MB-MDRadjust (corrective methods 
that are integrated as part of MB-MDR) , range from 6 to 100% for M170, p=0.1, from 3 to 
100% for M27 with p=0.25 and from 1 to 100% for M27 with p=0.5, when additive 
corrections are performed. Under codominant corrections the estimates range from 4 to 100% 












The identification of genetic susceptibility loci for human complex diseases has been rather 
successful due to the ability to combine different genome-wide association studies via meta-
analyses. In the quest for the missing heritability, genome-wide association interaction studies 
have become increasingly popular and the field shows a boost in methodological 
developments [14]. When lower-order effects are not appropriately accounted for in epistasis 
screening, derived results may not be trustworthy and conclusions about genuine epistasis 
may be ungrounded. 
Indeed, the challenge is to find epistasis effects above and beyond singular marker 
contributing effects, should there be any. In this work, we investigated the power of MB-
MDR for quantitative traits and unrelated individuals, while targeting gene–gene interactions 
accounting for potential main effects.  
As was already observed in Mahachie John et al. [6],  MB-MDR adequately controls type I 
rate at 5% when no association is present (null data).  Under additive corrections, type I error 
and false positive rates are high irrespective of the adjustment method considered but 
controlled under codominant corrections. This is due to the existence of SNP4, which was 
simulated with both additive and dominance effects (advantageous heterozygous). Hence, 
additive adjustment does not fully remove the effect of SNP4. As shown before in Table 2.3, 
the consequence is that a number of SNPs appear to be significantly interacting with SNP4. 
Not surprisingly, this occurs more often under additive correction compared to codominant 
correction. This is because when we correct for main effects using the codominant model, we 
remove all the effect of SNP4, and hence false positive results are only by chance (5% 
nominal error rate). When no main effects adjustment is implemented, MB-MDR gives even 
higher false positive rate rates. 
Lower power profiles under codominant corrections in Figure 2.3 are explained by the 
different contributions of additive and dominance effects to the total main effects variance as 
already shown in Table 2.1. When there is a remarkable contribution of dominance effect, as 
mentioned before, additive coding does not fully remove main effect contribution of the 
interacting SNPs. For instance, under M27, when the contribution of main effects is 
maximum (p=0.5), almost 33% of the main effects variance is dominance, hence a huge 




Interestingly, easy-to-use automatic subset selection procedures (MRAIC) and single 
regression-based identification of important main effects prior to MB-MDR screening result 
in lower power and almost zero false positive rates. Often, a list of top SNPs is generated to 
derive disease genetic risk scores. Some of these SNPs may reach user-defined significance, 
some may even reach genome-wide significance and some may not be significant at all. 
Hence, correcting for SNPs in such a list (e.g. top5, 10, 15) may remove more of the trait‘s 
variability than is really necessary, especially when correction for multiple testing is not 
performed. Note that we considered a minimum of 5 top findings since at least 4 SNPs were 
allowed to contribute to the main effects variance.  
In order to attain sufficient power, any main effects corrective method that leads to an over-
correction during epistasis screening should be avoided. All considered residual-based 
approaches (MRAIC, SR0.05, SRperm, SRtop5, SRtop10, SRtop15) led to uncontrolled false positive 
rates.  This can be explained by either the way the residuals were obtained (inappropriate 
main effects coding) or by the non-exhaustive list of markers considered in the residual 
computation.  
Only codominantly correcting for significant SNPs as integral part of MB-MDR screening 
perform much better. However, the poor performance of MB-MDR1D and MB-MDRlist and 
the excellent performance of MB-MDRadjust in terms of controlling false positive epistasis 
rates support the intuition that it (only) matters to correct for those SNPs that are involved in 
the SNP pair under investigation, when no other SNPs are expected to modify the effect of 
that pair. 
The aforementioned discussion clearly raises questions about how to best correct for lower-
order effects when higher-order (>2) interactions are targeted. In either case, to aid in 
interpretation of results,  it is always a good practice to assess the joint information of clusters 
of SNPs that contribute to the trait variability [15].  
Finally, we emphasize that most statistical epistasis detection methods can be decomposed 
into a core component and a multiple testing correction component. Keeping the core 
component, but using a more refined multiple testing correction can generally enhance its 
performance. For instance, assumptions underlying the maxT procedure of Westfall and 
Young [16] that is implemented in MB-MDR are likely to be violated for MB-MDR1D  and 
MB-MDRlist. Indeed, the null and the alternative hypotheses per pair of SNPs under 




In conclusion, rather than adjusting for lower-order effects prior to MB-MDR and using 
residuals as the new trait, or adjusting only for significant SNP(s), we advocate an ―on-the-
fly‖ main effects adjustment (MB-MDRadjust). This type of adjustment only removes potential 
main effects contributions in the pair under investigation but keeps the null and alternative 
hypotheses similar from one pair of SNPs to another. We have shown that the commonly used 
additive coding in the ―on-the-fly‖ adjustment (MB-MDRadjust) is not sufficient and leads to 
overly optimistic results and that codominant adjustments are to be preferred.  This will 
ensure an acceptable balance between type I error and power to identify the interactions.   
Realistic settings often involve both additive and dominance genetic effects to the trait under 
investigation. Equivalent to our codominant coding, a perhaps biologically more meaningful 
coding involves introducing 2 variables X1 and X2 with values -1, 0, 1 and -1/2, 1/2, -1/2, 
respectively, for homogenous wild type, heterozygote and homozygote mutant genotypes.  In 
such a coding scheme, both additive and dominant scales are represented. This 2-parameter 
coding is statistically attractive since it is invariant to allele coding (i.e. whether coding 
homogenous wild type as 1 or homozygote mutant genotypes as 1 for X1) [17]. The utility of 
the aforementioned coding as a way to adjust for lower-order effects in MB-MDR higher-
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Chapter 3 
A Robustness Study of Parametric and Non-parametric Tests in Model-






Applying a statistical method implies identifying underlying (model) assumptions and 
checking their validity in the particular context. One of these contexts is association modeling 
for epistasis detection. Here, depending on the technique used, violation of model 
assumptions may result in increased type I error, power loss, or biased parameter estimates. 
Remedial measures for violated underlying conditions or assumptions include data 
transformation or selecting a more relaxed modeling or testing strategy. Model-Based 
Multifactor Dimensionality Reduction (MB-MDR) for epistasis detection relies on association 
testing between a trait and a factor consisting of multilocus genotype information. For 
quantitative traits, the framework is essentially ANalysis Of VAriance (ANOVA) that 
decomposes the variability in the trait amongst the different factors. In this study, we assess 
through simulations, the cumulative effect of deviations from normality and homoscedasticity 
on the overall performance of quantitative Model-Based Multifactor Dimensionality 
Reduction (MB-MDR) to detect 2-locus epistasis signals in the absence of main effects. Our 
simulation study focuses on pure epistasis models with varying degrees of epistatic influence 
on a quantitative trait. Conditional on a multilocus genotype, we consider quantitative trait 
distributions that are normal, chi-square or Student‘s t with constant or non-constant 
phenotypic variances.  All data are analyzed with MB-MDR using the built-in Student‘s t-test 
for association, as well as a novel MB-MDR implementation based on Welch‘s t-test. Traits 
are either left untransformed or are transformed into new traits via logarithmic, 
standardization or rank-based transformations, prior to MB-MDR modeling. The simulation 
results show that MB-MDR controls type I error and false positive rates irrespective of the 
association test considered.  Empirically-based MB-MDR power estimates for MB-MDR with 
Welch‘s t-tests are generally lower than those for MB-MDR with Student‘s t-tests.  Trait 
transformations involving ranks tend to lead to increased power compared to the other 
considered data transformations. When performing MB-MDR screening for gene-gene 
interactions with quantitative traits, we recommend to first rank-transform traits to normality 





The search for epistasis or gene-gene interaction effects on traits of interest is marked by an 
exponential growth. From an application point of view, these searches often focus on 
candidate genes or pathways. The reasons for this are often logistic ones: First, genome-wide 
screening for epistasis requires large sample sizes to ensure sufficient power detection, which 
may only become available when having access to consortia data. Second, exhaustive 
genome-wide epistasis screenings assumes the availability of sufficient computer power and 
an adequate infrastructure to store and analyze the data, as well as to store and process the 
analysis results. From a methodological point of view, searches for epistasis effects are 
performed with the goal in mind to develop methods that can narrow the gap between 
statistical and biological epistasis.  
To date, several epistasis detection approaches exist, each addressing differential aspects of 
the underlying theoretical epistasis model, and with different performances in terms of Type I 
error control or power detection [1].  Although methods are often thoroughly compared to 
competing methods in this sense, using a variety of simulation settings that are hoped to 
reflect realistic mechanisms of disease-causing genetic variants, they usually do not involve 
comprehensive statements neither about the underlying assumptions, nor about how violations 
of these assumptions may affect the method‘s performance. Modeling or testing techniques 
usually come with specific assumptions that need to be fulfilled in order to produce valid 
analysis results. This also applies to methods to detect epistasis. Good standard practice in this 
context would  include 1) to investigate the underlying assumptions of the epistasis detection 
or modeling technique, 2) to check whether these are valid, and  3) to take remedial measures 
or to accommodate the  effects of identified violations.  
Model-Based Multifactor Dimensionality Reduction (MB-MDR) is an intrinsic non-
parametric method since no assumptions are made regarding genetic modes of inheritance [2]. 
The ‗modeling‘ part in MB-MDR arises from the need to embrace parametrics when adjusting 
for lower-order (main) effects within a regression framework. The necessity of lower-order 
effects corrections in quantitative MB-MDR analyses has been discussed elsewhere [3]. In 
pure epistasis scenarios (i.e., no significant main effects), there is no need to adjust for main 
effects and MB-MDR analysis essentially involves the consecutive application of one-way 
Analysis of Variance (ANOVA) F-tests that compare (groups of) multi-locus genotype cells 




that of an ANOVA computed for two groups; the t-statistic is the square root of the F-statistic 
used in ANOVA. Hence, in principle, the validity of MB-MDR epistasis results may depend 
on whether or not ANOVA assumptions are met, which warrants further investigation. Many 
authors have studied the effects of model violations in regression settings in general and have 
suggested alternative strategies when violations cannot be remediated [4, 5].  
Due to the aforementioned link between MB-MDR and ANOVA, we are particularly 
interested in violations regarding the latter. The three main ANOVA assumptions are: 1) the 
observations are independent, 2) the sample data have a normal distribution within factor 
levels (e.g., multilocus genotype classes) and 3) the dependent variable‘s variances within 
each factor level are homogeneous (homoscedasticity) [4]. Generally speaking, when either 
the assumption of normality or homoscedasticity or both are violated, highly inflated type I 
errors and false positives can arise, suggesting a non-robustness of parametric methods under 
these scenarios [6]. It should be noted though that F- and t-tests are scarcely affected 
by non-normality of population distributions (e.g, [7, 8]). Nevertheless, when the dependent 
variable does not meet ANOVA‘s normality assumption, the non-parametric Kruskal-Wallis 
or Mann-Whitney U test [9] is commonly taken to replace the ANOVA‘s F or a Student‘s t-
test. However, these non-parametric counterparts are not an immediate solution to the 
problem of unequal variances (heteroscedasticity), as was shown before [10-12]. 
Alternatively, data transformations can be considered to induce normality. For instance, 
Wolfe et al. [13] used the logarithmic transformation to transform a skewed distribution to a 
distribution that is approximately normal. On the other hand, Jin et al. [14] highlighted that, 
when the logarithmic transformation is used, it may over-compensate right-skewed data and 
create left-skewed data, which can hardly be seen as an improvement. The Mann-Whitney U 
test avoids making distributional assumptions other than requiring group distributions of 
identical shape. For two-group comparisons, it is equivalent to an ordinary Student‘s t-test 
performed on the ranks of the original outcome measurements and its p-values are 
mathematically identical to Kruskal–Wallis one-way analysis of variance by ranks [15, 16]. 
The additional difficulties with data transformations prior to analysis (whether based on ranks 
or not) are that a chosen transformation may not address all issues at once (this is: addressing 
non-normality and unequal variances), and that several linear or non-linear data 
transformations will have different implications on post-analysis interpretability. A road map 
for the appropriate use of non-parametric and parametric two-group comparison tests when 




The event of unbalanced data (i.e., unequal sample sizes in group comparisons) affects the 
choice for a particular test as well. Gibbons and Chakraborti [17] emphasized that for 
unbalanced ANOVA designs, Mann–Whitney U tests are not a suitable replacement for 
Student‘s  t-tests when variances are unequal, irrespective of whether the assumption of 
normality is satisfied or violated. When normality and homogeneity of variance are violated 
together, Zimmerman and Zumbo [18] suggest that the Welch‘s  t-test, alias the unequal 
variance t-test, can effectively replace the Mann–Whitney U test when the data are first 
transformed to ranks prior to testing.  However, it has been reported in Danh [19] that the test 
with Welch correction becomes too conservative when sample sizes are strongly unequal 
compared to the Student‘s  t-test. Instead,  Szymczak [20] and Rupar [21] suggest focusing on 
medians (e.g. Mood‘s Median test). However, Pett [22] has argued that medians tests are less 
powerful than other non-parametric tests (e.g. Mann-Whitney and Kruskal-Wallis one-way 
ANOVA by ranks) because these only use two possibilities for scores: scores either above or 
below/equal to the median and the absolute value of the difference between the observed 
scores and the median is not accounted for. Figure 3.1 summarizes the utility of some popular 
parametric and non-parametric two-group comparison tests when group sizes are unequal 
[23].  
In the context of genetics, model violations and effects of imbalanced data have primarily 
been discussed in the context of gene expression studies and t-test/ANOVA models (e.g., [20, 
24, 25] . The topic is severely under-appreciated in the context of epistasis screening, as 
indicated before. For the latter, violations may pertain to prioritization or pre-screening 
algorithms, to the actual epistasis modeling and testing, as well as to the implemented 
corrections for multiple testing. Also for MB-MDR it has never been investigated what the 
cumulative effect is of violated association test assumptions, acknowledging that the presence 
and extent of these violations may differ within and between several stages of the MB-MDR 
analysis. However, concerns about distributional data assumptions for MB-MDR association 
testing can easily be removed by adopting a non-parametric viewpoint based on ranks (Figure 
3.1). In this study, we use simulations to assess the cumulative effect of deviations from 
normality and homoscedasticity on the overall performance of quantitative Model-Based 
Multifactor Dimensionality Reduction (MB-MDR) with variable association tests to detect 2-
locus epistasis signals. We investigate the utility of data transformations to maintain or to 
increase MB-MDR‘s efficiency and to control false positive rates. Since important lower-




positive epistatic findings, as discussed in [2, 3], we restrict our attention to pure epistasis 
two-locus models (i.e., no main effects). 
 
 
Figure 3. 1 Group comparison test, maintaining adequate Type 1 error control, when group sizes 
are unequal. 
Legend When several tests are listed, they are listed from most (top) to least (bottom) powerful. 
The tests in a square box and blue font should be avoided in MB-MDR due to reasons mentioned 






3.2 Materials and Methods  
3.2.1 Analysis method: MB-MDR 
Model-Based Multifactor Dimensionality Reduction (MB-MDR) is a data mining technique 
that enables the fast identification of gene-gene interactions among 1000nds of SNPs, without 
the need to make restrictive assumptions about the genetic modes of inheritance. The most 
commonly used implementation of MB-MDR involves testing one multi-locus genotype cell 
versus the remaining multi-locus cells (i.e. 1 cell versus 8 remaining cells, in case of 2 bi-
allelic loci). By construction, this procedure creates two (possibly highly) imbalanced genetic 
groups that subsequently need to be compared in terms of mean or median trait differences.  
To date, MB-MDR has used Student‘s t-test to make such group comparisons for quantitative 
traits. This implementation is based on simulation studies that assumed traits to be normally 
distributed with equal genotypic variances for each of the multi-locus genotype combinations 
corresponding to a bi-allelic functional SNP pair [2, 3]. The MB-MDR outputted final test 
statistics for epistasis evidence are presented as ANOVA F-statistics. Naturally, different 
numbers of individuals contribute to specific multilocus genotype combinations. More 
importantly, MB-MDR‘s internally performed group comparison tests involve possibly highly 
unequal group sizes. Hence, parametric t-tests are always pooled variance t-tests. A novel 
implementation allowing unequal group variances based on the Welch‘s t-test (WT) for two-
group comparisons is included in the MB-MDR software version 2.7.4.  
All simulated data are analyzed with MB-MDR, with Student‘s t-test (ST) as well as the novel 
Welch‘s t-test (WT) implementation to assess power and type I error. Prior to MB-MDR 
submission, original traits are either left untransformed or transformed into new traits via 
logarithm transformations (Log), standardization transformation (Stz) or via rank-based 
transformations. The latter transformations involve the assignment of absolute ranks to all 
available trait measurements in a serially increasing order (Rank), after which the ranks are 
transformed to normality (Rtn). Data transformations are conducted in R.2.15.0 [26].   We are 
currently working on a MB-MDR version that will optionally use a rank-transformation of 
original trait values, allowing MB-MDR analyses with parametric t- or non-parametric Mann-
Whitney U- tests of association. Overall significance is assessed at 5% level of significance 
after correction for multiple testing via the permutation-based step-down maxT multiple 




Small group sizes in group comparisons are dealt with by requiring a minimum contribution 
of 10 individuals to each group.  
3.2.2 Data Simulation 
We simulate 18  two-locus settings of an epistasis model following Evans et al. [29], each 
setting involving 1000 replicates and consisting  of 500 unrelated individuals per replicate. In 
particular, simulations are based on model M170 which requires an individual to be 
heterozygous at one locus and homozygous at the other in order to have an increased 
quantitative phenotype. Minor allele frequencies (MAFs) for the causal epistatic pair (SNP1 
and SNP2) are prespecified at 50%, hereby a pure epistasis model (M170 becomes a pure 
epistasis model when the MAFs of the two SNPs are set at 50%).  An additional 98 SNPs are 
generated with MAFs randomly sampled from a uniform distribution; U(0.05,0.5). We 
assume all SNPs to be in Hardy-Weinberg Equilibrium and assume linkage equilibrium 
between them. The proportion of phenotypic variation that is due to epistatic variation (
2
g ) 
between individuals is varied as 0, 5 and 10%.   
To assess the effect of violated normal trait distributions, we consider trait distributions that 
are, apart from normal, also chi-squared or Student‘s t; the same distribution is assumed for 
each of the 9 levels of the two-locus genotypes derived from SNP1 and SNP2 combined. To 
investigate the MB-MDR cumulative effects of heteroscedasticity, we consider for every 
aforementioned setting, constant and non-constant phenotypic variances according to the 
following scenarios. 
Scenario1: Normal distribution  
We simulate 9 variances from U[1,10], one for every two-locus genotype combination 
corresponding to SNP1 and SNP2. Homoscedasticity or constant variance is induced by 
simulating traits with multi-locus specific variance equal to the average of the 9 genotypic 
variances mentioned before. 
Scenario 2: Chi-square distribution  
Quantitative traits are generated from a central chi-square distribution with 2 degrees of 
freedom (df), inducing a constant trait variance for every two-locus genotype combination. To 
simulate settings with heteroscedasticity, non-central chi-square distributions are used, df 




for every two-locus genotype combination is taken to be the difference between a preset 
maximum (maxncp) of 10 and the genotype combination-specific df.  This results in a 
constant trait mean for all multi-locus genotypes (equal to maxncp) and phenotypic variances 
(twice the df + 4 times the ncp) ranging from 20 to 36. 
Scenario 3: t-distribution  
We consider quantitative traits from a t-distribution with 3 degrees of freedom. Non-equal 
phenotypic variances are introduced by generating data for the 9 multilocus genotype 







3.3.1 Data related 
Figure 3.2 shows density plots for the normal and chi-squared distributed original data (panel 
A) and rank-transformed to normality traits (panel B) with equal and unequal variances. The 9 
density groups refer to the 9 possible multi-locus genotypes the causal SNP pair and are based 
on a single replicate, so as to keep the total sample size to 500 individuals. For each scenario, 
the first generated dataset was used. Cell 0-0 on row 1 and column 1 (cell 2-2 on row 3 and 
column 3) refers to homozygous most (least) frequent allele individuals. The contribution of 
the epistatic variance to the trait variance is 10%. Other replicate data or assumptions about 
epistatic evidence give rise to similar plots (not shown). Rank-transformation to normality 
(Rtn) (cfr. panel B) effectively deals with multimodal data distributions (cfr. panel A). Testing 
whether the multilocus genotype-specific traits can be assumed to come from a normal 
population (Shapiro-Wilk‘s test) highlights a successful transformation from potentially non-
normal data (panel A) to approximate normal data (panel B). 
For the same scenarios as before, yet using all SNP pairs, and the 999 permutations F-
statistics data, we create quantile-quantile plots (qq-plots) for a theoretical F distribution with 
(g-1, n-g) degrees of freedom. Here, n=500 is the number of individuals in a dataset and g=2 
is the number of groups (i.e. 1 cell versus 8 remaining cells). Note that since no missing data 
were considered, all theoretical distributions for Student‘s t association tests within MB-
MDR, whatever SNP pair is considered, should be F(1,498). Whereas Figure 3.3 shows the 
qq-plots for association tests (squared Student‘s t) comparing a single multi-locus genotype 
(in particular, cell 0-0) with the 8 remaining ones, Figure 3.4 shows the qq-plots related to the 
SNP pairs and their MB-MDR step 2 test statistics (i.e., the maximum of association tests 
involving H-cells versus {L,O}-cells and one comparing the L-cells versus {H,O}-cells). 
Comparison of Figure 3.3 with Figure 3.4 could suggest that deviations from a theoretical F-
distribution is not so much of a concern at MB-MDR‘s dimensionality reduction step (i.e., 
labeling of multilocus genotypes according to ―severity‖), but seems to be quite dramatic for 
MB-MDR‘s step 2 two-locus test. This observation can be made, irrespective of whether traits 
initially are normally or chi-squared distributed, and irrespective of whether the original traits 






Figure 3. 2 Density plots for original trait (panel A) and rank transformed traits (panel B) for 
one simulated data replicate with epistatic variance, 10%. 
Legend Numbers as they appear with color lines in the legend:  1=normal constant variance, 
2=normal non-constant variance, 3=chi-square constant variance, 4=chi-square non-constant 
variance. Wild-type individuals (homozygous for the major allele) are coded as 0, heterozygous 
individuals as 1, and individuals homozygous for the minor allele as 2. Figures in brackets 







Figure 3. 3 Qq-plots  of squared Student‘s t- test values for association between the multi-locus 
genotype combination cell  0-0 versus the pooled remaining multi-locus genotypes, for normal 
and chi-squared trait distributions or non-transformed and rank-transformed to normal data.   
Legend Each time, one replicate with epistatic variance, 10% is considered and F-statistics are 
pooled for all SNP pairs over the 999 permutations. A theoretical F-distribution according to 






Figure 3. 4 Qq-plots of MB-MDR step 2 test values (squared Student‘s t), for normal and chi-
squared trait distributions, and non-transformed or rank-transformed to normal data. 
Legend For each setting, one replicate with genetic variance, 10% is considered and F-
statistics are pooled for all SNP pairs over the 999 permutations. A theoretical F-distribution 








However, recreating Figure 3.3, now for cell (2,2) instead of (0,0) (hence, the multilocus 
genotype cell which has the smallest number of individuals contributing to it), also highlights  
hard to ignore deviations from the theoretical F(1,498) distribution at cell labeling stage (see 
Figure 3.5).  
 
Figure 3. 5 Qq-plots  of squared Student‘s t- test values for association between the multi-locus 
genotype combination cell  2-2 versus the pooled remaining multi-locus genotypes, for normal 
and chi-squared trait distributions or non-transformed and rank-transformed to normal data.   
Legend Each time, one replicate with epistatic variance, 10% is considered and F-statistics are 
pooled for all SNP pairs over the 999 permutations. A theoretical F-distribution according to 





3.3.2 Familywise error rates and false positive rates 
Table 3.1 and Table 3.2 report the familywise error rates (FWER) corresponding to the 
simulation scenario 
2
g =0 (no epistasis, no main effects) and false positive rates 
corresponding to 
2
g =0.05 and 0.1 (scenarios of epistasis in the absence of main effects). We 
observe that, irrespective of the original trait distribution and whether or not a data 
transformation preceded MB-MDR analysis, the estimated rates satisfy Bradley‘s [30]  liberal 
criterion of robustness for the significance level α=0.05 . This criterion requires that the error 
rates are controlled for any level α of significance, if the empirical rate ˆ  is contained in the 



















   
 
TRAIT STATUS Familywise error rate (Type I) 
Distributions Variances ST WT Rank_ST Rank_WT Log_ST Log_WT Rtn_ST Rtn_WT 
Normal Equal 0.040 0.053 0.049 0.049 0.044 0.051 0.050 0.058 
Normal Unequal 0.058 0.066 0.044 0.051 0.064 0.056 0.053 0.058 
Chi-square Equal 0.045 0.036 0.052 0.051 0.055 0.038 0.058 0.056 
Chi-square Unequal 0.053 0.057 0.048 0.052 0.051 0.054 0.043 0.047 
t-distribution Equal 0.048 0.053 0.050 0.059 0.049 0.056 0.052 0.057 
t-distribution Unequal 0.057 0.044 0.042 0.051 0.053 0.048 0.045 0.039 
ST-Student‘s t-test, WT-Welch‘s t-test, Rtn- Rank transformation to normal 
 
Table 3. 1 Type I error rates for data generated under the null hypothesis of no genetic association. 
 
 
  TRAIT STATUS FALSE POSITIVES 
2
g  Distributions Variances ST WT Rank_ST Rank_WT Log_ST Log_WT Rtn_ST Rtn_WT 
 Normal Equal 0.040 0.047 0.053 0.048 0.051 0.047 0.050 0.051 
 Normal Unequal 0.051 0.060 0.044 0.061 0.052 0.065 0.048 0.068 
 Chi-square Equal 0.037 0.056 0.051 0.053 0.042 0.054 0.045 0.056 
0.05 Chi-square Unequal 0.040 0.055 0.047 0.042 0.042 0.053 0.047 0.052 
 t-distribution Equal 0.051 0.048 0.048 0.051 0.047 0.047 0.047 0.033 
 t-distribution Unequal 0.053 0.047 0.058 0.057 0.054 0.048 0.051 0.052 
 Normal Equal 0.040 0.067 0.058 0.058 0.053 0.061 0.054 0.063 
 Normal Unequal 0.050 0.065 0.044 0.058 0.048 0.063 0.045 0.057 
 Chi-square Equal 0.048 0.059 0.061 0.060 0.053 0.055 0.057 0.056 
0.1 Chi-square Unequal 0.063 0.041 0.051 0.041 0.061 0.040 0.053 0.036 
 t-distribution Equal 0.048 0.053 0.047 0.049 0.050 0.054 0.044 0.051 
 t-distribution Unequal 0.033 0.050 0.055 0.059 0.036 0.051 0.037 0.051 
False positive percentage is defined as the proportion of simulation samples for which at least one pair other than the causal pair 
(SNP1, SNP2) are significant. 
ST-Student‘s t-test, WT-Welch‘s t-test, Rtn- Rank transformation to normal 
 




3.3.3 Empirical power estimates 
MB-MDR empirical power estimates for correctly identifying the causal epistatic SNP are 
given in Table 3.3. For all scenarios higher MB-MDR power is achieved with increasing 
2
g , 
i.e., with increasing proportion of epistatic variance to total trait variance. MB-MDR analysis 
with Welch‘s t-test has generally lower power than MB-MDR with the Student‘s t-test. This 
power loss is most severe for normal data. A (moderate) power gain is observed for settings 
where traits are t-distributed, variance homogeneity is present, epistatic variance is 10% and 
data are either left untransformed or are log-transformed prior to MB-MDR analysis. 
Parametric Student‘s t-tests with the original trait measurements lead to reduced overall MB-
MDR power when trait distributions deviate from normality.  For non-normally distributed 
traits, there is a tendency for MB-MDR with Student‘s t applied to rank-transformed data to 
outperform other MB-MDR analysis approaches (this is: association tests other than Student‘s 
t and other types of transformation, or no transformation at all). A worthy competitor is MB-
MDR with Student‘s t after rank-transforming original traits to normality. The differences in 
power performance between MB-MDR using untransformed traits or transformed traits are 
the largest for rank-based transformations compared to logarithmic transformations. No 
significant differences are observed between empirical power estimates derived from MB-
MDR analysis on untransformed traits compared to those analyses based on trait 
standardization transformations (results not shown).   
A graphical representation of the  1000 MB-MDR epistasis test results for the causal SNP pair  
(p-values, multiple testing corrected, as outputted by the MB-MDR software), one for each 
data set generated under a particular simulation setting (in particular, 
2
g  = 10%), is given in 
Figure 3.6. Here, MB-MDR with Student‘s t is considered. Results are depicted for scenarios 
where the original trait data are derived from a normal (symmetric) or from a chi-squared 
(non-symmetric) distribution, and then subjected to different data transformation strategies. 
The scatter plot matrices of Figure 3.6 suggest a tendency for smaller MB-MDR p-values to 
be generated after rank-based data transformations compared to other type of transformations, 
including the identity transformation (see for instance Panels A and B for normally distributed 
traits). This tendency becomes more extreme for chi-square distributed traits with non-equal 
variance (Panel D). Here, it becomes apparent that rank-transformation generally leads to 
larger p-values as compared to rank-transformations to normality. For settings where traits are 




(Panel C) are in agreement with the corresponding results in Table 3.3 (power estimates of 
100% in the event of a non-identity transformation compared to 90% for MB-MDR applied to 
untransformed traits). If there were no differences between the untransformed and 
















 TRAIT STATUS POWER 
2
g  Distributions Variances ST WT Rank_ST Rank_WT Log_ST Log_WT Rtn_ST Rtn_WT 
 Normal Equal 0.400 0.046 0.367 0.001 0.377 0.039 0.378 0.041 
 Normal Unequal 0.330 0.083 0.391 0.001 0.331 0.069 0.344 0.051 
 Chi-square Equal 0.221 0.000 0.953 0.130 0.929 0.466 0.978 0.802 
0.05 Chi-square Unequal 0.317 0.005 0.511 0.002 0.402 0.012 0.578 0.135 
 t-distribution Equal 0.344 0.239 0.920 0.042 0.338 0.240 0.806 0.320 
 t-distribution Unequal 0.383 0.116 0.615 0.002 0.380 0.122 0.543 0.132 
 Normal Equal 0.950 0.634 0.952 0.087 0.959 0.626 0.958 0.650 
 Normal Unequal 0.963 0.743 0.975 0.152 0.955 0.727 0.959 0.690 
 Chi-square Equal 0.897 0.126 1.000 0.922 1.000 1.000 1.000 1.000 
0.1 Chi-square Unequal 0.938 0.350 0.989 0.255 0.975 0.548 0.991 0.884 
 t-distribution Equal 0.873 0.881 1.000 0.885 0.853 0.876 0.999 0.987 
 t-distribution Unequal 0.921 0.801 0.995 0.409 0.921 0.806 0.989 0.834 
Power is defined as the proportion of simulated samples of which the causal pair (SNP1, SNP2) is significant. 
ST-Student‘s t-test, WT-Welch‘s t-test, Rtn- Rank transformation to normal 
 





Figure 3. 6 Scatter plot matrices of MB-MDR multiple testing corrected p-values for the causal 
SNP pair for a variety of a priori data transformations. 
Legend Only MB-MDR results with Student‘s t testing for associations are shown. The epistatic 
contribution to the trait variance is set to 10%. Different scenario‘s of trait distribution are 
considered: normal traits and homogeneity (panel A); normal traits and heteroscedasticity (panel 
B); chi-squared distributed traits and homogeneity (panel C); chi-squared distributed traits and 





Proposed data mining methods for epistasis detection are seldom thoroughly discussed in 
terms of their underlying (model) assumptions and their effects on overall power or type I 
error control. For instance, another well-known data dimensionality reduction method for 
quantitative traits (generalized MDR - GMDR) [31] is based on score statistics to define 
differential multilocus genotype groups related to the trait of interest. Although the GMDR 
method is not necessarily likelihood-based (least-squares regression or other statistical 
methods for non-normal continuous traits can be employed as well, in theory), continuous 
phenotypes were only investigated in terms of a normal model, and the software 
implementation for continuous traits relies on the classical linear regression paradigm to build 
the score statistics. The authors did not explicitly investigate the power of their method when 
non-normal continuous data are involved in the context of epistasis screening.   Previously, 
we commented on the advantages and disadvantages of GMDR-like methods compared to 
MB-MDR (e.g., [28, 32]). Based on these comments, we here focused on MB-MDR while 
investigating the effects of model-violations on the performance of 2-locus multifactor 
dimensionality reduction methods for quantitative traits. 
For every 2 loci (for 2 bi-allelic SNPs, there are theoretically 9 multilocus genotype 
combinations), MB-MDR with association t-tests subsequently creates two groups, where one 
group refers to one multilocus genotype and the other to the remaining multilocus genotype 
combinations. Internally, 2-group comparison tests are performed so as to assign a ―label‖ to 
each multilocus genotype. This procedure naturally creates highly imbalanced groups, with 
potentially extreme cases of heteroscedasticity. Although Welch‘s test is designed to give a 
valid t-test in the presence of different population variances, Welch‘s t-test combined with 
MB-MDR shows no improved power over the Student‘s t-test for scenarios with unequal 
variances, even for normally distributed traits (cfr Table 3.3). This can be explained by the 
fact that the degrees of freedom for the Welch‘s test become smaller for strongly unequal 
groups, resulting in a highly conservative test in the event of extreme unbalanced data (see 
e.g.,  [33] and Figure 3.1). This motivates our choice to continue working with MB-MDR 
analyses based on Student‘s t testing to identify groups of multilocus genotypes with 
differential trait values, despite the underlying trait distribution.  
It is well-know that parametric methods have improved statistical power over non-parametric 




residuals detects violations of assumptions of normality and heterogeneity of variance of 
errors across groups for ANOVA, remedial measures that log-transform the dependent 
variable and consideration of an ANOVA model assuming unequal variances, may work well. 
However, in screening settings involving many factors at a time, it is usually impractical to 
find a single transformation that is universally optimal for all factors. When study data do not 
meet the distributional assumptions of parametric methods, even after transformation, or when 
data involve non-interval scale measurements, a non-parametric context is more appropriate. 
Such a context usually implies testing based on ranks or applying data rank transformations 
prior to the application of a parametric test.  
Strong power increases were observed when data were rank-transformed prior to MB-MDR 
testing with Student‘s t association testing. This can be understood by noting that the ranks, 
which are computed for the pooled set of all available quantitative trait measurements, in 
general reduces the influence of skewness and deviations from normality in the population 
distribution [35, 36].  The same is achieved by a percentile transformation (Rtn), which – at 
the same time - preserves the relative magnitude of scores between groups as well as within 
groups. Only for normally distributed data with equal variances, the ideal scenario for a t-test 
on original traits, a small power loss is observed. Goh and Yap [36] also concluded that rank-
based transformation tends to improve power regardless of the distribution. In general, as with 
traditional two group t-testing, deviations from normality seem to be more influential to the 
power of an MB-MDR analysis with Student‘s t than deviations from homoscedasticity 
(Table 3.3). This is also in line with the observation that power estimates generally become 
more optimal for scenarios in which data are transformed to normality prior to MB-MDR 
analysis compared to scenarios in which they are not. The identical results obtained for 
untransformed traits and standardized traits (not shown) are not surprising as well. 
Standardization involves linearly transforming original trait values using the overall trait 
mean and overall standard deviation. Such a transformation does not affect the two-group t-
tests within MB-MDR.    
Although data transformations are valuable tools, with several benefits, care has to be taken 
when interpreting results based on transformed data. The inference of epistasis depends upon 
the scale of measurement in a way that interaction effects can be reduced or eliminated by 
non-linear monotonic transformations of a dependent variable [37], so also by some rank-
based transformations. However, for our simulation scenarios, we have not seen any evidence 




analysis (Tables 3.1-3.3, Rank). Application of any epistasis screening tool to real-life data 
will face the challenge to match observed statistical significance with biological relevance [1]. 
Despite MB-MDR internal inflations (Figures 3.4 and 3.5), there is no evidence for a 
cumulative or combined effect on MB-MDR‘s final results (Tables 3.1 and 3.2), irrespective 
of the assumed model violation (in terms of deviations from normality or homoscedasticity). 
This can be explained by the permutation-based step-down maxT approach, which is currently 
adopted by MB-MDR to correct for multiple testing of SNP pairs. 
In many of our practical applications, though we observed a tendency of increased numbers of 
significant epistasis results with MB-MDR applied to quantitative traits, even after SNP 
pruning (r
2
 below 75%) to avoid potential false positives (or redundant interactions) due to 
highly correlated SNPs. No such observation was previously made for dichotomous traits. For 
dichotomous traits, MB-MDR uses a score test, in particular, the Pearson's chi-squared test. 
This test is known to be affected by unbalanced data, or sparse data, as is the case for rare 
variants [38]. However, these data artifacts, which question the use of large sample 
distributions for test statistics, are minimized by requiring a threshold sample size for a 
multilocus genotype combination, irrespective of whether a dichotomous or quantitative trait 
is used. Hence, an explanation for the apparent discrepancies between practical and theoretic 
MB-MDR results may be found in the way the null distribution for multiple testing is derived. 
It is often forgotten that also permutation-based multiple testing corrective procedures make 
some assumptions. For instance, for the step-down maxT approach, currently the default 
multiple testing strategy in MB-MDR, the Family-Wise Error Rate (FWER) is strongly 
controlled provided the assumption of subset pivotality holds [27]. The subset pivotality 
ensures that the distribution of any sub-vector of p-values does not depend on the truth or 
falseness of the hypotheses not considered by this sub-vector [39]. 
Preliminary results on the effect of linkage disequilibrium on MB-MDR error control, as well 
as on the effect of highly variable minor allele frequencies (and thus highly variable available 
samples sizes for multilocus genotypes) show that subset pivotality is likely to be violated in 
real-life settings, giving rise to inflated error rates in the presence of multiple epistasis signals 
(work in progress).  Note that the standard bootstrap method provides the asymptotically 
correct null distribution for multiple testing and does not require the subset pivotality 
condition given in Westfall and Young [27]. Resampling-based multiple testing with 
asymptotic strong control of type I error as corrective method for multiple testing in MB-




Summarizing, we observed that non-normally distributed traits can affect the power of final 
test statistics of MB-MDR with classical t-tests for association, and that this influence is 
primarily driven by the sparser multilocus genotype combinations. Improved power can be 
obtained by pre-analysis data transformation to normality. MB-MDR permutation-based 
maxT correction for multiple testing keeps type I error and false positive rates under control, 
since in all considered simulation scenarios‘, the assumption of the maxT permutation 
strategy was plausible.    
When performing MB-MDR screening for gene-gene interactions with quantitative traits, we 
recommend to rank-transform traits to normality prior to MB-MDR analysis with Student‘s t 
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Analysis 1 
Analysis of the High Affinity IgE Receptor Genes Reveals Epistatic 





1.1 Aim of the Analysis 
We investigated the association of 27 FCER1A, FCER1B (MS4A2), and FCER1G variants 
with IgE in a large population-based cohort and tested for epistatic effects using the MB-
MDR method. In addition, we investigated a potential interaction between 10 FLG and 
FCER1A variants in a large collection of eczema cases and population controls. We believe 
that small-scaled genetic studies, based on candidate genes rather than genome-wide data, are 
useful in methodological development: Due to the complexities of high-dimensional genomic 
data analysis, both from the biology and statistics perspective, any statistical epistasis 
detection method is believed to have little viability when not useful on a much smaller scale. 
Thus, if a method does not work on small-scaled data it will certainly not work on large-scale 
data sets. 
1.2 Data description 
KORA S4 is an epidemiological study group including 4261 unrelated German adult 
individuals representative of the population within the age range of 25–74 years in the city 
and region of Augsburg (Bavaria, Germany); probands were recruited from 1999 to 2001 [1]. 
In addition to demographic data, all subjects had to complete a standardized questionnaire that 
included the basic allergy questions of the European Community Respiratory Health Survey 
on respiratory health [2]. Total and specific IgE antibodies to aeroallergens (Sx1) were 
measured using RAST FEIA CAP system (Pharmacia, Freiburg, Germany). Allergic 
sensitization was defined as specific IgE levels ≥0.35KU/l (CAP class ≥1). DNA was 
available for 4261 individuals (50.9% females), and all subsequent analyses were based on 
this number. All German patients with eczema were unrelated and of white origin, with 
eczema diagnosed on the basis of a skin examination by experienced dermatologists using the 
UK diagnostic criteria [3]. The collection of 1018 individuals (59.5% females) was recruited 
in the department of dermatology of the University hospitals of Bonn and Munich. 
1.3 MB-MDR Results and Discussion  
Results on total IgE indicated strong epistasis between the two FCER1A variants rs2251746 
and rs16842010 (p-value <0.001). These variants were found to be weakly correlated (r
2
 = 
0.003) and can thus be regarded as uncorrelated. Taking eczema as outcome, MB-MDR 




gene. Because of their known and confirmed remarkably strong effect on eczema risk, we 
additionally performed the algorithm with adjustment for FLG effects to determine whether 
these results were attributed to genuine epistasis. After this correction, the interaction between 
FLG and FCER1A polymorphisms vanished, but we identified statistical epistasis between 
the two FCER1A SNPs rs10489854 and rs2511211 (p-value =0.046). Concerning linkage 
disequilibrium, the two variants of the FCER1A genes also showed a weak correlation (r
2
 = 
0.01). With correction of main effects, no significant results were observed for variants of the 
FCER1B and FCER1G and FLG genes. In addition, all investigated SNPs were in Hardy-
Weinberg Equilibrium. The significant interactions observed from the MB-MDR analysis 
indicated that these outcome respective two SNPs jointly have a strong effect on total IgE and 
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2.1 Aim of the Analysis 
We explored the utility of several methods, both parametric and non-parametric, to test for or 
model genetic associations using population-based and family-based data from Genetic 
Analysis Workshop 17 (GAW17). Here, we focus on MB-MDR related analyses (MB-MDR-
population data and FAM-MDR-family data) incorporating the maxT and minP of Westfall 
and Young [4] for multiple testing correction. 
2.2 Data description 
The data provided by GAW17 [5] included a subset of genes grouped according to pathways 
that had sequence data available in the 1000 Genomes Project. Effect sizes for coding variants 
within these genes were assigned using PolyPhen and SIFT predictions of the likelihood that 
the variant would be deleterious. Two hundred replicates were generated.  All simulated 
singular SNP effects (C4S1861, C4S1873, C4S1874, C4S1877, C4S1878, C4S1879, 
C4S1884, C4S1887, C4S1889, and C4S1890 in the KDR gene and C4S4935 in the VEGFC 
gene) are assumed to be additive on the quantitative trait scale, such that each copy of the 
minor allele increases or decreases the mean trait value by an equal amount. The sample size 
for both population- and family-based data was 697 with family data comprising 8 families 
with 202 founders and 3 offspring generations. The founders were randomly sampled from 
the unrelated individuals‘ data set, and genotypes of offspring were sampled using Mendelian 
inheritance. 
Our analyses involved the quantitative trait Q1, which was simulated as a normally distributed 
phenotype. Furthermore, we restricted attention to the available single-nucleotide 
polymorphisms (SNPs) on chromosome 4 (944 SNPs). In total, 200 replicates were generated. 
2.3 MB-MDR Results and Discussion 
We observed that the MB-MDR approach for unrelated individuals had some power (0.14 for 
max T and 0.34 for min P) to find C4S1878, the marker with the largest MAF (0.16), but also 
elevated FWER estimates (0.13 and 0.50, respectively). On the other hand, the FAM-MDR 
approach had not only some power (0.18 for max T and 0.17 for min P) to detect C4S4935 
but also kept the FWER under control. The total contribution of markers in linkage 
disequilibrium with functional markers (r
2
>0.9) was only 0.01 to FWER, hence this can be 




MB-MDR analyses on simulation data with normal traits led us to postulate that the rarity of 
certain marker alleles hampers the validity of model assumptions and distributional properties 
of test statistics as well as assumptions underlying some commonly used measures to correct 
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3.1 Aim of the Analysis  
We investigated polymorphisms in selected autophagy genes for their association with 
susceptibility to Crohn‘s disease. Autophagy has been recently implicated in various human 
pathological and physiological conditions including cancer, heart diseases, liver disease 
Crohn‘s disease etc. The autophagy connection is presented in Figure 3.1. 
3.2 Data description 
In the framework of the IBD genetics study conducted at the IBD unit of the University 
Hospital in Leuven, Belgium, we studied 1282 Crohn‘s disease (CD) patients of Western 
European origin and a control group of 548 unrelated healthy volunteers without a family 
history of IBD or other immune-related disorders. Diagnosis of IBD was based on accepted 
clinical, endoscopic, radiologic, and histologic criteria [7, 8]. As an exploratory cohort, a total 
of 70 haplotype tagging single nucleotide polymorphisms (tSNPs) in 12 genes were 
genotyped in a cohort of 947 CD patients and 548 controls. A confirmatory cohort consisting 
of 335 trios with father, mother, and a child affected with CD was also available. DNA was 
extracted as described in Miller et al. [9]. Samples and data were stored in a coded and 
anonymized database. 
3.3 MB-MDR Results and Discussion 
We found a novel association between one haplotype tagging SNP (rs12303764) in the ULK1 
gene and CD. MB-MDR confirmed this association which also was found both in a single 
SNP analysis and TDT in 335 parent–child CD trios. To further clarify the role of ULK1 in 
CD, an in-depth investigation of the variation in the region and possible role for copy number 
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4.1 Aim of the Analysis  
We investigated association between Chrohn‘s disease (CD) and 11 SNPs in the autophagy 
genes ATG16L1, IRGM and MTMR3; the endoplasmic reticulum (ER) stress gene ORMDL3; 
and the bacterial sensing gene NOD2 in a large Belgian CD cohort. In addition, we also 
evaluated these SNPs in a large Belgian Ulcerative Colitis (UC) cohort, to determine whether 
these variants were specific for CD or also important in UC. 
4.2 Data description  
The study population consisted of 3451 individuals in total: 1744 CD patients (42% males) 
and 793 UC patients (55% males) from the IBD unit of the University Hospitals Leuven, and 
a control group of 914 unrelated healthy controls (48% males). Both patients and controls 
were of Caucasian origin. Diagnosis of CD or UC was based on accepted clinical, endoscopic, 
radiologic and histological criteria [7]. Informed consent was obtained from all participants. 
All DNA samples and data in this study were handled anonymously.  
4.3 MB-MDR Results and Discussion 
For CD, MB-MDR analysis showed a significant two-way interaction between ATG16L1 and 
IRGM (p-value=0.001): rs2241880 (ATG16L1) – rs10065172 (IRGM). Both of these genes 
belong to the autophagy pathway with a weak correlation between them, r² = 0.006. For UC, 
no significant interactions were observed.   Despite the known functional interaction between 
pathways, we did not find gene-gene interactions between the three pathways of ER stress, 
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Chapter 1: Discussion 
1.1 General objective 
The main objective of this thesis was to investigate the performance of Model-Based 
Multifactor Dimensionality Reduction method for quantitative traits, under a variety of 
settings and assumptions about the operation epistasis mechanisms. 
1.2 General Discussion  
Most common complex human diseases are caused by multiple genetic variants. Identifying 
such genetic variants, as well as the potential modifying effect they have on each other has 
been and still is a big challenge in genetic epidemiology. Indeed, although genome-wide 
association (GWA) studies have highlighted many loci associated with common diseases 
using (mostly) binary or quantitative traits, similar studies targeting gene–gene interactions 
(epistasis), as in genome-wide association interaction (GWAI) studies have been less 
successful. Yet, it is believed that epistatic interactions may play a significant role in 
improving pathogenesis, prevention, diagnosis and treatment of complex human diseases, it 
needs to be seen how important gene-gene interactions are as a potential source of the so-
called missing heritability [1]. The limited success of worldwide GWAI studies efforts as 
compared to GWA studies efforts can be attributed to several factors. A major challenge in 
analyzing epistasis in GWA studies is the enormous computational demands it involves while 
analyzing billions of SNP combinations. Whereas many human GWA studies test on the order 
of one million SNPs (only), considering all pairs of SNPs amounts to approximately 500 
billion tests; the number of pairs of SNPs scales quadratically with the number of markers [2]. 
Due to the large number of interaction tests that need to be performed, in particular, when 
using traditional statistical testing approaches, searching for epistatic effects poses both 
computational and statistical challenges. Last but not least, there is a conceptual difficulty 
related to the success of GWAI studies in that they aim to identify biological mechanisms via 
mathematical/statistical models; models that may be too simplistic to capture the complexity 
of the underlying phenomena and are often restricted by scales of measurements.  
Having the aforementioned challenges in mind, several methods have been developed to 
detect (causal) interacting genes. According to Onkamo and Toivonen [3], these methods can 
be categorized into tree-based methods (e.g, random forests), pattern recognition methods 




reduction). Driven by the popular case-control design, most of the developed methods are 
restricted to dichotomous traits or at least require categorizing a given quantitative trait into 
distinct phenotypic categories prior to application. Obviously, often the variability exhibited 
by many traits fails to fit into  distinct discrete phenotypic classes (discontinuous variability), 
but instead forms a spectrum of phenotypes that blend imperceptively (continuous 
variability), and this should be acknowledged [4].  
We developed a data-mining method, Model-Based Multifactor Dimensionality Reduction 
(MB-MDR) to detect epistatic interactions under different types of traits [5-7]. MB-MDR is a 
data mining technique that enables the fast identification of gene-gene interactions among 
1000nds of SNPs, without the need to make restrictive assumptions about the genetic modes 
of inheritance. In this thesis, we zoomed in on curtailing the MB-MDR methodology to 
quantitative traits and on finding the most optimal conditions and settings for quantitative trait 
MB-MDR analysis via extensive simulation studies.   
Most simulation studies in this thesis involve small data sets in terms of marker design (10 - 
100 markers), though the quantitative MB-MDR method applies to GWA data as well. 
However, given the fact the MB-MDR employs an exhaustive search strategy on the input 
data, applying the method as such to genomewide SNP data might be infeasible, due to 
limitations of the available IT environment that may not be able to handle the computational 
and storage demands a GWAI study induces. To make the MB-MDR methodology less 
dependent on the properties of the IT environment it operates in, we are developing a protocol 
for optimal Genome-Wide Association Interaction (GWAI) analysis [8]. This minimal 
protocol includes input/output data properties and  pre-analysis data quality contol procedures 
(involving Hardy-Weinberg Equilibrium test, marker call rates and marker frequencies) 
related to GWA analysis in general and GWAI analysis in particular (missing data handling 
and LD control). The protocol also gives recommendations with respect to integrating 
available knowledge into the MB-MDR analysis by further reducing the interaction search 
space, for instance via Biofilter [9].  
Biofilter explicitly uses biological information about gene-gene relationships and gene-disease 
relationships to construct multi-SNP models, hereby adopting a gene-centric approach.  An 
upgraded release of Biofilter is expected, and will allow using even a larger amount of 
available biological and statistical knowledge on gene-gene interactions, for a priori data 




It should be noted that pre-filtering can also be done based on statistical knowledge. For 
instance, Hoh et al. [10]  proposed a 2-stage approach in which SNPs that meet some 
threshold in a test at the first stage are subsequently followed up for modeling interactions at 
the second stage. Alternatively, Oh et al. [11] developed Gene-MDR. This analysis method is 
also a 2-stage approach. The first stage, a within-gene analysis, summarises each gene‘s effect 
from several SNPs within the same gene. The second stage, the between-gene analysis, 
involves performing interaction analysis using summarized gene effects derived from stage 1.  
Although pre-filtering or multi-stage analyses may come at the cost of losing potentially 
interesting signals (for instance, failure to detect interactions involving markers without 
significant marginal effects), in particular prefilitering may be highly beneficial in bridging 
the gap between statistical and biological or genetical epistasis.  
In traditional applications of MDR, model selection within a cross-validation framework is 
used to select a single best model. This misses other important multilocus models that could 
be biologically meaningful. Recently, Oki and Motsinger-Reif [12], developed a filter-based 
approach, using MDR modeling to evaluate and rank (based on classification error) all 
univariate effects and two-locus epistatic effects hereby prioritizing models for follow-up in 
replication studies. 
In this thesis, we focused on 2-order interactions for bi-allelic SNPs. The MB-MDR software 
can handle multi-allelic genetic markers and is fairly easily extended to investigate higher-
order interactions (i.e. > 2-way interactions) [13]. However, it is questionable whether valid 
biological interpretations can be given to higher order interactions (>2), when it is already so 
difficult to do so for order 2. In addition, building sensible animal models to support the 
statistical findings seems almost untangible. Yet, still emphasizing 2-way genetic interactions, 
a beta-version of the MB-MDR software allows to tackle research questions such as ―How 
does a fixed (non-) genetic factor (such as smoking or gender) modify the effect of gene-gene 
interactions?‖ (see also [14] with smoking as a potential modifying explanatory variable), or  
phrased differently ―Can we observe different gene-gene interaction patterns according to 
different population subgroups?‖   
We chose not to include multi-allelic markers in MB-MDR analyses, due to issues related to 
―sparseness‖ and ―unavailable‖ multilocus genotypes. These issues require more detailed 
investigations, as was indicated by our work on epistasis with rare variants. The latter clearly 
showed that analyzing rare variants with current implementations of MB-MDR highly inflates 




I errors by setting a lower bound on the number of individuals required for each multilocus 
genotype (see Chapter 3 of PART 2). Additional measures are needed when multi-allelic 
markers or rare variants are involved. In either case, as the aforementioned lower bound in the 
context of bi-allelic SNPs increases, MB-MDR‘s type I errors decrease as well (results not 
shown).  
In general, in the case of missing genotypes, the implementation of MB-MDR uses available 
data. However, MDR and MDR related extensions commonly require complete cases to run 
the analysis. In order to have complete data, there are mainly two options to follow: 1) simply 
removing individuals with missing genotypes or 2) imputing missing genotypes. The first 
option is the least desirable option because it usually leads to invalid analyses when data are 
not completely missing at random [15], besides throwing away possibly valuable (expensive) 
information.  The second option is to be preferred. The original MDR software adopted a 
frequency-based imputation strategy to impute missing genotypes with the most common 
genotype of the respective SNP.  Thus, the imputation method is performed for one SNP at 
the time, prior to MDR analysis. This may be a reasonable option when the extent of missing 
genotypes is not dramatic, and when missingness occurs at random across cases and controls. 
Recently, Namkung et al. [16] developed a procedure called ‗EM impute‘ which imputes 
missing genotypes using the expectation-maximization (EM) algorithm within the MDR 
process. Thus, unlike the frequency-based imputation, ‗EM impute‘ does not require a 
separate step of imputation, but rather it imputes missing values within the MDR analysis. 
‗EM impute‘ has been made available through the package imputeMDR of the R software 
[17]. Actually, this R package also allows for two other ways of handling missing data: using 
all available data for given number of SNPs under consideration, or treating missing 
genotypes as another (usually fourth) genotype category.  
The R software also offers a number of other imputation procedures through the R package 
imputation [18]. These and other imputation software tools can obviously also be applied to 
―complete‖ data prior to MB-MDR analysis. These tools were primarily developed in the 
context of biostatistics or GWA studies. We specifically mention the BEAGLE software of 
Browning and Browning [19], allowing to impute missing ungenotyped markers using a 
reference panel. This panel may contain data for parent-offspring trios, parent-offspring pairs 
or unrelated individuals. However, whereas GWA studies exploit LD between markers to find 
the true causal variants, LD in GWAI studies may induce redundant [20, 21] interactions. (See 




The practical application section presented in this thesis identified several significant genetic 
interacation effects with quantitative MB-MDR that could be confirmed with other statistical 
methodologies. The concern remains whether these findings can be translated into 
biologically relevant mechanisms. In the general introduction of this thesis, we discussed the 
difference between statistical epistasis and biological epistasis, and indicated that a 
statistically significant interaction is not necessarily biologically significant. This leads into 
the discussion about replicating epistastic findings. Should a finding be replicated in an 
independent data set? Is that possible in the context of GWAI studies where large sample 
sizes are needed and over 50 epistasis [22] models  exist for two bi-allelic loci?  Should 
results be confirmed by animal models or human cell cultures? [23] When using the same 
criteria as for GWA studies, replication in GWAI studies is likely to fail. In our opinion, not 
being able to replicate epistasis findings in this sense is not the end of the story. As Greene at 
al. [24] pointed out as well, failure to replicate may provide important clues about ‗some 
hidden‘ genetic architecture, and it is should be our mission to unravel this architecture.  
Chapter 2: Future Perspectives 
2.1 Introduction 
In this thesis, we presented epistasis screening results of MB-MDR on different scenarios. For 
all simulated data, we assumed all SNPs to be in Hardy-Weinberg equilibrium and assumed 
linkage equilibrium between them. In addition, analyses were performed on single traits 
(univariate phenotypes). However, in reality, markers located on the same chromosome may 
be in linkage disequilibrium, and when not properly accounted for may lead to spurious 
results [25]. Moreover, genetic epidemiological studies typically contain data collected on 
multiple traits that are jointly associated to genes and their interactions.  Testing several traits 
jointly may be more powerful than testing a single trait at a time [26].  Our ongoing and future 
research activities aim at adjusting for linkage disequilibrium patterns and accommodating 
multiple traits in MB-MDR epistasis screening. Thus, we intend to assess MB-MDR‘s 
flexibility in handling data under linkage disequilibrium and/or data with multiple traits. 
2.2 Linkage Disequilibrium 
Modeling and detecting gene-gene interactions at multiple quantitative trait loci often assume 




real-life GWAI study populations. Genetic association studies owe their success to the ability 
to detect association signals via markers that are in high linkage disequilibrium (LD) with 
disease predisposing loci.  Indeed, an association between a genetic marker and a trait can  be 
direct (the allele under investigation directly influences the trait) or indirect (the allele is in 
LD with the disease-predisposing mutation) [28]. The underlying assumption of genetic 
association studies is that there are some disease causing loci in the genome, and that if the 
SNPs under investigation and the disease-causing loci are in close proximity, the marker 
alleles will be associated with the alleles at the disease-causing loci and can be used as proxy 
to identify the true causal variant [29]. Motsinger et al. [30]  showed that strong patterns of 
LD increase the power of grammatical evolution neural networks (GENN) to detect genetic 
associations: The higher the LD between the causal variants (involved in an interaction) and 
their proxy‘s, the better the chance to find an epistatic association with the trait of interest. In 
other words, whereas GWA studies exploit strong LD between a genetic marker and causative 
variant, GWAI studies exploit relation between the causal pair and their proxys‘ [31].  
Little is understood about how to best incorporate LD patterns between genetic markers or 
genetic markers and true causal variants in epistasis studies, knowing that LD between two 
genetic markers may induce a ‗redundant‘ epistatic effect of them on the trait under 
investigation. According to Zhao et al. [32], LD-based measures can serve as useful statistics 
to detect gene-gene interaction between two unlinked loci. These authors investigated the 
effect of a variety of LD patterns on the power of an epistasis study, in the presence of gene-
gene interactions between two disease-susceptibility loci in Hardy-Weinberg equilibrium and 
between two unlinked marker loci, each of which in LD with either of two interacting loci. 
Grady et al. [33] investigated the effect of LD on MDR epistasis screening incoperating 
varying amounts of LD and different positions of functional loci on a block(s) of LD.  
In our future research, we aim at setting up simulations involving varying degrees of LD 
between genetic markers and investigate the impact of LD within the context of MB-MDR 
epistasis modeling. This study will enable us to validate the epistasis strategy when imputed 
data are used, pruned back and then perfom analysis [34]. 
2.3 MB-MDR for Multivariate Traits 
Many complex diseases such as asthma and Crohn‘s disease, consist of a large number of 
highly related, rather than independent, clinical or molecular phenotypes.Identification of 




for associations between single markers and the phenotype, despite the fact that multiple trait 
mapping has proven to be more powerful than single trait mapping in the regression 
framework [35, 36]. A new technical challenge arises when identifying genetic variations 
associated simultaneously with correlated traits. 
A natural extension of Student‘s t testing (for 2-group comparisons) or ANOVA (for >2 
comparisons) is testing based on Hotelling-Lawley‘s T2 (short: Hotelling‘s T2). Therefore, we 
developed a multivariate version of the MB-MDR strategy, replacing all univariate t
2 
association tests at steps 1 and 2 with their multivariate counterparts, and proposed a 
discriminant function-based approach to differentiate between High and Low multilocus 
genotype cells.  
Multivariate MB-MDR can potentially be used to analyze categorical traits as well, by first 
fitting a multinomial logistic regression model and second considering the multivariate 
residuals as new traits for MB-MDR. In a pilot study, we applied our multivariate MB-MDR 
1D to screen for main effects with a categorical outcome on wheezing, which was defined as a 
categorical variable with 3 category levels. The data involved 1671 patients from the birth 
cohort Prevalence and Incidence of Asthma and Mite Allergy (PIAMA) and 101 SNPs. In 
practice, we fitted a multinomial logistic regression model adjusting for non-genetic 
confounding factors and took residuals based on this model as the new traits for MB-MDR. 
Goodness of fit for the residuals was performed via  the score test of Goeman and Le Cessie 
[37]. We then ranked the test results on all SNPs (highest rank translates to lowest p-value), 
per analysis method. This led to a matrix of ranks with rows corresponding to ‗observations‘ 
(i.e., SNP pairs) and columns referring to ‗variables‘ (i.e., analysis methods). Next, we 
performed a Principal Components Analysis (PCA) on the results matrix and visualized the 
output via a biplot (surpressing the observations).  The cosine of the angle between two 
arrows approximates the correlation between the variables they represent. It can be seen from 
Appendix Figure A4 that the results from a multivariate MB-MDR 1D and the standard 
analysis method based on multinomial logistic regression (codominant coding) largely agree.   
In our future research, we will thoroughly check the flexibility of MB-MDR for multivariate 
traits to detect epistasis, by setting up simulations and evaluating power and type I error in the 
same way we did for MB-MDR for univariate traits. One of the challenges is to incooperate 






2.4 Molecular Reclassification of Cases 
Most human diseases have a heterogeneous disorder with differences in severity, location or 
behavior. The heterogeneity of the disease has important implications towards clinical 
management, intensity of follow-up, therapy and mode of delivery [38]. For instance in 
Crohn‘s disease (CD),  patients with a more severe disease course might benefit from early 
introduction of immunomodulators and/or biologicals, while patients with favorable disease 
prognosis could be spared from intense treatment and possible side-effects [39].  We recently 
showed in Cleynen et al. [39] that genetic variants enable the classification of CD patients in 
distinct clusters (subgroups), which are different from clusters seen in healthy individuals. No 
significant association between the genetic-based subgroups and a selection of clinical 
phenotypes was found. Our results indicated that molecular markers show a promising role in 
disease stratification and pathogenesis.  
Some relevant questions in this context still remain: Do the genetically defined clusters in 
[39] give clues to clinically meaningful subphenotypes of CD? Can we use these 
subphenotypes as new traits or a multicategorical trait for epistasis screening? Do different 
subphenotypes lead to or are dictated by different epistatic pattern?  
In our future research, we aim to investigate whether interacting loci can contribute as well to 
identifying sub-phenotypes.  
2.5 Population Stratification 
Genome-wide association studies have proven to be successful in identifying common SNPs 
associated with complex and common traits [40, 41]. One of the common problems in 
population-based GWA studies is population stratification. Several approaches have been 
used to correct population stratification, including genomic control, structured association, 
and principal components analysis [42, 43]. In GWA studies, population substructure can be 
identified through a principal components analysis, which models ancestral genetic 
differences between cases and controls and then corrects for this in the analysis [43]. If  
population structure is not accounted for, it  can lead to spurious associations GWA studies 
and in this context several methods have been proposed to deal with this problem [44].  
However, as much as population stratification has been investigated in GWA studies, very 
few or none of the studies have given attention to population stratification in epistasis 




stratification. We performed a preliminary study in which we simulated data to assess the 
effect of population stratification on epistasis screening using MB-MDR, hereby creating 
three scenarios‘.  
Scenario 1: We first generated null data (no population stratificiation, no main effects and no 
epistasis), with a normally distributed trait. In particular, the data consisted of 100 replicates 
with 1000 SNPs and 1000 individuals.  
Scenario 2: Secondly, we simulated two heterogeneous populations using HAPSIMU, a 
genetic platform for population based association studies of Zhang et al. [45]. The populations 
consisted of the western European ancestry (CEPH) and Yoruba from Ibadan (YRI) of Africa. 
Also these data had 100 replicated sets of 1000 SNPs (999 of which were null SNPs, 1 main 
effect SNP) and 1000 individuals. In line with the recommendations given in PART 2, 
Chapter 3, we rank-transformed to normal the traits under study (Rtn).  In addition, we 
derived residuals from a polygenic model for the Rtn traits (Polygenic_Rtn). The traits under 
investigation (Rtn and Polygenic_Rtn) were additionally permuted in order to remove the 
main effect and to create the 3
rd
 and last scenario.  
Since none of the simulated data involved epistasis (SNP-SNP interaction), any MB-MDR 
significant result should be labeled as ―false positive‖. MB-MDR results obtained from 
exhaustive 2-locus epistasis screening showed that type I error was under control for 
scenario‘s 1 and 3. Elevated false positive rates were observed for scenario 2 (see Figure A5 
in Appendix). 
Our next steps will include an in-depth investigation of the effects of population stratification 
on epistasis screening, and an assessment of different strategies to correct for population 
stratification in the framework of an MB-MDR analysis. Thus, we will use simulations 
involving different population structures and will evaluate false positive rates. 
2.6 Multiple Testing in MB-MDR Revisited 
Clearly, due to the multi-stage nature of the MB-MDR methodology, step 2 MB-MDR test 
statistics are not F-distributed (even for normal data, and constant variances – see Figure 3.4). 
Hence, under all circumstances, marginal p-values (per two-locus test) need to be derived 
from permutation based null distributions, after which a multiple testing correction can still 
take place. There are several multiple testing procedures provided in the multtest  package in 




In the methodological part of this thesis (Chapter 3), we observed that despite actual 
deviations from the theoretical distribution of test statistics used in MB-MDR (e.g. Figures 
3.3, 3.4 and 3.5), there was  no evidence for a negative cumulative or combined effect on MB-
MDR‘s type I errors or false positive rates (Tables 3.1 and 3.2). This can be explained by the 
fact that significance assessment in MB-MDR was done via the permutation-based step-down 
maxT approach, which adjusts p-values to correct for large-scale multiple testing. It takes into 
account the joint distribution of the epistasis test statistics and is less conservative than 
Bonferroni [47], which is highly conservative in the presence of correlated tests (e.g., due to 
the fact that they involve a common marker, or due to specific LD patterns between markers). 
Note that our simulations assumed no LD between markers.  
In real-life applications, we do not know a priori which nulls are true and which are false. In 
addition, preliminary results on the effect of linkage disequilibrium on MB-MDR error 
control, as well as on the effect of highly variable minor allele frequencies (and thus highly 
variable available samples sizes for multilocus genotypes) show that subset pivotality is likely 
to be violated in real-life settings, hampering strong control of FWER [47].   
Our future steps will involve further investigation of resampling-based multiple testing 
strategies in conjunction with MB-MDR. 
2.7 Increased Efficiency in Lower-Order Effect Correction 
In our methodological paper on ―Lower-order Effects Adjustment in Quantitative Traits 
Model-Based Multifactor Dimensionality Reduction‖ [48], we concluded that always 
correcting for lower-order effects during epistasis screening should be made standard.  The 
correction for lower-order effects is carried at both steps 1 and 2 of MB-MDR. Correction at 
the two steps implies longer computation times, since what is done at step 1 in terms of 
covariates adjustment is repeated at step 2. Computational intensity might seem not to be 
much for 2-way interactions but increases dramatically for higher-order interactions.  
In order to reduce the computational intensity, we assessed correction at step 2 only, using 
same data with quantitative trait as used before (see PART 2, Chapter 2).  The false positives 
and power profiles under codominant correction are presented in Appendix Figures A6 and 
A7. The profiles for this correction and the one on both steps are quite similar, with the new 
implementation being approximately 2.5 times faster. This is a promising result. More work is 




In our future research, we aim at rigorously comparing the two correction scenarios under a 
variety of epistasis models, not only in terms of power performance and false positive 
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Table A1 Empirical power of MB-MDR to detect the correct two functional loci, excluding 
scenarios of simulated genetic heterogeneity 
 




Main Effects Correction 
No 
Correction 
Main Effects Correction 
p 2
g  Noisiness Additive Codominant Additive Codominant 
  None 0.446 0.056 0.018 0.542 0.006 0.006 
  MG5 0.338 0.018 0.004 0.414 0.014 0.004 
  MG10 0.308 0.012 0.004 0.312 0.008 0.000 
 0.01 GE5 0.180 0.012 0.002 0.194 0.000 0.000 
  GE10 0.094 0.000 0.000 0.116 0.000 0.000 
  PM25 0.152 0.016 0.010 0.180 0.004 0.002 
  PM50 0.034 0.000 0.000 0.028 0.000 0.000 
  None 0.904 0.264 0.146 0.930 0.144 0.072 
  MG5 0.862 0.240 0.108 0.908 0.096 0.046 
  MG10 0.784 0.190 0.068 0.800 0.070 0.040 
 0.02 GE5 0.620 0.092 0.030 0.666 0.050 0.004 
  GE10 0.366 0.018 0.010 0.444 0.006 0.002 
  PM25 0.506 0.084 0.018 0.554 0.010 0.010 
  PM50 0.134 0.012 0.006 0.126 0.002 0.000 
  None 0.996 0.592 0.384 0.996 0.392 0.182 
  MG5 0.990 0.526 0.272 0.992 0.348 0.182 
  MG10 0.960 0.412 0.240 0.976 0.244 0.102 
0.1 0.03 GE5 0.912 0.232 0.070 0.922 0.136 0.008 
  GE10 0.648 0.084 0.060 0.748 0.054 0.002 
  PM25 0.834 0.210 0.096 0.856 0.094 0.046 
  PM50 0.286 0.038 0.016 0.284 0.006 0.004 
  None 1.000 0.884 0.842 1.000 0.904 0.554 
  MG5 1.000 0.850 0.774 1.000 0.790 0.442 
  MG10 1.000 0.772 0.684 1.000 0.680 0.370 
 0.05 GE5 0.994 0.598 0.488 1.000 0.488 0.098 
  GE10 0.940 0.272 0.238 0.970 0.198 0.026 
  PM25 0.990 0.562 0.346 1.000 0.314 0.168 
  PM50 0.598 0.150 0.050 0.664 0.034 0.030 
  None 1.000 1.000 1.000 1.000 1.000 0.958 
  MG5 1.000 0.992 0.998 1.000 1.000 0.928 
  MG10 1.000 0.990 0.994 1.000 0.996 0.844 
 0.1 GE5 1.000 0.978 0.978 1.000 0.982 0.638 
  GE10 1.000 0.876 0.874 1.000 0.750 0.310 
  PM25 1.000 0.904 0.874 1.000 0.942 0.662 















Table A1 Continued  
 




Main Effects Correction 
No 
Correction 
Main Effects Correction 
p 2
g  Noisiness Additive Codominant Additive Codominant 
  None 0.424 0.038 0.024 0.376 0.300 0.180 
  MG5 0.340 0.042 0.030 0.332 0.266 0.154 
  MG10 0.284 0.018 0.010 0.248 0.184 0.082 
 0.01 GE5 0.298 0.012 0.010 0.232 0.184 0.084 
  GE10 0.198 0.018 0.006 0.084 0.070 0.032 
  PM25 0.146 0.010 0.000 0.144 0.112 0.048 
  PM50 0.024 0.002 0.000 0.026 0.014 0.006 
  None 0.912 0.178 0.138 0.908 0.864 0.710 
  MG5 0.836 0.150 0.108 0.846 0.780 0.616 
  MG10 0.780 0.130 0.104 0.766 0.714 0.532 
 0.02 GE5 0.840 0.136 0.088 0.674 0.626 0.440 
  GE10 0.696 0.078 0.050 0.428 0.342 0.210 
  PM25 0.480 0.046 0.040 0.440 0.384 0.250 
  PM50 0.116 0.012 0.006 0.110 0.080 0.040 
  None 0.998 0.500 0.444 0.992 0.990 0.952 
  MG5 0.984 0.426 0.356 0.992 0.984 0.936 
  MG10 0.970 0.306 0.252 0.972 0.960 0.856 
0.25 0.03 GE5 0.980 0.310 0.242 0.922 0.886 0.752 
  GE10 0.930 0.212 0.130 0.728 0.668 0.484 
  PM25 0.796 0.122 0.096 0.788 0.722 0.546 
  PM50 0.224 0.016 0.006 0.234 0.182 0.090 
  None 1.000 0.878 0.838 1.000 1.000 1.000 
  MG5 1.000 0.822 0.784 1.000 1.000 1.000 
  MG10 1.000 0.740 0.678 1.000 1.000 0.998 
 0.05 GE5 1.000 0.730 0.630 0.998 1.000 0.994 
  GE10 1.000 0.546 0.384 0.978 0.964 0.906 
  PM25 0.992 0.434 0.362 0.990 0.978 0.934 
  PM50 0.580 0.078 0.054 0.588 0.528 0.328 
  None 1.000 1.000 1.000 1.000 1.000 1.000 
  MG5 1.000 1.000 1.000 1.000 1.000 1.000 
  MG10 1.000 0.996 0.996 1.000 1.000 1.000 
 0.1 GE5 1.000 1.000 0.992 1.000 1.000 1.000 
  GE10 1.000 0.986 0.982 1.000 1.000 1.000 
  PM25 1.000 0.960 0.932 1.000 1.000 1.000 
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Main Effects Correction 
No 
Correction 
Main Effects Correction 
p 2
g  Noisiness Additive Codominant Additive Codominant 
  None 0.386 0.050 0.000 0.332 0.256 0.206 
  MG5 0.306 0.034 0.002 0.284 0.206 0.152 
  MG10 0.222 0.024 0.000 0.252 0.168 0.124 
 0.01 GE5 0.272 0.022 0.000 0.188 0.128 0.096 
  GE10 0.260 0.015 0.000 0.116 0.068 0.028 
  PM25 0.140 0.020 0.002 0.100 0.058 0.032 
  PM50 0.034 0.006 0.000 0.024 0.012 0.008 
  None 0.848 0.200 0.000 0.850 0.798 0.770 
  MG5 0.780 0.152 0.000 0.792 0.728 0.668 
  MG10 0.732 0.110 0.000 0.700 0.632 0.606 
 0.02 GE5 0.782 0.132 0.000 0.612 0.540 0.454 
  GE10 0.740 0.092 0.000 0.374 0.284 0.212 
  PM25 0.400 0.044 0.002 0.426 0.346 0.288 
  PM50 0.098 0.012 0.000 0.088 0.052 0.036 
  None 0.978 0.460 0.016 0.984 0.988 0.978 
  MG5 0.978 0.354 0.004 0.974 0.960 0.948 
  MG10 0.926 0.266 0.000 0.942 0.910 0.898 
0.5 0.03 GE5 0.966 0.344 0.004 0.898 0.860 0.832 
  GE10 0.956 0.246 0.002 0.680 0.616 0.516 
  PM25 0.704 0.116 0.000 0.780 0.688 0.618 
  PM50 0.224 0.020 0.000 0.200 0.138 0.098 
  None 1.000 0.832 0.034 1.000 1.000 1.000 
  MG5 1.000 0.768 0.026 0.998 0.998 0.998 
  MG10 1.000 0.714 0.024 0.998 1.000 1.000 
 0.05 GE5 1.000 0.738 0.012 0.998 1.000 0.998 
  GE10 0.998 0.658 0.006 0.958 0.948 0.916 
  PM25 0.982 0.366 0.008 0.968 0.952 0.950 
  PM50 0.514 0.078 0.000 0.466 0.358 0.294 
  None 1.000 0.998 0.316 1.000 1.000 1.000 
  MG5 1.000 0.998 0.286 1.000 1.000 1.000 
  MG10 1.000 0.994 0.168 1.000 1.000 1.000 
 0.1 GE5 1.000 0.998 0.266 1.000 1.000 1.000 
  GE10 1.000 0.988 0.142 1.000 1.000 1.000 
  PM25 1.000 0.902 0.052 1.000 1.000 1.000 




Table A2 False positive percentage of analyses with identified significant epistasis models 
other than the correct two functional interacting loci, in the absence of GH.  
 




Main Effects Correction 
No 
Correction 
Main Effects Correction 
p 2
g  Noisiness Additive Codominant Additive Codominant 
  None 0.148 0.038 0.034 0.278 0.062 0.056 
  MG5 0.124 0.046 0.044 0.216 0.046 0.040 
  MG10 0.126 0.050 0.044 0.200 0.034 0.032 
 0.01 GE5 0.114 0.046 0.044 0.146 0.046 0.044 
  GE10 0.102 0.048 0.038 0.154 0.058 0.048 
  PM25 0.082 0.050 0.054 0.142 0.038 0.040 
  PM50 0.064 0.046 0.046 0.086 0.044 0.038 
  None 0.282 0.048 0.044 0.556 0.054 0.032 
  MG5 0.290 0.048 0.038 0.534 0.034 0.020 
  MG10 0.242 0.040 0.030 0.470 0.054 0.040 
 0.02 GE5 0.224 0.034 0.038 0.374 0.050 0.034 
  GE10 0.182 0.038 0.032 0.286 0.028 0.030 
  PM25 0.156 0.042 0.038 0.286 0.044 0.044 
  PM50 0.084 0.044 0.034 0.120 0.052 0.046 
  None 0.534 0.042 0.032 0.792 0.092 0.052 
  MG5 0.436 0.026 0.024 0.766 0.038 0.024 
  MG10 0.432 0.046 0.042 0.742 0.088 0.066 
0.1 0.03 GE5 0.338 0.058 0.050 0.608 0.052 0.036 
  GE10 0.232 0.034 0.030 0.436 0.042 0.032 
  PM25 0.240 0.042 0.034 0.434 0.054 0.038 
  PM50 0.122 0.044 0.044 0.182 0.050 0.042 
  None 0.754 0.036 0.034 0.986 0.160 0.038 
  MG5 0.750 0.022 0.018 0.988 0.100 0.030 
  MG10 0.694 0.048 0.034 0.970 0.096 0.038 
 0.05 GE5 0.682 0.054 0.056 0.920 0.062 0.032 
  GE10 0.514 0.034 0.022 0.754 0.076 0.062 
  PM25 0.480 0.050 0.040 0.776 0.080 0.038 
  PM50 0.184 0.048 0.038 0.288 0.060 0.042 
  None 0.990 0.072 0.056 1.000 0.394 0.050 
  MG5 0.988 0.050 0.030 1.000 0.340 0.030 
  MG10 0.970 0.066 0.048 1.000 0.302 0.042 
 0.1 GE5 0.944 0.068 0.050 1.000 0.172 0.044 
  GE10 0.884 0.050 0.036 0.996 0.078 0.030 
  PM25 0.822 0.050 0.036 0.992 0.158 0.038 
  PM50 0.404 0.034 0.036 0.690 0.060 0.036 














Main Effects Correction 
No 
Correction 
Main Effects Correction 
p 2
g  
Noisiness Additive Codominant Additive Codominant 
  None 0.260 0.044 0.034 0.060 0.050 0.026 
  MG5 0.212 0.044 0.036 0.074 0.056 0.048 
  MG10 0.218 0.060 0.048 0.076 0.070 0.048 
 0.01 GE5 0.250 0.060 0.052 0.088 0.066 0.060 
  GE10 0.210 0.032 0.026 0.052 0.038 0.042 
  PM25 0.158 0.042 0.044 0.060 0.046 0.038 
  PM50 0.082 0.048 0.048 0.072 0.044 0.038 
  None 0.556 0.048 0.032 0.108 0.048 0.034 
  MG5 0.522 0.050 0.038 0.092 0.058 0.042 
  MG10 0.534 0.050 0.036 0.092 0.058 0.044 
 0.02 GE5 0.518 0.066 0.046 0.094 0.052 0.040 
  GE10 0.452 0.066 0.056 0.080 0.044 0.032 
  PM25 0.268 0.056 0.040 0.076 0.052 0.040 
  PM50 0.128 0.040 0.030 0.054 0.048 0.032 
  None 0.850 0.064 0.028 0.122 0.056 0.034 
  MG5 0.786 0.054 0.028 0.134 0.056 0.042 
  MG10 0.728 0.052 0.040 0.110 0.054 0.044 
0.25 0.03 GE5 0.738 0.072 0.036 0.106 0.048 0.030 
  GE10 0.694 0.050 0.026 0.120 0.056 0.030 
  PM25 0.492 0.018 0.018 0.074 0.038 0.028 
  PM50 0.198 0.058 0.042 0.064 0.040 0.032 
  None 0.992 0.098 0.034 0.242 0.082 0.044 
  MG5 0.976 0.078 0.032 0.208 0.062 0.028 
  MG10 0.964 0.078 0.038 0.190 0.064 0.034 
 0.05 GE5 0.984 0.076 0.024 0.206 0.070 0.034 
  GE10 0.934 0.066 0.020 0.176 0.056 0.038 
  PM25 0.786 0.054 0.026 0.132 0.058 0.034 
  PM50 0.354 0.062 0.046 0.086 0.046 0.040 
  None 1.000 0.212 0.028 0.528 0.120 0.032 
  MG5 1.000 0.196 0.040 0.502 0.110 0.032 
  MG10 1.000 0.178 0.036 0.462 0.078 0.022 
 0.1 GE5 1.000 0.216 0.040 0.412 0.112 0.036 
  GE10 0.998 0.154 0.040 0.358 0.088 0.040 
  PM25 0.992 0.108 0.044 0.286 0.090 0.032 




Table A2 Continued 
 
 




Main Effects Correction 
No 
Correction 
Main Effects Correction 
p 2
g  
Noisiness Additive Codominant Additive Codominant 
  None 0.378 0.088 0.022 0.056 0.046 0.036 
  MG5 0.324 0.056 0.022 0.044 0.034 0.024 
  MG10 0.308 0.066 0.026 0.058 0.068 0.048 
 0.01 GE5 0.362 0.066 0.030 0.058 0.048 0.042 
  GE10 0.322 0.077 0.026 0.038 0.022 0.014 
  PM25 0.210 0.084 0.036 0.044 0.032 0.034 
  PM50 0.112 0.052 0.036 0.046 0.038 0.028 
  None 0.772 0.216 0.036 0.074 0.054 0.044 
  MG5 0.750 0.168 0.026 0.052 0.032 0.030 
  MG10 0.692 0.130 0.028 0.044 0.050 0.038 
 0.02 GE5 0.744 0.140 0.036 0.032 0.026 0.022 
  GE10 0.684 0.130 0.038 0.054 0.042 0.032 
  PM25 0.420 0.100 0.036 0.050 0.044 0.034 
  PM50 0.160 0.062 0.034 0.064 0.052 0.054 
  None 0.954 0.376 0.042 0.044 0.034 0.028 
  MG5 0.948 0.284 0.046 0.060 0.042 0.036 
  MG10 0.910 0.242 0.054 0.064 0.030 0.028 
0.5 0.03 GE5 0.924 0.270 0.038 0.052 0.034 0.030 
  GE10 0.912 0.224 0.032 0.052 0.038 0.034 
  PM25 0.648 0.154 0.026 0.046 0.038 0.032 
  PM50 0.270 0.088 0.044 0.044 0.040 0.030 
  None 0.998 0.608 0.028 0.058 0.056 0.040 
  MG5 1.000 0.576 0.036 0.042 0.032 0.024 
  MG10 0.998 0.522 0.042 0.038 0.028 0.036 
 0.05 GE5 1.000 0.594 0.042 0.060 0.042 0.030 
  GE10 1.000 0.500 0.038 0.034 0.038 0.036 
  PM25 0.968 0.314 0.042 0.048 0.042 0.036 
  PM50 0.458 0.124 0.040 0.036 0.032 0.026 
  None 1.000 0.978 0.028 0.056 0.038 0.030 
  MG5 1.000 0.956 0.036 0.054 0.046 0.034 
  MG10 1.000 0.928 0.040 0.048 0.044 0.040 
 0.1 GE5 1.000 0.982 0.024 0.052 0.040 0.028 
  GE10 1.000 0.912 0.032 0.054 0.038 0.028 
  PM25 1.000 0.732 0.026 0.050 0.036 0.030 




























  None 0.005 0.803 0.006 0.592 0.004 0.408 0.011 
  MG5 0.005 0.755 0.006 0.576 0.004 0.424 0.010 
  MG10 0.005 0.820 0.006 0.575 0.004 0.425 0.010 
 0.01 GE5 0.003 0.828 0.004 0.633 0.002 0.367 0.006 
  GE10 0.003 0.910 0.003 0.702 0.001 0.298 0.005 
  PM25 0.003 0.803 0.004 0.601 0.002 0.399 0.006 
  PM50 0.001 0.790 0.001 0.566 0.001 0.434 0.002 
  None 0.009 0.772 0.012 0.581 0.008 0.419 0.020 
  MG5 0.009 0.785 0.012 0.593 0.008 0.407 0.020 
  MG10 0.009 0.789 0.012 0.581 0.008 0.419 0.020 
 0.02 GE5 0.007 0.834 0.008 0.648 0.005 0.352 0.013 
  GE10 0.006 0.912 0.007 0.709 0.003 0.291 0.010 
  PM25 0.005 0.787 0.006 0.577 0.005 0.423 0.011 
  PM50 0.002 0.794 0.003 0.578 0.002 0.422 0.005 
  None 0.013 0.772 0.017 0.590 0.012 0.410 0.030 
  MG5 0.013 0.772 0.017 0.561 0.013 0.439 0.030 
  MG10 0.014 0.787 0.018 0.588 0.013 0.412 0.031 
0.1 0.03 GE5 0.011 0.837 0.013 0.651 0.007 0.349 0.020 
  GE10 0.009 0.894 0.010 0.682 0.005 0.318 0.015 
  PM25 0.007 0.779 0.010 0.572 0.007 0.428 0.017 
  PM50 0.003 0.799 0.004 0.576 0.003 0.424 0.008 
  None 0.023 0.770 0.030 0.580 0.021 0.420 0.051 
  MG5 0.024 0.800 0.030 0.589 0.021 0.411 0.050 
  MG10 0.022 0.767 0.029 0.576 0.021 0.424 0.050 
 0.05 GE5 0.018 0.841 0.021 0.649 0.011 0.351 0.032 
  GE10 0.015 0.899 0.016 0.685 0.007 0.315 0.024 
  PM25 0.013 0.777 0.017 0.592 0.011 0.408 0.028 
  PM50 0.006 0.786 0.007 0.567 0.005 0.433 0.012 
  None 0.045 0.783 0.057 0.583 0.041 0.417 0.098 
  MG5 0.046 0.792 0.058 0.582 0.041 0.418 0.099 
  MG10 0.047 0.793 0.059 0.593 0.041 0.407 0.100 
 0.1 GE5 0.037 0.835 0.044 0.654 0.023 0.346 0.068 
  GE10 0.031 0.896 0.034 0.705 0.014 0.295 0.049 
  PM25 0.026 0.782 0.033 0.581 0.024 0.419 0.056 
  PM50 0.011 0.783 0.014 0.577 0.010 0.423 0.025 
Whereas g
2 
represents the total genetic variance corresponding to error-free data, 
2
gen now refers to 































  None 0.000 0.429 0.001 0.103 0.009 0.897 0.010 
  MG5 0.000 0.460 0.001 0.100 0.009 0.900 0.010 
  MG10 0.000 0.329 0.001 0.142 0.009 0.858 0.010 
 0.01 GE5 0.000 0.436 0.001 0.135 0.006 0.865 0.007 
  GE10 0.000 0.454 0.001 0.166 0.004 0.834 0.005 
  PM25 0.000 0.436 0.001 0.113 0.005 0.887 0.006 
  PM50 0.000 0.441 0.000 0.126 0.002 0.874 0.002 
  None 0.001 0.408 0.002 0.117 0.018 0.883 0.020 
  MG5 0.001 0.414 0.002 0.124 0.017 0.876 0.020 
  MG10 0.001 0.391 0.003 0.148 0.017 0.852 0.019 
 0.02 GE5 0.001 0.473 0.002 0.142 0.012 0.858 0.014 
  GE10 0.001 0.556 0.002 0.158 0.009 0.842 0.010 
  PM25 0.000 0.395 0.001 0.107 0.010 0.893 0.011 
  PM50 0.000 0.361 0.001 0.130 0.005 0.870 0.005 
  None 0.001 0.410 0.004 0.121 0.026 0.879 0.030 
  MG5 0.001 0.355 0.003 0.113 0.027 0.887 0.030 
  MG10 0.001 0.379 0.003 0.117 0.026 0.883 0.030 
0.25 0.03 GE5 0.001 0.455 0.003 0.132 0.018 0.868 0.021 
  GE10 0.001 0.485 0.003 0.172 0.013 0.828 0.015 
  PM25 0.001 0.450 0.002 0.110 0.015 0.890 0.016 
  PM50 0.000 0.377 0.001 0.124 0.007 0.876 0.007 
  None 0.002 0.414 0.006 0.118 0.044 0.882 0.050 
  MG5 0.002 0.389 0.006 0.120 0.044 0.880 0.050 
  MG10 0.003 0.452 0.006 0.115 0.045 0.885 0.051 
 0.05 GE5 0.002 0.474 0.005 0.147 0.030 0.853 0.035 
  GE10 0.002 0.547 0.004 0.160 0.021 0.840 0.025 
  PM25 0.001 0.407 0.003 0.124 0.024 0.876 0.028 
  PM50 0.001 0.389 0.001 0.118 0.011 0.882 0.013 
  None 0.005 0.407 0.011 0.114 0.088 0.886 0.100 
  MG5 0.005 0.403 0.011 0.113 0.089 0.887 0.100 
  MG10 0.004 0.367 0.011 0.115 0.088 0.885 0.100 
 0.1 GE5 0.004 0.454 0.010 0.139 0.060 0.861 0.070 
  GE10 0.004 0.508 0.008 0.155 0.044 0.845 0.052 
  PM25 0.003 0.400 0.007 0.121 0.049 0.879 0.056 




































  None 0.000 0.374 0.000 0.000 0.010 1.000 0.010 
  MG5 0.000 0.778 0.000 0.001 0.010 0.999 0.010 
  MG10 0.000 0.758 0.000 0.001 0.011 0.999 0.011 
 0.01 GE5 0.000 0.795 0.000 0.000 0.007 1.000 0.007 
  GE10 0.000 0.591 0.000 0.002 0.005 0.998 0.005 
  PM25 0.000 0.363 0.000 0.002 0.006 0.998 0.006 
  PM50 0.000 0.898 0.000 0.002 0.002 0.998 0.002 
  None 0.000 0.318 0.000 0.001 0.020 0.999 0.020 
  MG5 0.000 0.516 0.000 0.000 0.020 1.000 0.020 
  MG10 0.000 0.461 0.000 0.001 0.020 0.999 0.020 
 0.02 GE5 0.000 0.885 0.000 0.001 0.015 0.999 0.015 
  GE10 0.000 0.768 0.000 0.001 0.011 0.999 0.011 
  PM25 0.000 0.424 0.000 0.002 0.011 0.998 0.011 
  PM50 0.000 0.795 0.000 0.001 0.005 0.999 0.005 
  None 0.000 0.197 0.000 0.000 0.030 1.000 0.030 
  MG5 0.000 0.649 0.000 0.000 0.031 1.000 0.031 
  MG10 0.000 0.850 0.000 0.000 0.031 1.000 0.031 
0.5 0.03 GE5 0.000 0.248 0.000 0.000 0.022 1.000 0.022 
  GE10 0.000 0.893 0.000 0.001 0.016 0.999 0.016 
  PM25 0.000 0.906 0.000 0.000 0.017 1.000 0.017 
  PM50 0.000 0.228 0.000 0.001 0.008 0.999 0.008 
  None 0.000 0.561 0.000 0.000 0.050 1.000 0.050 
  MG5 0.000 0.552 0.000 0.000 0.050 1.000 0.050 
  MG10 0.000 0.974 0.000 0.000 0.050 1.000 0.050 
 0.05 GE5 0.000 0.851 0.000 0.000 0.037 1.000 0.037 
  GE10 0.000 0.852 0.000 0.000 0.027 1.000 0.027 
  PM25 0.000 0.899 0.000 0.000 0.027 1.000 0.027 
  PM50 0.000 0.675 0.000 0.001 0.012 0.999 0.012 
  None 0.000 0.979 0.000 0.000 0.100 1.000 0.100 
  MG5 0.000 0.881 0.000 0.000 0.100 1.000 0.100 
  MG10 0.000 0.863 0.000 0.000 0.100 1.000 0.100 
 0.1 GE5 0.000 0.924 0.000 0.000 0.075 1.000 0.075 
  GE10 0.000 0.756 0.000 0.000 0.055 1.000 0.055 
  PM25 0.000 0.918 0.000 0.000 0.056 1.000 0.056 



























  None 0.003 0.948 0.003 0.324 0.007 0.676 0.010 
  MG5 0.003 0.954 0.003 0.298 0.007 0.702 0.010 
  MG10 0.003 0.941 0.003 0.314 0.007 0.686 0.010 
 0.01 GE5 0.002 0.964 0.002 0.363 0.004 0.637 0.006 
  GE10 0.002 0.984 0.002 0.407 0.003 0.593 0.005 
  PM25 0.002 0.947 0.002 0.318 0.004 0.682 0.006 
  PM50 0.001 0.937 0.001 0.345 0.002 0.655 0.003 
  None 0.006 0.953 0.006 0.309 0.013 0.691 0.020 
  MG5 0.006 0.954 0.006 0.322 0.014 0.678 0.020 
  MG10 0.006 0.939 0.006 0.308 0.014 0.692 0.021 
 0.02 GE5 0.005 0.969 0.005 0.372 0.009 0.628 0.014 
  GE10 0.004 0.981 0.004 0.408 0.006 0.592 0.010 
  PM25 0.003 0.963 0.004 0.330 0.007 0.670 0.011 
  PM50 0.002 0.971 0.002 0.332 0.003 0.668 0.005 
  None 0.009 0.951 0.009 0.320 0.020 0.680 0.030 
  MG5 0.009 0.942 0.010 0.313 0.021 0.687 0.031 
  MG10 0.009 0.952 0.010 0.321 0.020 0.679 0.030 
0.1 0.03 GE5 0.007 0.943 0.007 0.368 0.012 0.632 0.020 
  GE10 0.006 0.979 0.006 0.408 0.009 0.592 0.015 
  PM25 0.005 0.960 0.005 0.322 0.011 0.678 0.017 
  PM50 0.002 0.926 0.002 0.308 0.005 0.692 0.007 
  None 0.015 0.953 0.016 0.312 0.034 0.688 0.050 
  MG5 0.016 0.945 0.017 0.324 0.035 0.676 0.051 
  MG10 0.015 0.945 0.016 0.311 0.035 0.689 0.050 
 0.05 GE5 0.012 0.953 0.013 0.372 0.021 0.628 0.034 
  GE10 0.010 0.985 0.010 0.419 0.014 0.581 0.025 
  PM25 0.008 0.938 0.009 0.313 0.019 0.687 0.028 
  PM50 0.004 0.932 0.004 0.319 0.009 0.681 0.013 
  None 0.030 0.943 0.031 0.314 0.068 0.686 0.100 
  MG5 0.031 0.946 0.033 0.326 0.068 0.674 0.101 
  MG10 0.030 0.942 0.032 0.316 0.070 0.684 0.102 
 0.1 GE5 0.024 0.953 0.025 0.366 0.043 0.634 0.068 
  GE10 0.020 0.979 0.021 0.416 0.029 0.584 0.049 
  PM25 0.016 0.946 0.017 0.314 0.038 0.686 0.055 
  PM50 0.007 0.941 0.008 0.313 0.017 0.687 0.025 
Whereas 
2
g represents the total genetic variance corresponding to error-free data, 
2
gen now refers to 




























  None 0.005 0.856 0.006 0.605 0.004 0.395 0.010 
  MG5 0.005 0.855 0.006 0.630 0.004 0.370 0.010 
  MG10 0.005 0.845 0.006 0.624 0.004 0.376 0.010 
 0.01 GE5 0.005 0.865 0.006 0.649 0.003 0.351 0.009 
  GE10 0.004 0.900 0.005 0.667 0.002 0.333 0.007 
  PM25 0.003 0.867 0.004 0.623 0.002 0.377 0.006 
  PM50 0.001 0.861 0.001 0.571 0.001 0.429 0.003 
  None 0.010 0.865 0.012 0.617 0.008 0.383 0.020 
  MG5 0.011 0.869 0.012 0.625 0.007 0.375 0.020 
  MG10 0.010 0.851 0.012 0.613 0.007 0.387 0.019 
 0.02 GE5 0.010 0.856 0.011 0.637 0.006 0.363 0.018 
  GE10 0.009 0.892 0.010 0.658 0.005 0.342 0.015 
  PM25 0.006 0.859 0.007 0.624 0.004 0.376 0.011 
  PM50 0.003 0.871 0.003 0.628 0.002 0.372 0.005 
  None 0.016 0.852 0.019 0.609 0.012 0.391 0.031 
  MG5 0.016 0.864 0.019 0.610 0.012 0.390 0.030 
  MG10 0.015 0.861 0.018 0.606 0.012 0.394 0.030 
0.25 0.03 GE5 0.014 0.870 0.017 0.642 0.009 0.358 0.026 
  GE10 0.013 0.885 0.015 0.652 0.008 0.348 0.022 
  PM25 0.009 0.864 0.010 0.610 0.007 0.390 0.017 
  PM50 0.004 0.853 0.005 0.623 0.003 0.377 0.007 
  None 0.026 0.855 0.031 0.609 0.020 0.391 0.050 
  MG5 0.026 0.855 0.030 0.605 0.020 0.395 0.050 
  MG10 0.026 0.851 0.030 0.611 0.019 0.389 0.050 
 0.05 GE5 0.024 0.864 0.028 0.641 0.015 0.359 0.043 
  GE10 0.022 0.873 0.025 0.666 0.012 0.334 0.037 
  PM25 0.015 0.864 0.017 0.605 0.011 0.395 0.028 
  PM50 0.007 0.856 0.008 0.618 0.005 0.382 0.012 
  None 0.052 0.861 0.060 0.609 0.039 0.391 0.099 
  MG5 0.053 0.862 0.062 0.609 0.040 0.391 0.102 
  MG10 0.052 0.853 0.061 0.611 0.039 0.389 0.100 
 0.1 GE5 0.046 0.855 0.054 0.632 0.031 0.368 0.085 
  GE10 0.044 0.885 0.049 0.656 0.026 0.344 0.075 
  PM25 0.029 0.856 0.033 0.599 0.022 0.401 0.056 




























  None 0.006 0.667 0.009 0.844 0.002 0.156 0.010 
  MG5 0.006 0.698 0.009 0.845 0.002 0.155 0.010 
  MG10 0.006 0.662 0.009 0.854 0.001 0.146 0.010 
 0.01 GE5 0.005 0.693 0.008 0.874 0.001 0.126 0.009 
  GE10 0.005 0.705 0.008 0.875 0.001 0.125 0.009 
  PM25 0.003 0.653 0.005 0.851 0.001 0.149 0.006 
  PM50 0.001 0.708 0.002 0.857 0.000 0.143 0.002 
  None 0.012 0.675 0.017 0.852 0.003 0.148 0.020 
  MG5 0.011 0.655 0.017 0.863 0.003 0.137 0.020 
  MG10 0.011 0.660 0.017 0.846 0.003 0.154 0.020 
 0.02 GE5 0.011 0.697 0.016 0.859 0.003 0.141 0.018 
  GE10 0.010 0.702 0.015 0.877 0.002 0.123 0.017 
  PM25 0.006 0.667 0.010 0.850 0.002 0.150 0.011 
  PM50 0.003 0.677 0.004 0.859 0.001 0.141 0.005 
  None 0.017 0.664 0.026 0.855 0.004 0.145 0.030 
  MG5 0.017 0.680 0.026 0.865 0.004 0.135 0.030 
  MG10 0.017 0.679 0.025 0.856 0.004 0.144 0.030 
0.5 0.03 GE5 0.016 0.683 0.024 0.870 0.004 0.130 0.027 
  GE10 0.016 0.717 0.022 0.870 0.003 0.130 0.026 
  PM25 0.009 0.661 0.014 0.864 0.002 0.136 0.016 
  PM50 0.004 0.646 0.007 0.866 0.001 0.134 0.008 
  None 0.028 0.669 0.042 0.854 0.007 0.146 0.049 
  MG5 0.029 0.669 0.043 0.858 0.007 0.142 0.050 
  MG10 0.028 0.659 0.042 0.851 0.007 0.149 0.050 
 0.05 GE5 0.027 0.669 0.040 0.871 0.006 0.129 0.046 
  GE10 0.026 0.693 0.038 0.876 0.005 0.124 0.043 
  PM25 0.016 0.678 0.024 0.858 0.004 0.142 0.028 
  PM50 0.007 0.659 0.011 0.856 0.002 0.144 0.013 
  None 0.058 0.672 0.086 0.862 0.014 0.138 0.100 
  MG5 0.057 0.669 0.085 0.855 0.014 0.145 0.099 
  MG10 0.057 0.667 0.085 0.856 0.014 0.144 0.100 
 0.1 GE5 0.055 0.682 0.080 0.864 0.013 0.136 0.093 
  GE10 0.052 0.701 0.074 0.875 0.011 0.125 0.085 
  PM25 0.032 0.663 0.049 0.861 0.008 0.139 0.056 





Table A5-i Empirical variance decomposition of the total genetic variance due to 



















pairgenepi   
 
2
, pairgen  
  0.01 0.001 0.789 0.001 0.552 0.001 0.448 0.003 
  0.02 0.002 0.789 0.003 0.562 0.002 0.438 0.005 
0.1 0.1 0.03 0.004 0.793 0.005 0.596 0.003 0.404 0.008 
  0.05 0.006 0.770 0.008 0.604 0.005 0.397 0.013 
  0.1 0.012 0.782 0.015 0.582 0.012 0.418 0.026 
  0.01 0.000 0.436 0.000 0.133 0.002 0.867 0.003 
  0.02 0.000 0.329 0.001 0.112 0.005 0.888 0.005 
0.25 0.25 0.03 0.000 0.382 0.001 0.117 0.007 0.883 0.008 
  0.05 0.000 0.398 0.001 0.119 0.011 0.881 0.012 
  0.1 0.001 0.393 0.003 0.109 0.022 0.891 0.025 
  0.01 0.000 0.527 0.000 0.001 0.003 0.999 0.003 
  0.02 0.000 0.490 0.000 0.001 0.005 0.999 0.005 
0.5 0.5 0.03 0.000 0.764 0.000 0.000 0.007 1.000 0.007 
  0.05 0.000 0.770 0.000 0.002 0.013 1.000 0.013 
  0.1 0.000 0.991 0.000 0.000 0.025 1.000 0.025 
Whereas 
2
g represents the total genetic variance corresponding to error-free data, 
2
, pairgen now refers 







Table A5-ii Empirical variance decomposition of the total genetic variance due to 



















pairsgenepi   
 
2
2, pairsgen  
  0.01 0.002 0.770 0.003 0.568 0.002 0.432 0.005 
  0.02 0.004 0.789 0.006 0.569 0.004 0.431 0.010 
0.1 0.1 0.03 0.007 0.795 0.009 0.594 0.006 0.407 0.015 
  0.05 0.012 0.771 0.015 0.593 0.011 0.408 0.026 
  0.1 0.023 0.781 0.029 0.583 0.021 0.417 0.050 
  0.01 0.000 0.405 0.001 0.132 0.004 0.868 0.005 
  0.02 0.000 0.386 0.001 0.117 0.009 0.883 0.010 
0.25 0.25 0.03 0.001 0.360 0.002 0.119 0.013 0.881 0.015 
  0.05 0.001 0.416 0.003 0.117 0.022 0.883 0.025 
  0.1 0.002 0.396 0.006 0.112 0.044 0.888 0.050 
  0.01 0.000 0.794 0.000 0.002 0.005 0.998 0.005 
  0.02 0.000 0.719 0.000 0.001 0.010 0.999 0.010 
0.5 0.5 0.03 0.000 0.603 0.000 0.000 0.014 1.000 0.014 
  0.05 0.000 0.694 0.000 0.001 0.026 0.999 0.026 
  0.1 0.000 0.777 0.000 0.000 0.050 1.000 0.050 
Whereas 
2
g represents the total genetic variance corresponding to error-free data, 
2
2, pairsgen now 




Table A5-iii Empirical variance decomposition of the total genetic variance due to 



















pairgenepi   
 
2
, pairgen  
  0.01 0.001 0.956 0.001 0.320 0.002 0.680 0.003 
  0.02 0.001 0.947 0.002 0.287 0.004 0.713 0.005 
0.1 0.1 0.03 0.002 0.934 0.002 0.293 0.006 0.707 0.008 
  0.05 0.004 0.955 0.004 0.338 0.008 0.662 0.013 
  0.1 0.008 0.940 0.008 0.324 0.017 0.676 0.025 
  0.01 0.001 0.853 0.002 0.557 0.001 0.443 0.003 
  0.02 0.003 0.859 0.003 0.607 0.002 0.393 0.005 
0.25 0.25 0.03 0.004 0.856 0.005 0.615 0.003 0.386 0.007 
  0.05 0.006 0.857 0.007 0.605 0.005 0.395 0.012 
  0.1 0.013 0.845 0.016 0.604 0.010 0.396 0.026 
  0.01 0.001 0.669 0.002 0.849 0.000 0.151 0.003 
  0.02 0.003 0.671 0.004 0.868 0.001 0.132 0.005 
0.5 0.5 0.03 0.004 0.645 0.007 0.869 0.001 0.131 0.008 
  0.05 0.007 0.662 0.011 0.863 0.002 0.137 0.013 
  0.1 0.014 0.667 0.021 0.855 0.004 0.145 0.025 
Whereas 
2
g represents the total genetic variance corresponding to error-free data, 
2
, pairgen now refers 







Table A5-iv Empirical variance decomposition of the total genetic variance due to 



















pairsgenepi   
 
2
2, pairsgen  
  0.01 0.002 0.953 0.002 0.314 0.004 0.686 0.005 
  0.02 0.003 0.953 0.003 0.307 0.007 0.693 0.010 
0.1 0.1 0.03 0.004 0.939 0.005 0.307 0.011 0.693 0.015 
  0.05 0.008 0.948 0.008 0.322 0.017 0.678 0.025 
  0.1 0.015 0.935 0.016 0.323 0.034 0.677 0.050 
  0.01 0.003 0.868 0.003 0.603 0.002 0.398 0.005 
  0.02 0.005 0.861 0.006 0.625 0.004 0.375 0.010 
0.25 0.25 0.03 0.008 0.856 0.009 0.609 0.006 0.391 0.015 
  0.05 0.013 0.858 0.015 0.610 0.010 0.391 0.025 
  0.1 0.026 0.847 0.031 0.607 0.020 0.393 0.050 
  0.01 0.003 0.675 0.004 0.851 0.001 0.149 0.005 
  0.02 0.006 0.666 0.008 0.845 0.002 0.155 0.010 
0.5 0.5 0.03 0.009 0.656 0.013 0.867 0.002 0.133 0.015 
  0.05 0.014 0.659 0.022 0.858 0.004 0.142 0.025 
  0.1 0.028 0.665 0.042 0.852 0.007 0.149 0.050 
Whereas 
2
g represents the total genetic variance corresponding to error-free data, 
2
2, pairsgen now 





Table A6 Theoretically derived proportions of the genetic variance in error-prone or error-




genmain     
22
genepi    
Model p GE5 GE10 Other GE5 GE10 Other 
 0.1 0.373 0.420 0.319 0.627 0.580 0.681 
M27 0.25 0.635 0.659 0.609 0.365 0.341 0.391 
 0.5 0.865 0.873 0.857 0.135 0.127 0.143 
 0.1 0.650 0.701 0.581 0.350 0.299 0.419 
M170 0.25 0.139 0.161 0.118 0.861 0.839 0.882 
 0.5 0.000 0.000 0.000 1.000 1.000 1.000 
   
22
mainadd   
  
22
maindom   
 
Model p GE5 GE10 Other GE5 GE10 Other 
 0.1 0.957 0.979 0.947 0.043 0.021 0.053 
M27 0.25 0.865 0.884 0.857 0.135 0.116 0.143 
 0.5 0.680 0.698 0.667 0.320 0.302 0.333 
 0.1 0.837 0.898 0.780 0.163 0.102 0.220 
M170 0.25 0.447 0.502 0.400 0.553 0.498 0.600 
 0.5 0.957 0.979 0.947 0.043 0.021 0.053 
Results are presented for 5% and 10% GE scenarios.  ―Other‖ scenarios refer to error-free settings, 




Table A7 Power of MB-MDR to detect different power definitions from genetic 
heterogeneity settings (Pair1=SNP1 x SNP2, Pair2=SNP3 x SNP4), and false positives, FP 
(any pair that is not strictly a functional pair).  
  Model M27 Model M170 
 p1 p2 
2

















   0.01 0.014 0.022 0.036 0.000 0.074 0.018 0.022 0.040 0.000 0.110 
  0.02 0.102 0.144 0.234 0.012 0.130 0.138 0.108 0.224 0.022 0.172 
0.1 0.1 0.03 0.296 0.306 0.508 0.094 0.212 0.294 0.298 0.512 0.080 0.380 
  0.05 0.650 0.572 0.852 0.370 0.336 0.690 0.688 0.906 0.472 0.688 
  0.1 0.936 0.958 0.994 0.900 0.742 0.976 0.980 1.000 0.956 0.968 
  0.01 0.020 0.016 0.036 0.000 0.116 0.016 0.020 0.036 0.000 0.072 
  0.02 0.100 0.094 0.186 0.008 0.200 0.096 0.078 0.168 0.006 0.076 
0.25 0.25 0.03 0.226 0.266 0.442 0.050 0.368 0.224 0.196 0.378 0.042 0.066 
  0.05 0.564 0.596 0.830 0.330 0.628 0.510 0.546 0.792 0.264 0.112 
  0.1 0.980 0.964 1.000 0.944 0.962 0.960 0.972 1.000 0.932 0.202 
  0.01 0.020 0.044 0.064 0.000 0.148 0.016 0.022 0.038 0.000 0.052 
  0.02 0.070 0.072 0.134 0.008 0.278 0.074 0.072 0.138 0.008 0.062 
0.5 0.5 0.03 0.206 0.174 0.332 0.048 0.520 0.162 0.172 0.306 0.028 0.054 
  0.05 0.490 0.488 0.750 0.228 0.810 0.494 0.430 0.710 0.214 0.036 
  0.1 0.938 0.958 0.996 0.900 1.000 0.954 0.918 1.000 0.872 0.080 
   0.01 0.002 0.002 0.004 0.000 0.024 0.002 0.000 0.002 0.000 0.030 
  0.02 0.006 0.006 0.012 0.000 0.036 0.002 0.002 0.004 0.000 0.038 
0.1 0.1 0.03 0.040 0.024 0.064 0.000 0.036 0.002 0.012 0.014 0.000 0.036 
  0.05 0.096 0.106 0.192 0.010 0.014 0.030 0.034 0.062 0.002 0.060 
  0.1 0.476 0.482 0.718 0.240 0.058 0.280 0.286 0.494 0.072 0.128 
  0.01 0.000 0.000 0.000 0.000 0.030 0.012 0.006 0.018 0.000 0.042 
  0.02 0.008 0.004 0.012 0.000 0.028 0.078 0.040 0.116 0.002 0.048 
0.25 0.25 0.03 0.012 0.016 0.028 0.000 0.044 0.152 0.168 0.284 0.036 0.036 
  0.05 0.056 0.066 0.118 0.004 0.042 0.438 0.496 0.740 0.194 0.028 
  0.1 0.348 0.346 0.586 0.108 0.074 0.954 0.962 0.998 0.918 0.056 
  0.01 0.000 0.004 0.004 0.000 0.054 0.006 0.006 0.012 0.000 0.030 
  0.02 0.008 0.008 0.016 0.000 0.064 0.044 0.038 0.076 0.006 0.042 
0.5 0.5 0.03 0.016 0.014 0.030 0.000 0.118 0.108 0.112 0.204 0.016 0.036 
  0.05 0.066 0.048 0.110 0.004 0.180 0.430 0.336 0.606 0.160 0.026 
  0.1 0.312 0.356 0.572 0.096 0.500 0.920 0.898 0.994 0.824 0.054 
   0.01 0.000 0.000 0.000 0.000 0.016 0.000 0.000 0.000 0.000 0.024 
  0.02 0.000 0.004 0.004 0.000 0.036 0.002 0.000 0.002 0.000 0.026 
0.1 0.1 0.03 0.016 0.008 0.024 0.000 0.024 0.004 0.008 0.012 0.000 0.032 
  0.05 0.036 0.042 0.078 0.000 0.010 0.024 0.030 0.054 0.000 0.028 
  0.1 0.260 0.264 0.454 0.070 0.028 0.154 0.162 0.294 0.022 0.028 
  0.01 0.000 0.000 0.000 0.000 0.014 0.000 0.000 0.000 0.000 0.034 
  0.02 0.006 0.006 0.012 0.000 0.018 0.036 0.030 0.066 0.000 0.038 
0.25 0.25 0.03 0.008 0.012 0.020 0.000 0.030 0.072 0.070 0.136 0.006 0.022 
  0.05 0.044 0.032 0.072 0.004 0.026 0.296 0.316 0.540 0.072 0.018 
  0.1 0.310 0.280 0.514 0.076 0.028 0.874 0.854 0.976 0.752 0.014 
  0.01 0.000 0.000 0.000 0.000 0.024 0.002 0.006 0.008 0.000 0.022 
  0.02 0.000 0.000 0.000 0.000 0.018 0.024 0.016 0.038 0.002 0.028 
0.5 0.5 0.03 0.000 0.000 0.000 0.000 0.014 0.078 0.064 0.132 0.010 0.032 
  0.05 0.002 0.000 0.002 0.000 0.018 0.324 0.296 0.526 0.094 0.014 
  0.1 0.010 0.014 0.024 0.000 0.018 0.894 0.876 0.992 0.778 0.038 
Considered analyses methods are MB-MDR without main effects correction, with additive or 
codominant lower order effects adjustment. False positive percentages higher than 0.05 are highlighted 


































































Table A8 MB-MDR power and false positives under the epistasis model M170 
 
False positive percentage is defined as the proportion of simulation samples for which at least one pair 
other than the causal pair (SNP1, SNP2)  are significant. Power is defined as the proportion of 
simulated samples of which the causal pair (SNP1, SNP2) is significant. Results are for correction of 
main effects and for different ways of main effect correction. In bold are values within Bradley‘s 
liberal criterion of robustness  
 











   MB-MDRadjust 0.064 0.036  0.726 0.074 
   MB-MDR1D 0.210 0.194  0.744 0.092 
   MB-MDRlist 0.226 0.208  0.752 0.084 
 0.01 0.326 SRperm 0.252 0.252 0.978 0.708 0.078 
   SR0.05 0.020 0.008  0.624 0.016 
   MRAIC 0.002 0.000  0.612 0.006 
   SRtop5 0.050 0.034  0.638 0.026 
   MB-MDRadjust 0.368 0.202  0.746 0.050 
   MB-MDR1D 0.642 0.534  0.748 0.052 
   MB-MDRlist 0.678 0.594  0.776 0.068 
 0.02 0.878 SRperm 0.582 0.496 0.982 0.728 0.128 
   SR0.05 0.060 0.014  0.640 0.012 
   MRAIC 0.024 0.004  0.620 0.004 
   SRtop5 0.122 0.050  0.638 0.022 
   MB-MDRadjust 0.794 0.540  0.708 0.060 
   MB-MDR1D 0.856 0.644  0.734 0.064 
   MB-MDRlist 0.874 0.696  0.766 0.060 
0.1 0.03 0.996 SRperm 0.632 0.406 0.996 0.712 0.120 
   SR0.05 0.260 0.018  0.606 0.006 
   MRAIC 0.216 0.010  0.592 0.004 
   SRtop5 0.314 0.072  0.630 0.034 
   MB-MDRadjust 0.990 0.940  0.718 0.050 
   MB-MDR1D 0.992 0.922  0.724 0.034 
   MB-MDRlist 0.994 0.924  0.742 0.036 
 0.05 1.000 SRperm 0.874 0.290 1.000 0.686 0.058 
   SR0.05 0.840 0.176  0.618 0.006 
   MRAIC 0.842 0.166  0.582 0.002 
   SRtop5 0.842 0.190  0.630 0.014 
   MB-MDRadjust 1.000 1.000  0.854 0.054 
   MB-MDR1D 1.000 1.000  0.854 0.060 
   MB-MDRlist 1.000 1.000  0.852 0.050 
 0.1 1.000 SRperm 1.000 0.942 1.000 0.772 0.054 
   SR0.05 1.000 0.930  0.740 0.008 
   MRAIC 1.000 0.922  0.710 0.000 
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   MB-MDRadjust 0.264 0.234  0.730 0.050 
   MB-MDR1D 0.234 0.232  0.740 0.064 
   MB-MDRlist 0.234 0.230  0.736 0.056 
 0.01 0.234 SRperm 0.262 0.280 0.988 0.680 0.058 
   SR0.05 0.228 0.214  0.638 0.018 
   MRAIC 0.208 0.126  0.614 0.002 
   SRtop5 0.234 0.226  0.648 0.020 
   MB-MDRadjust 0.872 0.862  0.724 0.040 
   MB-MDR1D 0.862 0.856  0.726 0.050 
   MB-MDRlist 0.862 0.860  0.730 0.048 
 0.02 0.864 SRperm 0.880 0.874 0.974 0.648 0.058 
   SR0.05 0.858 0.786  0.588 0.004 
   MRAIC 0.842 0.728  0.574 0.006 
   SRtop5 0.864 0.812  0.596 0.010 
   MB-MDRadjust 0.996 0.996  0.700 0.054 
   MB-MDR1D 0.996 0.996  0.700 0.050 
   MB-MDRlist 0.996 0.996  0.724 0.054 
0.25 0.03 0.996 SRperm 0.996 0.994 0.982 0.662 0.070 
   SR0.05 0.994 0.982  0.590 0.006 
   MRAIC 0.986 0.964  0.572 0.000 
   SRtop5 0.990 0.988  0.602 0.012 
   MB-MDRadjust 1.000 1.000  0.728 0.040 
   MB-MDR1D 1.000 1.000  0.732 0.074 
   MB-MDRlist 1.000 1.000  0.746 0.082 
 0.05 1.000 SRperm 1.000 1.000 0.990 0.694 0.096 
   SR0.05 0.996 0.998  0.608 0.010 
   MRAIC 1.000 1.000  0.602 0.006 
   SRtop5 1.000 1.000  0.630 0.016 
   MB-MDRadjust 1.000 1.000  0.788 0.038 
   MB-MDR1D 1.000 1.000  0.806 0.082 
   MB-MDRlist 1.000 1.000  0.846 0.092 
 0.1 1.000 SRperm 1.000 1.000 0.992 0.820 0.132 
   SR0.05 1.000 1.000  0.668 0.006 
   MRAIC 1.000 1.000  0.630 0.004 
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   MB-MDRadjust 0.312 0.436  0.686 0.044 
   MB-MDR1D 0.196 0.192  0.676 0.044 
   MB-MDRlist 0.194 0.192  0.692 0.040 
 0.01 0.196 SRperm 0.214 0.220 0.972 0.616 0.036 
   SR0.05 0.196 0.206  0.588 0.014 
   MRAIC 0.166 0.194  0.568 0.006 
   SRtop5 0.198 0.206  0.598 0.016 
   MB-MDRadjust 0.896 0.948  0.716 0.048 
   MB-MDR1D 0.804 0.802  0.728 0.062 
   MB-MDRlist 0.804 0.802  0.730 0.054 
 0.02 0.806 SRperm 0.830 0.840 0.984 0.676 0.044 
   SR0.05 0.826 0.818  0.616 0.004 
   MRAIC 0.804 0.794  0.604 0.000 
   SRtop5 0.828 0.826  0.626 0.006 
   MB-MDRadjust 0.998 1.000  0.716 0.054 
   MB-MDR1D 0.992 0.992  0.714 0.040 
   MB-MDRlist 0.992 0.992  0.710 0.036 
0.5 0.03 0.992 SRperm 0.992 0.992 0.980 0.640 0.048 
   SR0.05 0.990 0.988  0.596 0.010 
   MRAIC 0.988 0.986  0.592 0.006 
   SRtop5 0.990 0.990  0.612 0.010 
   MB-MDRadjust 1.000 1.000  0.682 0.054 
   MB-MDR1D 1.000 1.000  0.684 0.030 
   MB-MDRlist 1.000 1.000  0.710 0.030 
 0.05 1.000 SRperm 1.000 1.000 0.984 0.640 0.026 
   SR0.05 0.998 0.998  0.584 0.004 
   MRAIC 1.000 1.000  0.572 0.000 
   SRtop5 1.000 1.000  0.586 0.010 
   MB-MDRadjust 1.000 1.000  0.686 0.040 
   MB-MDR1D 1.000 1.000  0.680 0.044 
   MB-MDRlist 1.000 1.000  0.684 0.044 
 0.1 1.000 SRperm 1.000 1.000 0.986 0.624 0.062 
   SR0.05 1.000 1.000  0.570 0.008 
   MRAIC 1.000 1.000  0.534 0.000 




Table A9 MB-MDR power and false positives under the epistasis model M27 











   MB-MDRadjust 0.088 0.140  0.672 0.032 
   MB-MDR1D 0.210 0.210  0.680 0.058 
   MB-MDRlist 0.212 0.216  0.700 0.050 
 0.01 0.242 SRperm 0.228 0.244 0.988 0.640 0.048 
   SR0.05 0.070 0.078  0.574 0.008 
   MRAIC 0.026 0.046  0.546 0.004 
   SRtop5 0.084 0.094  0.580 0.010 
   MB-MDRadjust 0.472 0.616  0.708 0.028 
   MB-MDR1D 0.774 0.778  0.728 0.062 
   MB-MDRlist 0.732 0.782  0.740 0.066 
 0.02 0.826 SRperm 0.680 0.754 0.98 0.676 0.086 
   SR0.05 0.236 0.274  0.618 0.018 
   MRAIC 0.110 0.096  0.592 0.002 
   SRtop5 0.344 0.414  0.620 0.030 
   MB-MDRadjust 0.834 0.926  0.706 0.070 
   MB-MDR1D 0.948 0.952  0.712 0.094 
   MB-MDRlist 0.936 0.952  0.718 0.094 
0.1 0.03 0.968 SRperm 0.824 0.880 0.984 0.676 0.142 
   SR0.05 0.370 0.388  0.612 0.006 
   MRAIC 0.238 0.236  0.590 0.000 
   SRtop5 0.484 0.538  0.612 0.018 
   MB-MDRadjust 0.998 1.000  0.732 0.052 
   MB-MDR1D 0.994 0.994  0.766 0.120 
   MB-MDRlist 0.996 0.994  0.756 0.126 
 0.05 1.000 SRperm 0.876 0.916 0.998 0.698 0.156 
   SR0.05 0.636 0.702  0.600 0.012 
   MRAIC 0.572 0.638  0.598 0.002 
   SRtop5 0.692 0.766  0.644 0.026 
   MB-MDRadjust 1.000 1.000  0.672 0.066 
   MB-MDR1D 1.000 1.000  0.688 0.064 
   MB-MDRlist 1.000 1.000  0.700 0.062 
 0.1 1.000 SRperm 1.000 1.000 1.000 0.628 0.068 
   SR0.05 1.000 1.000  0.556 0.010 
   MRAIC 1.000 1.000  0.536 0.002 
   SRtop5 1.000 1.000  0.576 0.020 
False positive percentage is defined as the proportion of simulation samples for which at least one pair 
other than the causal pair (SNP1, SNP2) are significant. Power is defined as the proportion of simulated 
samples of which the causal pair (SNP1, SNP2) is significant. Results are for correction of main effects 
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   MB-MDRadjust 0.032 0.042  0.662 0.048 
   MB-MDR1D 0.176 0.168  0.696 0.074 
   MB-MDRlist 0.152 0.170  0.700 0.062 
 0.01 0.266 SRperm 0.160 0.192 0.986 0.636 0.086 
   SR0.05 0.018 0.016  0.566 0.004 
   MRAIC 0.006 0.008  0.542 0.004 
   SRtop5 0.026 0.018  0.578 0.008 
   MB-MDRadjust 0.216 0.230  0.702 0.044 
   MB-MDR1D 0.588 0.558  0.722 0.096 
   MB-MDRlist 0.516 0.554  0.738 0.068 
 0.02 0.890 SRperm 0.440 0.410 0.998 0.666 0.106 
   SR0.05 0.106 0.094  0.582 0.010 
   MRAIC 0.094 0.096  0.570 0.010 
   SRtop5 0.124 0.104  0.602 0.016 
   MB-MDRadjust 0.514 0.538  0.734 0.032 
   MB-MDR1D 0.724 0.700  0.732 0.098 
   MB-MDRlist 0.698 0.676  0.756 0.064 
0.25 0.03 0.996 SRperm 0.588 0.464 0.994 0.710 0.116 
   SR0.05 0.380 0.336  0.630 0.010 
   MRAIC 0.354 0.304  0.602 0.002 
   SRtop5 0.410 0.330  0.650 0.018 
   MB-MDRadjust 0.930 0.934  0.732 0.056 
   MB-MDR1D 0.938 0.926  0.734 0.064 
   MB-MDRlist 0.944 0.930  0.746 0.042 
 0.05 1.000 SRperm 0.862 0.838 1.000 0.668 0.052 
   SR0.05 0.840 0.822  0.608 0.004 
   MRAIC 0.836 0.796  0.596 0.000 
   SRtop5 0.854 0.834  0.628 0.022 
   MB-MDRadjust 1.000 1.000  0.826 0.062 
   MB-MDR1D 1.000 1.000  0.834 0.064 
   MB-MDRlist 1.000 1.000  0.836 0.046 
 0.1 1.000 SRperm 1.000 1.000 1.000 0.716 0.046 
   SR0.05 1.000 1.000  0.660 0.014 
   MRAIC 1.000 1.000  0.628 0.002 
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   MB-MDRadjust 0.012 0  0.700 0.048 
   MB-MDR1D 0.084 0.068  0.714 0.100 
   MB-MDRlist 0.078 0.032  0.734 0.074 
 0.01 0.154 SRperm 0.074 0.04 0.980 0.682 0.080 
   SR0.05 0.006 0  0.582 0.006 
   MRAIC 0.004 0  0.570 0.006 
   SRtop5 0.006 0  0.610 0.016 
   MB-MDRadjust 0.120 0.006  0.736 0.050 
   MB-MDR1D 0.332 0.208  0.788 0.182 
   MB-MDRlist 0.312 0.062 0.994 0.790 0.086 
 0.02 0.712 SRperm 0.248 0.048  0.718 0.096 
   SR0.05 0.050 0  0.606 0.008 
   MRAIC 0.052 0  0.594 0.008 
   SRtop5 0.062 0  0.620 0.026 
   MB-MDRadjust 0.422 0.014  0.796 0.042 
   MB-MDR1D 0.556 0.17  0.844 0.144 
   MB-MDRlist 0.534 0.05  0.848 0.040 
0.5 0.03 0.970 SRperm 0.386 0.008 1.000 0.786 0.058 
   SR0.05 0.262 0.002  0.676 0.010 
   MRAIC 0.266 0.002  0.658 0.008 
   SRtop5 0.278 0.002  0.688 0.016 
   MB-MDRadjust 0.858 0.134  0.898 0.042 
   MB-MDR1D 0.878 0.132  0.906 0.054 
   MB-MDRlist 0.878 0.112  0.918 0.032 
 0.05 1.000 SRperm 0.730 0 1.000 0.876 0.054 
   SR0.05 0.704 0.004  0.834 0.004 
   MRAIC 0.688 0.004  0.810 0.002 
   SRtop5 0.720 0.002  0.852 0.018 
   MB-MDRadjust 1.000 0.684  1.000 0.056 
   MB-MDR1D 1.000 0.646  1.000 0.056 
   MB-MDRlist 1.000 0.646  1.000 0.046 
 0.1 1.000 SRperm 1.000 0.186 1.000 0.998 0.050 
   SR0.05 1.000 0.172  0.998 0.008 
   MRAIC 1.000 0.146  0.998 0.002 





 Figure A1-i Empirical power estimates for MB-MDR as the percentage of analyses where the 
correct interaction (SNP1 x SNP2) is significant at the 5% level, in the presence of 5% or 
10% missing genotypes.  
Legend no main effects adjustment (—), main effects adjustment via additive coding (…), 






Figure A1-ii Empirical power estimates for MB-MDR as the percentage of analyses where 
the correct interaction (SNP1 x SNP2) is significant at the 5% level, in the presence of 5% or 
10% genotyping errors.  
Legend no main effects adjustment (—), main effects adjustment via additive coding (…),and 





Figure A1-iii Empirical power estimates for MB-MDR as the percentage of analyses where 
the correct interaction (SNP1 x SNP2) is significant at the 5% level, in the presence of 25% or 
50% phenotypic mixture.  
Legend no main effects adjustment (—), main effects adjustment via additive coding (…), 





Figure A2 Empirical power estimates of MB-MDR as the percentage of analyses where the 
correct interaction (SNP1 x SNP2) is significant at the 5% level, for error-free and noise-
induced simulation settings involving 250 SNPs.  
Legend Results are shown for MB-MDR analysis without main effects adjustment and 





Figure A3 Group comparison test maintaining adequate Type 1 error control, when group sizes 
are equal.  
Legend When several tests are listed, they are listed from most (top) to least (bottom) powerful. 
The tests in a square box and blue font should be avoided in MB-MDR due to reasons mentioned 






Figure A4 Biplot of the PIAMA data for main effects analysis (MB-MDR and Multinomial).  
Legend Data points are suppressed. The cosine of the angle between the lines approximates 






Figure A5  MB-MDR 2-order epistasis screening results.  
Legend  Rtn– the quantitative trait normalized by rank transformation; Polygenic_Rtn – the 
residuals derived from the polygenic model applied to the Rtn; ME adjust. – main effect 
adjustment; FP- False positive rate is estimated as percentage of analyses with identified MB-





Figure A6 False positive percentage of analyses with identified significant epistasis models 
other than the correct two functional interacting loci (SNP1 x SNP2).  
Legend Profiles are shown for codominant coding when no correction is performed, 






Figure A7 Empirical power estimates for MB-MDR as the percentage of analyses where the 
correct interaction (SNP1 x SNP2) is significant at the 5% level.  
Legend Profiles are shown for codominant coding when no correction is performed, 
correction performed at both MB-MDR steps and when correction is only perfomed at step2. 
 
 
  
 
 
 
 
 
 
 
 
